Genome-wide association study identifies novel breast cancer susceptibility loci

DOI: 10.1038/nature05887
Nature, 2007, 447, 1087-93.

#	Paper	IF	Citations
2081	Cancer genomics and genetics of FGFR2 (Review). **1992**, 33, 233		5
2080	Genome-wide association studies of cancer. **2007**, 3, 419-27		10
2079	Is phenomenology the best approach to health research?. **2007**, 166, 1109-15		9
2078	The molecular anatomy of spontaneous germline mutations in human testes. **2007**, 5, e224		53
2077	A genome-wide association study of sporadic ALS in a homogenous Irish population. **2008**, 17, 768-74		151
2076	Identification of novel modifier loci of Apc Min affecting mammary tumor development. **2007**, 67, 11226-33		8
2075	Power to detect risk alleles using genome-wide tag SNP panels. **2007**, 3, 1827-37		77
2074	Copy number variants and common disorders: filling the gaps and exploring complexity in genome-wide association studies. **2007**, 3, 1787-99		157
2073	Review of: Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. **2007**, 10,		
2072	Genetics of late-onset Alzheimer's disease: progress and prospect. **2007**, 8, 1747-55		12
2071	Germline genetic variation and breast cancer survival: prognostic and therapeutic implications. **2007**, 3, 491-5		3
2070	Successful design and conduct of genome-wide association studies. **2007**, 16 Spec No. 2, R220-5		61
2069	Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. **2007**, 67, 11368-76		71
2068	Genetics of sporadic amyotrophic lateral sclerosis. **2007**, 16 Spec No. 2, R233-42		125
2067	Interpreting P values in pharmacogenetic studies: a call for process and perspective. **2007**, 25, 4513-5		33
2066	Hereditary Breast Cancer. **2007**,		
2065	Point: genetic risk feedback for common disease time to test the waters. **2007**, 16, 1724-6		10

2064	Turning the pump handle: evolving methods for integrating the evidence on gene-disease association. **2007**, 166, 863-6		22
2063	Germ line variation at 8q24 and endometrial cancer risk. **2007**, 16, 2166-8		4
2062	Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers. **2007**, 5, 119-43		
2061	Determining the efficacy of dietary phytochemicals in cancer prevention. **2007**, 35, 1358-63		23
2060	Basic science: (JUNE 2007). **2007**, 10,		
2059	Implementation of genetics to personalize medicine. **2007**, 4, 248-65		20
2058	Fine mapping versus replication in whole-genome association studies. **2007**, 81, 995-1005		45
2057	Personalized medicine in the era of genomics. **2007**, 298, 1682-4		151
2056	The promise and limitations of genome-wide association studies to elucidate the causes of breast cancer. *Breast Cancer Research*, **2007**, 9, 114	8.3	15
2055	Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes. *Breast Cancer Research*, **2007**, 9, 113	8.3	35
2054	Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. *Breast Cancer Research*, **2007**, 9, R78	8.3	59
2053	Breast cancer risk-assessment models. *Breast Cancer Research*, **2007**, 9, 213	8.3	90
2052	Further susceptibility genes for breast cancer identified. **2007**, 4, 500-500		
2051	The biotechnology era: has the promise been fulfilled?. **2007**, 2, 1549-53		2
2050	A role for biomarkers in the screening and diagnosis of breast cancer in younger women. **2007**, 7, 533-44		15
2049	Breast cancer: origins and evolution. **2007**, 117, 3155-63		369
2048	The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies. **2007**, 8, 68		7
2047	A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. **2007**, 8 Suppl 1, S6		94

2046	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. **2007**, 39, 1329-37	1130
2045	Guilt beyond a reasonable doubt. **2007**, 39, 813-5	130
2044	A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. **2007**, 39, 870-4	1240
2043	A common genetic risk factor for colorectal and prostate cancer. **2007**, 39, 954-6	304
2042	New models of collaboration in genome-wide association studies: the Genetic Association Information Network. **2007**, 39, 1045-51	258
2041	Long story short: the serotonin transporter in emotion regulation and social cognition. **2007**, 10, 1103-9	802
2040	Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. **2007**, 8, 639-46	335
2039	Finding needles in a haystack. **2007**, 8, 491-491	
2038	Genome-wide association studies provide new insights into type 2 diabetes aetiology. **2007**, 8, 657-62	468
2037	National study of colorectal cancer genetics. **2007**, 97, 1305-9	61
2036	Susceptibility genes in breast cancer: more is less?. **2007**, 72, 493-496	12
2035	Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. **2007**, 7, 160	41
2034	Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies. **2007**, 8, 299	23
2033	Genetics and Neuroscience in Dyslexia: Perspectives for Education and Remediation. **2007**, 1, 162-172	18
2032	ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. **2007**, 6, 869-77	168
2031	Genome-wide association studies and ALS: are we there yet?. **2007**, 6, 841-3	4
2030	Mammary cancer susceptibility: human genes and rodent models. **2007**, 18, 817-31	25
2029	Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. **2007**, 52, 963-977	10

2028	Common neurodegenerative diseases: dissection by genome-wide association. **2007**, 7, 425-7		
2027	G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. *Breast Cancer Research and Treatment*, **2008**, 110, 377-85	4.4	35
2026	The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer. *Breast Cancer Research and Treatment*, **2008**, 111, 171-7	4.4	38
2025	BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer. *Breast Cancer Research and Treatment*, **2008**, 111, 505-9	4.4	20
2024	NBS1 variant I171V and breast cancer risk. *Breast Cancer Research and Treatment*, **2008**, 112, 75-9	4.4	21
2023	TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. *Breast Cancer Research and Treatment*, **2008**, 112, 81-7	4.4	43
2022	The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian women. *Breast Cancer Research and Treatment*, **2008**, 112, 35-9	4.4	8
2021	Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations. *Breast Cancer Research and Treatment*, **2008**, 112, 343-9	4.4	6
2020	Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers. *Breast Cancer Research and Treatment*, **2008**, 112, 229-36	4.4	17
2019	Breast cancer risk and the BRCA1 interacting protein CTIP. *Breast Cancer Research and Treatment*, **2008**, 112, 351-2	4.4	3
2018	Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies. **2008**, 14, 18-36		9
2017	Mouse modifier genes in mammary tumorigenesis and metastasis. **2008**, 13, 337-42		14
2016	Predicting breast cancer risk: implications of a "weak" family history. **2008**, 7, 361-6		5
2015	Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. **2008**, 64, 133-57		42
2014	[Hereditary breast cancer]. **2008**, 79, 1047-54		5
2013	Familial chronic lymphocytic leukemia. **2008**, 3, 221-5		
2012	The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. **2008**, 10, 78-84		26
2011	Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. **2008**, 115, 1573-85		316

2010	Systems biology and its potential role in radiobiology. **2008**, 47, 5-23	23
2009	Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls. **2008**, 123, 1-14	159
2008	Genetic variation in CYP17 and endometrial cancer risk. **2008**, 123, 155-62	23
2007	Genetic variants in the 8q24 locus and risk of testicular germ cell tumors. **2008**, 123, 409-18	9
2006	Hereditary breast cancer: new genetic developments, new therapeutic avenues. **2008**, 124, 31-42	233
2005	Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. **2008**, 124, 161-70	94
2004	No germline mutations in supposed tumour suppressor genes SAFB1 and SAFB2 in familial breast cancer with linkage to 19p. **2008**, 9, 108	12
2003	Biological processes, properties and molecular wiring diagrams of candidate low-penetrance breast cancer susceptibility genes. **2008**, 1, 62	13
2002	Reasons for breast cancer heterogeneity. **2008**, 7, 6	57
2001	In search of causal variants: refining disease association signals using cross-population contrasts. **2008**, 9, 58	27
2000	Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous beta-catenin. **2008**, 29, 390-7	27
1999	Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. **2008**, 29, 1282-91	622
1998	Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. **2008**, 29, 1292-303	51
1997	Nijmegen Breakage Syndrome mutations and risk of breast cancer. **2008**, 122, 802-6	112
1996	Consortium analysis of 7 candidate SNPs for ovarian cancer. **2008**, 123, 380-388	66
1995	Variants in DNA double-strand break repair and DNA damage-response genes and susceptibility to lung and head and neck cancers. **2008**, 123, 457-463	18
1994	New cancer susceptibility loci: population and familial risks. **2008**, 123, 1726-9	11
1993	Novel breast cancer risk alleles and endometrial cancer risk. **2008**, 123, 2961-4	14

1992	Microarray-based DNA profiling to study genomic aberrations. **2008**, 60, 437-40		10
1991	Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. **2008**, 47, 680-96		73
1990	Examining the statistical properties of fine-scale mapping in large-scale association studies. **2008**, 32, 204-14		5
1989	Increasing the power of identifying gene x gene interactions in genome-wide association studies. **2008**, 32, 255-63		146
1988	Evaluating cost efficiency of SNP chips in genome-wide association studies. **2008**, 32, 387-95		21
1987	CANDID: a flexible method for prioritizing candidate genes for complex human traits. **2008**, 32, 779-90		67
1986	Biostatistical aspects of genome-wide association studies. **2008**, 50, 8-28		111
1985	Studies of genes in the FGF signaling pathway and oral clefts with or without dental anomalies. **2008**, 146A, 1614-7		15
1984	Calibration of credibility of agnostic genome-wide associations. **2008**, 147B, 964-72		18
1983	The positives, protocols, and perils of genome-wide association. **2008**, 147B, 1288-94		34
1982	From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. **2008**, 40, 187-224		129
1981	Accommodating linkage disequilibrium in genetic-association analyses via ridge regression. **2008**, 82, 375-85		96
1980	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. **2008**, 82, 937-48		218
1979	The success of the genome-wide association approach: a brief story of a long struggle. **2008**, 16, 554-64		85
1978	A glimmer of light for neuropsychiatric disorders. *Nature*, **2008**, 455, 890-3	50.4	75
1977	Prospective surveillance of women with a family history of breast cancer: auditing the risk threshold. **2008**, 98, 840-4		5
1976	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. **2008**, 98, 1457-66		358
1975	Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. **2008**, 40, 703-6		378

1974	NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. **2008**, 40, 844-53	163
1973	Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. **2008**, 40, 26-8	258
1972	The emerging landscape of breast cancer susceptibility. **2008**, 40, 17-22	365
1971	Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. **2008**, 40, 1307-12	332
1970	Multiple newly identified loci associated with prostate cancer susceptibility. **2008**, 40, 316-21	722
1969	Multiple loci identified in a genome-wide association study of prostate cancer. **2008**, 40, 310-5	787
1968	Can genes for mammographic density inform cancer aetiology?. **2008**, 8, 812-23	37
1967	Genome-wide association studies: progress and potential for drug discovery and development. **2008**, 7, 221-30	91
1966	Genome-wide association studies for complex traits: consensus, uncertainty and challenges. **2008**, 9, 356-69	2126
1965	Linkage disequilibrium--understanding the evolutionary past and mapping the medical future. **2008** , 9, 477-85	695
1964	To what extent do scans of non-synonymous SNPs complement denser genome-wide association studies?. **2008**, 16, 718-23	23
1963	Whole-genome association study of bipolar disorder. **2008**, 13, 558-69	571
1962	Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. **2008**, 14, 3-13	59
1961	Genetic association analysis: a primer on how it works, its strengths and its weaknesses. **2008**, 31, 546-56	22
1960	SNPFile--a software library and file format for large scale association mapping and population genetics studies. **2008**, 9, 526	4
1959	Assessing batch effects of genotype calling algorithm BRLMM for the Affymetrix GeneChip Human Mapping 500 K array set using 270 HapMap samples. **2008**, 9 Suppl 9, S17	51
1958	Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility. **2008**, 9, 12	22
1957	Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. **2008**, 8, 155	165

1956	Identification of low penetrance alleles for lung cancer: the GEnetic Lung CAncer Predisposition Study (GELCAPS). **2008**, 8, 244	36
1955	Mutation analysis of the MDM4 gene in German breast cancer patients. **2008**, 8, 52	9
1954	Germline polymorphisms as modulators of cancer phenotypes. **2008**, 6, 27	6
1953	Genetic mapping of mammary tumor traits to rat chromosome 10 using a novel panel of consomic rats. **2008**, 186, 41-8	9
1952	The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. **2008**, 32, 140-3	16
1951	Genome-wide association studies in aging-related processes such as diabetes mellitus, atherosclerosis and cancer. **2008**, 43, 39-43	32
1950	The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine. **2008**, 13, 481-7	13
1949	Navigating the channels and beyond: unravelling the genetics of the epilepsies. **2008**, 7, 231-45	219
1948	Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. **2008**, 12, 2533-51	41
1947	From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities. **2008**, 18, 75-88	38
1946	Genetic markers for prediction of normal tissue toxicity after radiotherapy. **2008**, 18, 126-35	90
1945	The human lexinome: genes of language and reading. **2008**, 41, 409-20	25
1944	Revealing the architecture of gene regulation: the promise of eQTL studies. **2008**, 24, 408-15	366
1943	MicroRNA target site polymorphisms and human disease. **2008**, 24, 489-97	285
1942	Molecular and in silico analysis of BRCA1 and BRCA2 variants. **2008**, 644, 64-70	34
1941	Study designs for genome-wide association studies. **2008**, 60, 465-504	40
1940	Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. **2008**, 8, 587-97	75
1939	Study Design and Statistical Issues in Pharmacogenetics Research. **2008**, 185-206	

1938	Genetic predisposition to breast cancer: past, present, and future. **2008**, 9, 321-45		202
1937	SNPs associated with molecular subtypes of breast cancer: on the usefulness of stratified Genome-wide Association Studies (GWAS) in the identification of novel susceptibility loci. **2008**, 2, 12-5		9
1936	Inherited susceptibility to common cancers. **2008**, 359, 2143-53		379
1935	Genetic interactions: the missing links for a better understanding of cancer susceptibility, progression and treatment. **2008**, 7, 4		7
1934	Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example. **2008**, 17, 173-89		11
1933	Identification of EpCAM as the gene for congenital tufting enteropathy. **2008**, 135, 429-37		157
1932	Anticipating issues related to increasing preimplantation genetic diagnosis use: a research agenda. **2008**, 17 Suppl 1, 33-42		18
1931	Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. *Breast Cancer Research*, **2008**, 10, R98	8.3	36
1930	The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. *Breast Cancer Research*, **2008**, 10, R108	8.3	42
1929	Breast cancer susceptibility loci and mammographic density. *Breast Cancer Research*, **2008**, 10, R66	8.3	23
1928	Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?. *Breast Cancer Research*, **2008**, 10, 208	8.3	58
1927	Molecular diversity of human breast cancer: clinical and therapeutic implications. *Breast Cancer Research*, **2008**, 10,	8.3	78
1926	Surviving breast cancer: can women expect to 'get back to normal'?. *Breast Cancer Research*, **2008**, 10,	8.3	78
1925	Identification of components of the ubiquitin system as targets for therapeutic intervention. *Breast Cancer Research*, **2008**, 10,	8.3	78
1924	Abnormal expression of p53 isoforms can be associated with poor survival in primary breast tumours. *Breast Cancer Research*, **2008**, 10,	8.3	78
1923	D133p53 isoform is a direct p53 target gene that modulates p53 tumour suppressor activity. *Breast Cancer Research*, **2008**, 10,	8.3	78
1922	Abstracts of the meeting of the Breast Cancer Campaign. London, United Kingdom. May 13, 2008. *Breast Cancer Research*, **2008**, 10 Suppl 2, L1-P95	8.3	
1921	Primary ductal carcinoma in situmammosphere formation: importance of the epidermal growth factor and Notch receptor signalling pathways. *Breast Cancer Research*, **2008**, 10,	8.3	78

1920	What is the psychological impact of mammographic screening on younger women with a family history of breast cancer? Findings from a prospective cohort study (PIMMS). *Breast Cancer Research*, **2008**, 10,	8.3	78
1919	Accurate prediction of BRCA1 and BRCA2 heterozygous genotypes using expression profiling of lymphocytes after irradiation-induced DNA damage. *Breast Cancer Research*, **2008**, 10,	8.3	78
1918	The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. *Breast Cancer Research*, **2008**, 10,	8.3	78
1917	Health inequalities in breast cancer screening. *Breast Cancer Research*, **2008**, 10,	8.3	2
1916	Inhibition of apoptosis by Notch signalling in breast epithelial cells. *Breast Cancer Research*, **2008**, 10,	8.3	78
1915	Urinary and serum biomarkers of phytoestrogen exposure are not associated with breast cancer risk in the European Prospective into Cancer Norfolk study. *Breast Cancer Research*, **2008**, 10,	8.3	78
1914	Quantitative proteomics reveals proteins associated with radiotherapy resistance in breast cancer cells. *Breast Cancer Research*, **2008**, 10,	8.3	1
1913	Regulation of cyclin D1by the BRCA1BARD1 complex. *Breast Cancer Research*, **2008**, 10,	8.3	78
1912	Investigation of the roles of novel apoptosis-controlling genes in breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1911	Proteomic screening of 725 antibodies simultaneously using antibody microarray technology to identify proteins associated with radiotherapy resistance in breast cancer cells. *Breast Cancer Research*, **2008**, 10,	8.3	78
1910	De novo expression of □8 integrin by myoepithelial cells in ductal carcinoma in situ may be an important marker of disease progression. *Breast Cancer Research*, **2008**, 10,	8.3	2
1909	Activation of TGF-beta signalling in breast cancer metastatic cells. *Breast Cancer Research*, **2008**, 10,	8.3	1
1908	Prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. *Breast Cancer Research*, **2008**, 10,	8.3	4
1907	Development of functional assays for BRCA1 missense mutations. *Breast Cancer Research*, **2008**, 10,	8.3	78
1906	Downregulation of 15-hydroxyprostaglandin dehydrogenase in hormone-resistant breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1905	Dietary patterns across the life course, mammographic density and implications for breast cancer: results from a British prospective cohort. *Breast Cancer Research*, **2008**, 10,	8.3	78
1904	Identification and definition of novel clinical phenotypes of breast cancer through consensus derived from automated clustering methods. *Breast Cancer Research*, **2008**, 10,	8.3	5
1903	Association of MMP8 gene variation with breast cancer prognosis. *Breast Cancer Research*, **2008**, 10,	8.3	1

1902	Characterization of a cytoskeletal signaling pathway underpinning CD44-initiated, integrin-mediated adhesion of breast cancer cells to bone marrow endothelium. *Breast Cancer Research*, **2008**, 10,	8.3	1
1901	Suppression of the NF-Β cofactor Bcl3 inhibits mammary epithelial cell apoptosis and, in breast tumours, correlates with poor prognosis. *Breast Cancer Research*, **2008**, 10,	8.3	1
1900	Prospective Study of Outcome in Sporadic versus Hereditary Breast Cancer: pros and cons of running a cohort study. *Breast Cancer Research*, **2008**, 10,	8.3	78
1899	Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1. *Breast Cancer Research*, **2008**, 10,	8.3	78
1898	Matrix metalloproteinase-8 is a regulator of the clinical aggressiveness of mammary tumours. *Breast Cancer Research*, **2008**, 10,	8.3	78
1897	Two functionally distinct epithelial progenitors exist within the luminal cell compartment of the mouse mammary gland. *Breast Cancer Research*, **2008**, 10,	8.3	1
1896	Chromosome translocations in breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1895	TARGIT: an international trial of intraoperative versus external beam radiotherapy. *Breast Cancer Research*, **2008**, 10,	8.3	78
1894	C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target. *Breast Cancer Research*, **2008**, 10,	8.3	78
1893	Insulin-like growth factor binding protein 3 modulates epidermal growth factor (EGF)-induced growth of breast epithelial cells by altering EGF receptor internalization. *Breast Cancer Research*, **2008**, 10,	8.3	1
1892	Lineage commitment in mammary epithelium is regulated by type 2 cytokines and Stat6. *Breast Cancer Research*, **2008**, 10,	8.3	0
1891	A novel role for C-terminal binding proteins in the regulation of mitotic fidelity in breast cancer cells. *Breast Cancer Research*, **2008**, 10,	8.3	78
1890	Bevacizumab resistance in breast cancer: are neuropilins the key?. *Breast Cancer Research*, **2008**, 10,	8.3	3
1889	Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1888	Assessment of angiogenesis in the hyperplasia preinvasive, invasive breast carcinoma sequence. *Breast Cancer Research*, **2008**, 10,	8.3	78
1887	Role of poly(ADPribosyl)ation of CTCF in cancer and normal breast cells. *Breast Cancer Research*, **2008**, 10,	8.3	78
1886	Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. *Breast Cancer Research*, **2008**, 10,	8.3	78
1885	Proapoptotic protein Bid is regulated by phosphorylation during anoikis and the cell cycle. *Breast Cancer Research*, **2008**, 10,	8.3	78

1884	Association of gene variants in the TGF-beta signalling pathways with invasive breast cancer risk. *Breast Cancer Research*, **2008**, 10,	8.3	78
1883	p53 isoform modulates differentially p53 transcriptional activity in response to stress. *Breast Cancer Research*, **2008**, 10,	8.3	78
1882	Investigation of immunoregulatory mechanisms relating to poor surgical wound healing and breast cancer recurrence. *Breast Cancer Research*, **2008**, 10,	8.3	78
1881	Cytochrome P450 modulates the therapeutic actions of tamoxifen, as evidenced in novel breast cancer models. *Breast Cancer Research*, **2008**, 10,	8.3	78
1880	Cellular localization of the proto-oncogenic p53 inhibitor AGR2 protein in breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1879	Exploring the breast cancer experiences, needs and preferences of women aged 70 years and over: a study in progress. *Breast Cancer Research*, **2008**, 10,	8.3	78
1878	Diagnosed with breast cancer whilst on a family history screening programme: an exploratory qualitative study. *Breast Cancer Research*, **2008**, 10,	8.3	1
1877	TSC22 in mammary gland development and breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1876	Adherence to hormone therapy in a chemoprevention randomised trial. *Breast Cancer Research*, **2008**, 10,	8.3	78
1875	Investigation into the molecular mechanism of the antiapoptotic functions of CTCF in breast cancer cells using a proteomics approach. *Breast Cancer Research*, **2008**, 10,	8.3	78
1874	Living with genetic risk of breast cancer: what have we learned?. *Breast Cancer Research*, **2008**, 10,	8.3	78
1873	MCPH1, a potential predictor for response to cancer chemotherapy. *Breast Cancer Research*, **2008**, 10,	8.3	78
1872	Homeopathy service in an NHS hospital breast cancer clinic: outcome study. *Breast Cancer Research*, **2008**, 10,	8.3	3
1871	TopBP1 contains transcriptional regulatory domains and regulates gene pathways involved in breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1870	Identification of proteins associated with radiotherapy resistance in breast cancer cells: a combined proteomic and microarray screening approach. *Breast Cancer Research*, **2008**, 10,	8.3	78
1869	PARP-1 inhibitor monotherapy and combination therapy in a preclinical mouse model of Brca2 mutant breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1868	Modelling estrogen receptor alpha-positive breast cancer by transformation of normal human mammary epithelial cells. *Breast Cancer Research*, **2008**, 10,	8.3	78
1867	Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	3

1866	Identification and role of migration stimulating factor isoforms in breast carcinomas. *Breast Cancer Research*, **2008**, 10,	8.3	78
1865	Reelin expression in breast tumours is associated with increased survival and is controlled by promoter methylation. *Breast Cancer Research*, **2008**, 10,	8.3	0
1864	Understanding and exploiting changes in O-linked glycosylation in breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1863	Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes. *Breast Cancer Research*, **2008**, 10,	8.3	78
1862	High-throughput optical proteomics and breast cancer patient profiling: novel applications to individualise prognosis and treatment. *Breast Cancer Research*, **2008**, 10,	8.3	78
1861	Chemotherapy-induced modulation of [18F]Fluoro-2-deoxy-D-glucose incorporation at the tumour cell level. *Breast Cancer Research*, **2008**, 10,	8.3	78
1860	Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis. *Breast Cancer Research*, **2008**, 10,	8.3	2
1859	Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor. *Breast Cancer Research*, **2008**, 10,	8.3	78
1858	Detection of gene amplification in matched tumour and plasma DNA from breast cancer patients by quantitative PCR. *Breast Cancer Research*, **2008**, 10,	8.3	1
1857	CD44 signalling increases cathepsin K and MT1MMP expression to potentiate breast cancer cell invasion through collagen I. *Breast Cancer Research*, **2008**, 10,	8.3	1
1856	Identification of genes involved in the formation of lymph node metastasis from human tumour xenograft models of breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1855	Role of the Hsp90 cochaperone, FKBPL, in oestrogen receptor signalling and breast cancer growth and survival. *Breast Cancer Research*, **2008**, 10,	8.3	1
1854	Lymphovascular invasion in breast cancer: improved methods of detection and clinical significance. *Breast Cancer Research*, **2008**, 10,	8.3	78
1853	Brk expression may affect the differentiation status of breast cancer cells. *Breast Cancer Research*, **2008**, 10,	8.3	78
1852	Role of CLEVER-1 in breast cancer metastasis. *Breast Cancer Research*, **2008**, 10,	8.3	78
1851	Actions of IGF-I are differentially regulated by fatty acids in normal and breast cancer epithelial cells. *Breast Cancer Research*, **2008**, 10,	8.3	78
1850	Interactions between BRCA2 protein and the meiosis-specific recombinase DMC1. *Breast Cancer Research*, **2008**, 10,	8.3	78
1849	ZNF366 is a novel corepressor for estrogen receptor alpha that mediates its effects through interaction with CtBP. *Breast Cancer Research*, **2008**, 10,	8.3	78

1848	Cambridge Breast Intensity Modulated Radiotherapy Trial: dosimetry results for 1,139 patients. *Breast Cancer Research*, **2008**, 10,	8.3	78
1847	Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?. *Breast Cancer Research*, **2008**, 10,	8.3	78
1846	Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity. *Breast Cancer Research*, **2008**, 10,	8.3	1
1845	Topoisomerase II expression as a determinant of chromosomal radiosensitivity and possible susceptibility in breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1844	RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours. *Breast Cancer Research*, **2008**, 10,	8.3	78
1843	Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid. *Breast Cancer Research*, **2008**, 10,	8.3	78
1842	Stromal fibroblasts with nuclear □catenin are present within breast tumours and increase proliferation and invasion of epithelial breast cancer cells. *Breast Cancer Research*, **2008**, 10,	8.3	78
1841	Altered myoepithelial cell expression and function in cancer-containing breasts. *Breast Cancer Research*, **2008**, 10,	8.3	78
1840	NRG1is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. *Breast Cancer Research*, **2008**, 10,	8.3	1
1839	An exploration of the management of menopausal symptoms for women with a diagnosis of breast cancer: lay and professional experiences and expectations. *Breast Cancer Research*, **2008**, 10,	8.3	1
1838	Exploring the acceptability of, and preferences for, an ongoing support network for known BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2008**, 10,	8.3	78
1837	Breast cancer and environmental risk factors: an appraisal of the scientific evidence. *Breast Cancer Research*, **2008**, 10,	8.3	4
1836	From association to cause: fine mapping of the TNRC9gene region, a novel susceptibility locus identified in the first genome-wide association study for breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	1
1835	Inhibitor of apoptosis proteins as a therapeutic target in breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1834	Discrepancies and challenge of ductal carcinoma in situfor health professionals. *Breast Cancer Research*, **2008**, 10,	8.3	78
1833	'The sooner the better' or 'too much too soon'? A pilot prospective longitudinal study to evaluate quality of life and body image following immediate latissimus dorsi breast reconstruction. *Breast Cancer Research*, **2008**, 10,	8.3	78
1832	Coactivation of estrogen receptor alpha by the DEAD-box RNA helicases p68 and p72 and its role in breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1831	Multicentre study of CASP8 polymorphisms in breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78

1830	Investigating h-Prune activation of Wnt signalling in breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1829	Food choice and phytoestrogen consumption in women previously treated for postmenopausal breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1828	'More positive about mammography' Reactions of women to a false positive recall: a qualitative study of women at risk of familial breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	78
1827	Regulation of estrogen receptor beta by 5' untranslated regions in breast carcinogenesis. *Breast Cancer Research*, **2008**, 10,	8.3	78
1826	Expression analysis of novel biomarkers for breast cancer. *Breast Cancer Research*, **2008**, 10,	8.3	2
1825	The QUEST study: a multicentre randomised trial to assess the impact of the type and timing of breast reconstruction on quality of life following mastectomy. *Breast Cancer Research*, **2008**, 10,	8.3	78
1824	Use of BRCA1 protein:protein interactions to classify cancer risk. *Breast Cancer Research*, **2008**, 10,	8.3	2
1823	Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. *Breast Cancer Research*, **2008**, 10, R26	8.3	66
1822	Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer postgenome cohort study. *Breast Cancer Research*, **2008**, 10, R13	8.3	43
1821	The role of single nucleotide polymorphisms in breast cancer metastasis. *Breast Cancer Research*, **2008**, 10, 301	8.3	7
1820	Genetic determinants of phenotypic diversity in humans. **2008**, 9, 215		24
1819	Classification of genetic profiles of Crohn's disease: a focus on the ATG16L1 gene. **2008**, 8, 199-207		10
1818	Performance of whole-genome amplified DNA isolated from serum and plasma on high-density single nucleotide polymorphism arrays. **2008**, 10, 249-57		16
1817	Assessment of cumulative evidence on genetic associations: interim guidelines. **2008**, 37, 120-32		451
1816	The future of mouse QTL mapping to diagnose disease in mice in the age of whole-genome association studies. **2008**, 42, 131-41		63
1815	Innovative Endocrinology of Cancer. **2008**,		5
1814	Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. **2008**, 109, 115-28		6
1813	Etiologic impact of known cancer susceptibility genes. **2008**, 658, 42-54		16

1812	Social and ethical implications of genomics, race, ethnicity, and health inequities. **2008**, 24, 254-61	11
1811	Can genetic testing guide treatment in breast cancer?. **2008**, 44, 2774-80	20
1810	Prediction of individual genetic risk of complex disease. **2008**, 18, 257-63	129
1809	Functional genomics of cancer. **2008**, 18, 251-6	17
1808	A systematic method for mapping multiple loci: an application to construct a genetic network for rheumatoid arthritis. **2008**, 408, 104-11	8
1807	[Most common benign epithelial breast diseases: diagnosis, treatment and cancer risk]. **2008**, 36, 788-99	7
1806	Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994. **2009**, 169, 54-66	72
1805	How to interpret a genome-wide association study. **2008**, 299, 1335-44	626
1804	Genetic mapping in human disease. **2008**, 322, 881-8	1086
1803	International registries of families at high risk of pancreatic cancer. **2008**, 8, 558-65	45
1802	The importance of replication in gene-gene interaction studies: multifactor dimensionality reduction applied to a two-stage breast cancer case-control study. **2008**, 29, 1215-8	21
1801	Reporting and interpretation in genome-wide association studies. **2008**, 37, 641-53	53
1800	Caffeic acid phenethyl ester induces apoptosis of human pancreatic cancer cells involving caspase and mitochondrial dysfunction. **2008**, 8, 566-76	50
1799	Genes and Sjğren's syndrome. **2008**, 34, 847-68, vii	43
1798	Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. **2008**, 14, 5931-7	36
1797	Chromosome copy number variation and breast cancer risk. **2008**, 123, 183-7	14
1796	The search for genes contributing to endometriosis risk. **2008**, 14, 447-57	156
1795	Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. **2008**, 105, 11264-9	155

1794	Population differences in breast cancer severity. **2008**, 9, 323-33		24
1793	Identification of personal risk of breast cancer: genetics. *Breast Cancer Research*, **2008**, 10 Suppl 4, S12	8.3	7
1792	A genomic "roadmap" to "better" drugs. **2008**, 40, 225-39		13
1791	Predicting Individual Radiation Sensitivity: Current and Evolving Technologies. **2008**, 170, 666-675		4
1790	Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. **2008**, 29, 2341-6		84
1789	Genetic susceptibility loci for breast cancer by estrogen receptor status. **2008**, 14, 8000-9		105
1788	Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. **2008**, 29, 2132-8		134
1787	Triple-negative breast cancer: risk factors to potential targets. **2008**, 14, 8010-8		336
1786	Required sample size and nonreplicability thresholds for heterogeneous genetic associations. **2008**, 105, 617-22		91
1785	Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. **2008**, 105, 4340-5		256
1784	Interrogating the genome to understand oestrogen-receptor-mediated transcription. **2008**, 10, e10		8
1783	Generating Linkage Disequilibrium Patterns in Data Simulations Using genomeSIMLA. **2008**, 24-35		29
1782	The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. **2008**, 68, 8104-12		108
1781	Comprehensive association testing of common genetic variation in DNA repair pathway genes in relationship with breast cancer risk in multiple populations. **2008**, 17, 825-34		38
1780	Familial risks for cancer as the basis for evidence-based clinical referral and counseling. **2008**, 13, 239-47		36
1779	Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies. **2008**, 9, 621-34		117
1778	The genome gets personal--almost. **2008**, 299, 1351-2		129
1777	Genomic profiles for disease risk: predictive or premature?. **2008**, 299, 1353-5		88

1776	Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy. **2008**, 17, 1457-64	32
1775	Genome-wide microarray expression analysis of CD4+ T Cells from nonobese diabetic congenic mice identifies Cd55 (Daf1) and Acadl as candidate genes for type 1 diabetes. **2008**, 180, 1071-9	19
1774	FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. **2008**, 17, 1060-5	47
1773	Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. **2008**, 100, 437-42	38
1772	Pharmacogenomics: candidate gene identification, functional validation and mechanisms. **2008**, 17, R174-9	49
1771	Association of genetic variants at 8q24 with breast cancer risk. **2008**, 17, 702-5	43
1770	Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. **2008**, 17, 3490-8	47
1769	Genomics and challenges toward personalized breast cancer local control. **2008**, 26, 4360-1; author reply 4361-2	75
1768	Expectations and challenges stemming from genome-wide association studies. **2008**, 23, 439-44	22
1767	The impact of direct-to-consumer marketing of cancer genetic testing on women according to their genetic risk. **2008**, 10, 888-94	18
1766	Genomic medicine in Mexico: initial steps and the road ahead. **2008**, 18, 1191-8	24
1765	Major trends in the imaging sciences: 2007 Eugene P. Pendergrass New Horizons Lecture. **2008**, 249, 403-9	8
1764	Comprehensive evaluation of ESR2 variation and ovarian cancer risk. **2008**, 17, 393-6	13
1763	Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. **2008**, 29, 1394-9	129
1762	Inherited predisposition to chronic lymphocytic leukemia. **2008**, 1, 51-61	17
1761	Penetrance analysis of the PALB2 c.1592delT founder mutation. **2008**, 14, 4667-71	84
1760	Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. **2008**, 100, 1037-41	192
1759	Polygenes, risk prediction, and targeted prevention of breast cancer. **2008**, 358, 2796-803	450

1758	Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. **2008**, 17, 2052-61	134
1757	Time to check CHEK2 in families with breast cancer?. **2008**, 26, 519-20	33
1756	Androgen receptor is a tumor suppressor and proliferator in prostate cancer. **2008**, 105, 12182-7	207
1755	CNVs and genetic medicine (excitement and consequences of a rediscovery). **2008**, 123, 7-16	16
1754	A range of cancers is associated with the rs6983267 marker on chromosome 8. **2008**, 68, 9982-6	103
1753	A germ-line-selective advantage rather than an increased mutation rate can explain some unexpectedly common human disease mutations. **2008**, 105, 10143-8	61
1752	Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk. **2008**, 23, 1661-8	12
1751	Variation of breast cancer risk among BRCA1/2 carriers. **2008**, 299, 194-201	213
1750	Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. **2008**, 4, e1000054	280
1749	Gene regulation in primates evolves under tissue-specific selection pressures. **2008**, 4, e1000271	115
1748	Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. **2008**, 17, 2665-72	66
1747	Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. **2008**, 29, 333-41	56
1746	Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. **2008**, 6, e108	220
1745	What can genome-wide association studies tell us about the genetics of common disease?. **2008**, 4, e33	102
1744	Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. **2008**, 4, e1000287	182
1743	IGF signaling pathway as a selective target of familial breast cancer therapy. **2008**, 8, 727-40	6
1742	Microarray technology and applications in the arena of genome-wide association. **2008**, 54, 1116-24	61
1741	Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. **2008**, 43, 505-15	214

1740	Performance of amplified DNA in an Illumina GoldenGate BeadArray assay. **2008**, 17, 1781-9	30
1739	Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. **2009**, 30, 269-74	79
1738	Evaluation of the potential excess of statistically significant findings in published genetic association studies: application to Alzheimer's disease. **2008**, 168, 855-65	34
1737	Drug-sensitive FGFR2 mutations in endometrial carcinoma. **2008**, 105, 8713-7	292
1736	Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. **2008**, 68, 8837-42	10
1735	Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. **2008**, 299, 2423-36	310
1734	The role of established breast cancer susceptibility loci in mammographic density in young women. **2008**, 17, 258-60	15
1733	Multiple loci with different cancer specificities within the 8q24 gene desert. **2008**, 100, 962-6	283
1732	Breast cancer onset in twins and women with bilateral disease. **2008**, 26, 4086-91	10
1731	Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. **2008**, 14, 1956-65	130
1730	An MCMC algorithm for haplotype assembly from whole-genome sequence data. **2008**, 18, 1336-46	88
1729	Hereditary Gynecologic Cancer. **2008**,	2
1728	Advances in breast cancer: pathways to personalized medicine. **2008**, 14, 7988-99	134
1727	Gene-environment interaction in genome-wide association studies. **2009**, 169, 219-26	208
1726	Translationale Forschung beim Mammakarzinom Workshop zur Erarbeitung neuer Forschungsideen im Rahmen des Biedenkopf Symposiums XIII der Banss-Stiftung. **2008**, 68, 1160-1165	
1725	Frequency of germline genomic homozygosity associated with cancer cases. **2008**, 299, 1437-45	40
1724	Taiwan Biobank: a project aiming to aid Taiwan's transition into a biomedical island. **2008**, 9, 235-46	81
1723	Pharmakogenetik in der antihormonellen Therapie von Patientinnen mit einem Mammakarzinom. **2008**, 68, 1192-1200	1

1722	The complex genetics of multiple sclerosis: pitfalls and prospects. **2008**, 131, 3118-31	83
1721	Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. **2008**, 68, 5997-6005	33
1720	Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists. **2008**, 17, 2007-11	29
1719	Cancer genetic association studies in the genome-wide age. **2008**, 5, 589-597	2
1718	SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways. **2008**, 7, 3564-76	49
1717	The environmental genome project: reference polymorphisms for drug metabolism genes and genome-wide association studies. **2008**, 40, 241-61	25
1716	Genome-wide association studies in cancer. **2008**, 17, R109-15	196
1715	Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. **2008**, 9, 561-84	18
1714	Disease phenocode analysis identifies SNP-guided microRNA maps (MirMaps) associated with human "master" disease genes. **2008**, 7, 3680-94	27
1713	Curses--winner's and otherwise--in genetic epidemiology. **2008**, 19, 649-51; discussion 657-8	360
1712	Identification of human minor histocompatibility antigens based on genetic association with highly parallel genotyping of pooled DNA. **2008**, 111, 3286-94	43
1711	Genome-wide association study identifies novel breast cancer susceptibility loci. **2008**, 2008, 18-20	1
1710	Early Phase Technology Assessment of Nanotechnology in Oncology. **2008**, 94, 284-291	10
1709	Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. **2008**, 3, e2656	116
1708	A HapMap harvest of insights into the genetics of common disease. **2008**, 118, 1590-605	683
1707	In Search of Breast Cancer Culprits: Suspecting the Suspected and the Unsuspected. **2008**, 1, 117822340800100	
1706	Comment prendre en compte le risque gñtique de cancer du sein ? Gñes impliqus et risques tumoraux associs. **2009**, 193, 2063-2085	
1705	Genomic Approaches to Complex Disease. **2009**, 33-46	

1704	. **2009**,	8
1703	Host genetic and epigenetic factors in toxoplasmosis. **2009**, 104, 162-9	18
1702	[Cancer genetics: estimation of the needs of the population in France for the next ten years]. **2009**, 96, 875-900	5
1701	[Estimation of individual breast cancer risk: relevance and limits of risk estimation models]. **2009**, 96, 979-88	6
1700	Translational Genomics: From Discovery to Clinical Practice. **2009**, 262-274	2
1699	An□isis de las mutaciones m□ frecuentes del gen BRCA1 (185delAG y 5382insC) en mujeres con c□cer de mama en Bucaramanga, Colombia. **2009**, 29, 61	4
1698	eRF3a/GSPT1 12-GGC allele increases the susceptibility for breast cancer development. **2009**, 21, 1551-8	18
1697	STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. **2009**, 6, e22	264
1696	Visualization of shared genomic regions and meiotic recombination in high-density SNP data. **2009**, 4, e6711	30
1695	How many genetic variants remain to be discovered?. **2009**, 4, e7969	41
1694	On Combining Data From Genome-Wide Association Studies to Discover Disease-Associated SNPs. **2009**, 24,	18
1693	A breast cancer risk haplotype in the caspase-8 gene. **2009**, 69, 2724-8	23
1692	High myopia is not associated with the SNPs in the TGIF, lumican, TGFB1, and HGF genes. **2009**, 50, 1546-51	37
1691	A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. **2009**, 30, 59-64	78
1690	Breast cancer single-nucleotide polymorphisms: statistical significance and clinical utility. **2009**, 101, 973-5	12
1689	Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. **2009**, 30, 2047-52	70
1688	Functional and clinical significance of variants localized to 8q24 in colon cancer. **2009**, 18, 2492-500	36
1687	Association of breast cancer susceptibility variants with risk of pancreatic cancer. **2009**, 18, 3044-8	20

1686	Polygenic susceptibility to breast cancer: current state-of-the-art. **2009**, 5, 689-701	29
1685	AXIS inhibition protein 2, orofacial clefts and a family history of cancer. **2009**, 140, 80-4	63
1684	Methods for analysis in pharmacogenomics: lessons from the Pharmacogenetics Research Network Analysis Group. **2009**, 10, 243-51	10
1683	DASSO-MB: Detection of Epistatic Interactions in Genome-Wide Association Studies Using Markov Blankets. **2009**,	0
1682	Local phylogeny mapping of quantitative traits: higher accuracy and better ranking than single-marker association in genomewide scans. **2009**, 181, 747-53	12
1681	Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. **2009**, 18, 2502-17	28
1680	Update on genetic predisposition to breast cancer. *Expert Review of Anticancer Therapy*, **2009**, 9, 1103-13 3.5	10
1679	Bladder cancer in cancer patients: population-based estimates from a large Swedish study. **2009**, 101, 1091-9	29
1678	Src stimulates fibroblast growth factor receptor-2 shedding by an ADAM15 splice variant linked to breast cancer. **2009**, 69, 4573-6	27
1677	An admixture scan in 1,484 African American women with breast cancer. **2009**, 18, 3110-7	42
1676	A neurologist's guide to genome-wide association studies. **2009**, 72, 558-65	26
1675	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. **2009**, 18, 2297-304	37
1674	A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. **2009**, 101, 24-36	143
1673	Association of ESR1 gene tagging SNPs with breast cancer risk. **2009**, 18, 1131-9	75
1672	Size matters: just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology. **2009**, 38, 263-73	192
1671	A Review of Lifetime Risk Factors for Mortality. **2009**, 15, 17-64	12
1670	Ancestral recombination graphs under non-random ascertainment, with applications to gene mapping. **2009**, 8, Article 35	1
1669	Genetic heterogeneity of 8q24 region in susceptibility to cancer. **2009**, 101, 278-9	11

1668	A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. **2009**, 69, 6685-93		53
1667	Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. **2009**, 18, 230-4		44
1666	Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. **2009**, 18, 1864-8		26
1665	The 6q22.33 locus and breast cancer susceptibility. **2009**, 18, 2468-75		22
1664	Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. **2009**, 18, 3079-85		51
1663	Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. **2009**, 15, 2181-91		46
1662	Statistical screening method for genetic factors influencing susceptibility to common diseases in a two-stage genome-wide association study. **2009**, 8, Article 46		
1661	Established and Suspected Risk Factors in Breast Cancer Aetiology. **2009**, 4, 82-87		11
1660	Identification of Novel Susceptibility Genes for Breast Cancer - Genome-Wide Association Studies or Evaluation of Candidate Genes?. **2009**, 4, 93-99		8
1659	FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). **2009**, 23, 307-11		87
1658	Genome-wide association studies: how predictable is a person's cancer risk?. *Expert Review of Anticancer Therapy*, **2009**, 9, 389-92	3.5	81
1657	Human genome connectivity code links disease-associated SNPs, microRNAs and pyknons. **2009**, 8, 925-30		4
1656	Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders. **2009**, 8, 3925-42		59
1655	Biomarkers for risk assessment and prevention of breast cancer. **2009**, 9, 482-99		12
1654	Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. **2009**, 10, 632-44		45
1653	Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. **2009**, 23, 1397-405		25
1652	Pharmakogenetik in der antihormonellen Therapie von Patientinnen mit einem Mammakarzinom. **2009**, 6, 104-112		
1651	Genome-wide association studies of coronary artery disease and heart failure: where are we going?. **2009**, 10, 213-23		18

1650	A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. **2009**, 69, 7459-65	121
1649	Genome-wide association analyses identify SPOCK as a key novel gene underlying age at menarche. **2009**, 5, e1000420	55
1648	Functional enhancers at the gene-poor 8q24 cancer-linked locus. **2009**, 5, e1000597	189
1647	Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. **2009**, 101, 1012-8	90
1646	Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility. **2009**, 30, 43-9	41
1645	Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. **2009**, 18, 3068-74	66
1644	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. **2009**, 18, 4442-56	91
1643	Mammary tumor development in dogs is associated with BRCA1 and BRCA2. **2009**, 69, 8770-4	88
1642	Landmarks in the history of cancer epidemiology. **2009**, 69, 2151-62	21
1641	GRM7 variants confer susceptibility to age-related hearing impairment. **2009**, 18, 785-96	145
1640	Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. **2009**, 30, 991-6	44
1639	State of the Evidence: The Connection Between Breast Cancer and the Environment. **2009**, 15, 43-78	53
1638	Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. **2009**, 18, 255-9	42
1637	CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. **2009**, 11, e12	119
1636	Common polymorphic transcript variation in human disease. **2009**, 19, 567-75	64
1635	FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. **2009**, 18, 1692-703	100
1634	The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. **2009**, 18, 2609-21	19
1633	No breast cancer association for transforming growth factor-beta pathway colorectal cancer single nucleotide polymorphisms. **2009**, 18, 1934-6	5

1632	Evaluation of the 8q24 prostate cancer risk locus and MYC expression. **2009**, 69, 5568-74	102
1631	Human genetic variations: Beacons on the pathways to successful ageing. **2009**, 130, 553-63	21
1630	HPD: an online integrated human pathway database enabling systems biology studies. **2009**, 10 Suppl 11, S5	32
1629	Missing call bias in high-throughput genotyping. **2009**, 10, 106	13
1628	Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients. **2009**, 10, 405	130
1627	Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study. **2009**, 9, 172	19
1626	Low-risk susceptibility alleles in 40 human breast cancer cell lines. **2009**, 9, 236	20
1625	A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population. **2009**, 9, 245	11
1624	Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort. **2009**, 9, 43	20
1623	Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study. **2009**, 112, 210-4	9
1622	Association of genetic profiles to Crohn's disease by linear combinations of single nucleotide polymorphisms. **2009**, 46, 131-8	3
1621	Negative regulation of fibroblast growth factor 10 (FGF-10) by polyoma enhancer activator 3 (PEA3). **2009**, 88, 371-84	7
1620	Genome-wide association studies and the genetic dissection of complex traits. **2009**, 84, 504-15	55
1619	Bipolar disorder in the Bulgarian Gypsies: genetic heterogeneity in a young founder population. **2009**, 150B, 191-201	9
1618	Bayes factors for genome-wide association studies: comparison with P-values. **2009**, 33, 79-86	266
1617	An optimal dose-effect mode trend test for SNP genotype tables. **2009**, 33, 114-27	16
1616	Unbiased estimation of odds ratios: combining genomewide association scans with replication studies. **2009**, 33, 406-18	42
1615	STrengthening the REporting of Genetic Association Studies (STREGA)--an extension of the STROBE statement. **2009**, 33, 581-98	134

1614	Genome-wide association scans for secondary traits using case-control samples. **2009**, 33, 717-28		89
1613	Correcting "winner's curse" in odds ratios from genomewide association findings for major complex human diseases. **2010**, 34, 78-91		58
1612	Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. **2009**, 30, 79-84		330
1611	Genetic variations as cancer prognostic markers: review and update. **2009**, 30, 1369-77		25
1610	Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations. **2009**, 124, 729-33		5
1609	Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. **2009**, 124, 2077-81		17
1608	FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan. **2009**, 125, 1946-52		45
1607	Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. **2009**, 125, 1868-75		56
1606	Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk. **2010**, 116, 8-19		19
1605	Breast cancer risk is not increased in individuals with TWIST1 mutation confirmed Saethre-Chotzen syndrome: an Australian multicenter study. **2009**, 48, 533-8		3
1604	The search for genetic polymorphisms in the homocysteine/folate pathway that contribute to the etiology of human neural tube defects. **2009**, 85, 285-94		65
1603	Breast cancer screening in women at high risk using MRI. **2009**, 22, 17-27		22
1602	Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. **2009**, 125, 131-51		136
1601	Analytical methods for inferring functional effects of single base pair substitutions in human cancers. **2009**, 126, 481-98		17
1600	Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population. *Breast Cancer Research and Treatment*, **2009**, 114, 347-55	4.4	51
1599	A pilot genome-wide association study of early-onset breast cancer. *Breast Cancer Research and Treatment*, **2009**, 114, 463-77	4.4	17
1598	Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?. *Breast Cancer Research and Treatment*, **2009**, 115, 381-90	4.4	76
1597	Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. *Breast Cancer Research and Treatment*, **2009**, 117, 183-91	4.4	43

1596	CHEK2 1100delC and male breast cancer in the Netherlands. *Breast Cancer Research and Treatment*, **2009**, 116, 397-400	4.4	42
1595	Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model. *Breast Cancer Research and Treatment*, **2009**, 117, 517-24	4.4	15
1594	Low penetrance breast cancer predisposition SNPs are site specific. *Breast Cancer Research and Treatment*, **2009**, 117, 151-9	4.4	34
1593	Surveying germline genomic landscape of breast cancer. *Breast Cancer Research and Treatment*, **2009**, 113, 601-3	4.4	3
1592	Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. *Breast Cancer Research and Treatment*, **2009**, 114, 121-6	4.4	12
1591	Family-based genetic association study of insulin-like growth factor I microsatellite markers and premenopausal breast cancer risk. *Breast Cancer Research and Treatment*, **2009**, 118, 415-24	4.4	5
1590	Family cancer history affecting risk of colorectal cancer in a prospective cohort of Chinese women. **2009**, 20, 1517-21		7
1589	Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. **2009**, 28, 269-80		29
1588	Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE statement. **2009**, 24, 37-55		35
1587	SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women. **2009**, 8, 135-44		4
1586	The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women. **2009**, 8, 399-402		9
1585	Genome-wide association studies in the genetics of asthma. **2009**, 9, 3-9		19
1584	Clinical implications of low-penetrance breast cancer susceptibility alleles. **2009**, 11, 8-14		4
1583	Novel strategies to mine alcoholism-related haplotypes and genes by combining existing knowledge framework. **2009**, 52, 163-72		2
1582	Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development. **2009**, 3, 31-40		4
1581	Refining BRCA1 and BRCA2 penetrance estimates in the clinic. **2009**, 1, 127-130		1
1580	Genome-wide association studies identify new breast cancer susceptibility genes. **2009**, 1, 131-138		3
1579	The PsyCoLaus study: methodology and characteristics of the sample of a population-based survey on psychiatric disorders and their association with genetic and cardiovascular risk factors. **2009**, 9, 9		133

1578	Genetics and visceral leishmaniasis: of mice and man. **2009**, 31, 254-66		80
1577	STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. **2009**, 39, 247-66		190
1576	The combined effect of SNP-marker and phenotype attributes in genome-wide association studies. **2009**, 40, 149-56		19
1575	Variation near complement factor I is associated with risk of advanced AMD. **2009**, 17, 100-4		290
1574	Genome-wide association studies in amyotrophic lateral sclerosis. **2009**, 17, 137-8		3
1573	Breast cancer susceptibility: current knowledge and implications for genetic counselling. **2009**, 17, 722-31		139
1572	Genomics and breast cancer: the different levels of inherited susceptibility. **2009**, 17, 855-6		17
1571	Joint analysis of tightly linked SNPs in screening step of genome-wide association studies leads to increased power. **2009**, 17, 1043-9		15
1570	Association of FGFR2 gene polymorphisms with the risk of breast cancer in population of West Siberia. **2009**, 17, 1688-91		23
1569	FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. *Journal of Investigative Dermatology*, **2009**, 129, 1861-7	4.3	59
1568	Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. **2009**, 22, 1401-14		91
1567	Genome-wide association analyses suggested a novel mechanism for smoking behavior regulated by IL15. **2009**, 14, 668-80		39
1566	Parental origin of sequence variants associated with complex diseases. *Nature*, **2009**, 462, 868-74	50.4	459
1565	Dynamic modularity in protein interaction networks predicts breast cancer outcome. **2009**, 27, 199-204		568
1564	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. **2009**, 41, 221-7		509
1563	Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. **2009**, 41, 324-8		434
1562	JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. **2009**, 41, 446-9		320
1561	A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). **2009**, 41, 579-84		452

1560	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. **2009**, 41, 585-90	393
1559	Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. **2009**, 41, 718-23	226
1558	Genome-wide association study identifies five susceptibility loci for glioma. **2009**, 41, 899-904	640
1557	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. **2009**, 41, 991-5	270
1556	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. **2009**, 41, 996-1000	240
1555	Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. **2009**, 41, 1110-5	356
1554	Identification of a new prostate cancer susceptibility locus on chromosome 8q24. **2009**, 41, 1055-7	201
1553	Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. **2009**, 41, 1122-6	281
1552	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. **2009**, 41, 1116-21	360
1551	Multiple loci on 8q24 associated with prostate cancer susceptibility. **2009**, 41, 1058-60	252
1550	High-resolution identification of balanced and complex chromosomal rearrangements by 4C technology. **2009**, 6, 837-42	75
1549	p53 polymorphisms: cancer implications. **2009**, 9, 95-107	492
1548	Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. **2009**, 9, 134-42	450
1547	Beyond odds ratios--communicating disease risk based on genetic profiles. **2009**, 10, 264-9	113
1546	Validating, augmenting and refining genome-wide association signals. **2009**, 10, 318-29	306
1545	Detecting gene-gene interactions that underlie human diseases. **2009**, 10, 392-404	990
1544	Systems genetics analysis of cancer susceptibility: from mouse models to humans. **2009**, 10, 651-7	45
1543	Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. **2009**, 100, 412-20	42

1542	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). **2009**, 101, 2048-54	13
1541	Risk factors for breast cancer in East Asian women relative to women in the West. **2009**, 5, 219-231	16
1540	Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. **2009**, 8, 460-72	279
1539	Molecular epidemiology of primary brain tumors. **2009**, 6, 427-35	72
1538	Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"?. **2009**, 16, 774-5; author reply 776-7	85
1537	Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. **2009**, 16, 772-3	97
1536	Reply to Human Genetic and Structural Genomic Variation: Would Genomewide Association Studies be the Solution of Cancer Complexity Like Alexander the Great for the Gordian Knot? **2009**, 16, 776-777	1
1535	Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. **2009**, 16, 1771-82	80
1534	Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. **2009**, 4, 461-87	155
1533	Epistasis and its implications for personal genetics. **2009**, 85, 309-20	262
1532	Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. **2009**, 85, 427-46	140
1531	Using lifetime risk estimates in personal genomic profiles: estimation of uncertainty. **2009**, 85, 786-800	27
1530	The Hygiene Hypothesis and Darwinian Medicine. **2009**,	17
1529	Breast cancer: beyond the cutting edge. **2009**, 10, 2479-98	9
1528	Evaluation of 11 breast cancer susceptibility loci in African-American women. **2009**, 18, 2761-4	71
1527	Genetic issues in patients with breast cancer. **2009**, 18, 53-71, viii	5
1526	Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer. **2009**, 47, 214-23	22
1525	Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study. **2009**, 45, 435-42	36

1524	HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. *Bone*, **2009**, 45, 1098-103	4.7	42
1523	Expression of DNA damage response genes indicate progressive breast tumors. **2009**, 273, 305-11		9
1522	Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. **2009**, 27, 373-6		14
1521	Genome-wide association studies in type 1 diabetes, inflammatory bowel disease and other immune-mediated disorders. **2009**, 21, 355-62		15
1520	Genetic association analysis of copy-number variation (CNV) in human disease pathogenesis. **2009**, 93, 22-6		145
1519	Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer. **2009** , 116, 134-53		11
1518	Gene polymorphisms that may influence the biological effects of progestins. **2009**, 62, 366-70		1
1517	Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. **2009**, 62, 597-608.e4		77
1516	Genomic instability in the breast microenvironment? A critical evaluation of the evidence. **2009**, 9, 667-78		8
1515	The contribution of BRCA1 and BRCA2 to ovarian cancer. **2009**, 3, 138-50		125
1514	Review on early technology assessments of nanotechnologies in oncology. **2009**, 3, 394-401		23
1513	The inherited genetic component of sporadic pancreatic adenocarcinoma. **2009**, 9, 206-14		8
1512	How to use an article about genetic association: A: Background concepts. **2009**, 301, 74-81		68
1511	Single-nucleotide polymorphism (SNP) analysis to associate cancer risk. *Methods in Molecular Biology*, **2010**, 576, 171-96	1.4	5
1510	The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. **2009**, 102, 360-70		155
1509	Nature versus nurture in determining athletic ability. **2009**, 54, 11-27		6
1508	High-Dimensional Data Analysis in Cancer Research. **2009**,		2
1507	Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast. *Breast Cancer Research*, **2009**, 11, R88	8.3	26

1506	A constant risk for familial breast cancer? A population-based family study. *Breast Cancer Research*, **2009**, 11, R30	8.3	2
1505	Association between breast cancer susceptibility loci and mammographic density: the Multiethnic Cohort. *Breast Cancer Research*, **2009**, 11, R10	8.3	22
1504	Enrichment of sequencing targets from the human genome by solution hybridization. **2009**, 10, R116		92
1503	Using prior knowledge and genome-wide association to identify pathways involved in multiple sclerosis. **2009**, 1, 65		21
1502	Systems medicine: the future of medical genomics and healthcare. **2009**, 1, 2		279
1501	The Breast. **2009**, 235-248		0
1500	A decade of cancer gene profiling: from molecular portraits to molecular function. *Methods in Molecular Biology*, **2010**, 576, 61-87	1.4	9
1499	DNA variations in human and medical genetics: 25 years of my experience. **2009**, 54, 1-8		52
1498	Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk. **2009**, 18, 1461-7		37
1497	Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases?. **2009**, 112, c213-21		24
1496	Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer. **2009**, 15, 2192-203		29
1495	Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. **2009**, 9, 1-6		92
1494	Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. **2009**, 92, 299-309		139
1493	Association between an 8q24 locus and the risk of colorectal cancer in Japanese. **2009**, 9, 379		32
1492	Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. **2009**, 175, 1292-302		55
1491	Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. **2009**, 18, 1332-42		112
1490	Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer. **2009**, 10, 181-90		51
1489	A genome-wide association study primer for clinicians. **2009**, 48, 89-95		15

1488	Triple negative breast cancers: clinical and prognostic implications. **2009**, 45 Suppl 1, 27-40		173
1487	Genetics of Asthma and Bronchial Hyperresponsiveness. **2009**, 161-187		
1486	TNRC9/LOC643714 polymorphisms are not associated with breast cancer risk in Chinese women. **2009**, 18, 285-90		12
1485	Genome-wide association study for type 2 diabetes: clinical applications. **2009**, 20, 87-91		34
1484	Genome-wide Association Studies. **2009**,		0
1483	Genome-wide Association Studies: The Success, Failure and Future. **2009**,		
1482	De Gruyter. **2009**, 81,		
1481	Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. **2009**, 113, 5575-82		80
1480	Enabling personal genomics with an explicit test of epistasis. *Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing*, **2010**, 327-36	1.3	31
1479	STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE Statement. **2009**, 150, 206-15		87
1478	??????SNP????????? ????????. **2009**, 47, 28-34		
1477	The role of a general cognitive factor in the evolution of human intelligence. 57-96		
1476	The Polycystic Ovary Syndrome □Challenges and Opportunities in Adolescent Medicine. **2009**, 316-339		1
1475	Molecular genetics analysis of hereditary breast and ovarian cancer patients in India. **2009**, 7, 13		16
1474	GIST and Breast Cancer: 3 Case Reports and a Review of the Literature. **2009**, 5, 100-104		0
1473	Pharmacogenetics and functional genomics in asthma. **2009**, 6, 409-416		0
1472	Breast cancer in the personal genomics era. **2010**, 11, 146-61		56
1471	ASSESSMENT OF EXPOSURE TO PERSISTENT ORGANOCHLORINE COMPOUNDS IN EPIDEMIOLOGICAL STUDIES ON BREAST CANCER: A LITERATURE REVIEW AND PERSPECTIVES FOR THE CECILE STUDY. **2010**, 65, 49-57		5

1470	Evaluating cancer epidemiologic risk factors using multiple primary malignancies. **2010**, 21, 366-72		15
1469	Recent advances in the genetics and genomics of asthma and related traits. **2010**, 22, 307-12		9
1468	Genetic bases for glaucoma. **2010**, 221, 1-10		47
1467	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. *Breast Cancer Research*, **2010**, 12, R110	8.3	74
1466	A principal stratification approach to assess the differences in prognosis between cancers caused by hormone replacement therapy and by other factors. **2010**, 6, Article 20		2
1465	Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer. **2010**, 17, 1675-81		7
1464	Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. **2010**, 10, 33-48		82
1463	Leveraging genetic variability across populations for the identification of causal variants. **2010**, 86, 23-33		103
1462	Powerful SNP-set analysis for case-control genome-wide association studies. **2010**, 86, 929-42		425
1461	Genetics of prostate cancer risk. **2010**, 77, 643-54		19
1460	Prioritizing candidate genetic modifiers of BRCA1 and BRCA2 using a combinatorial analysis of global expression and polymorphism association studies of breast cancer. *Methods in Molecular Biology*, **2010**, 653, 23-34	1.4	1
1459	Genome-wide association studies and beyond. **2010**, 31, 9-20 4 p following 20		96
1458	[Hereditary breast and ovarian cancers]. **2010**, 31, 438-44		1
1457	Das familiäre Mammakarzinom. **2010**, 43, 79-86		
1456	Power analysis for case-control association studies of samples with known family histories. **2010**, 127, 699-704		18
1455	[Genes beyond BRCA1 and BRCA2 for hereditary breast cancer]. **2010**, 160, 478-82		
1454	Estrogen receptor alpha polymorphisms and the risk of malignancies. **2010**, 16, 485-96		30
1453	Fibroblast growth factor receptors (FGFR) as possible therapeutic targets in human non-small cell lung cancer. **2010**, 3, 23-26		

1452	Evaluating variations of genotype calling: a potential source of spurious associations in genome-wide association studies. *Journal of Genetics*, **2010**, 89, 55-64	1.2	11
1451	Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. *Breast Cancer Research and Treatment*, **2010**, 119, 491-6	4.4	26
1450	Variation in genes required for normal mitosis and risk of breast cancer. *Breast Cancer Research and Treatment*, **2010**, 119, 423-30	4.4	26
1449	Association of genetic variation in mitotic kinases with breast cancer risk. *Breast Cancer Research and Treatment*, **2010**, 119, 453-62	4.4	21
1448	Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. *Breast Cancer Research and Treatment*, **2010**, 119, 511-27	4.4	3
1447	Mutation screening of the MERIT40 gene encoding a novel BRCA1 and RAP80 interacting protein in breast cancer families. *Breast Cancer Research and Treatment*, **2010**, 120, 165-8	4.4	12
1446	Genetic contribution of GADD45A to susceptibility to sporadic and non-BRCA1/2 familial breast cancers: a systematic evaluation in Chinese populations. *Breast Cancer Research and Treatment*, **2010**, 121, 157-67	4.4	7
1445	A novel germline CHEK2 deletion truncating the kinase domain identified in a French family with high-risk of breast/ovarian cancer. *Breast Cancer Research and Treatment*, **2010**, 120, 267-70	4.4	2
1444	Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1. *Breast Cancer Research and Treatment*, **2010**, 121, 485-96	4.4	26
1443	No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk. *Breast Cancer Research and Treatment*, **2010**, 121, 497-502	4.4	23
1442	Association of rare MSH6 variants with familial breast cancer. *Breast Cancer Research and Treatment* , **2010**, 123, 315-20	4.4	9
1441	Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. *Breast Cancer Research and Treatment*, **2010**, 119, 685-99	4.4	70
1440	Subtypes of familial breast tumours revealed by expression and copy number profiling. *Breast Cancer Research and Treatment*, **2010**, 123, 661-77	4.4	81
1439	Genetic variants on chromosome 5p12 are associated with risk of breast cancer in African American women: the Black Women's Health Study. *Breast Cancer Research and Treatment*, **2010**, 123, 525-30	4.4	24
1438	Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population. *Breast Cancer Research and Treatment*, **2010**, 124, 237-41	4.4	25
1437	Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. *Breast Cancer Research and Treatment*, **2010**, 123, 581-5	4.4	15
1436	Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis. *Breast Cancer Research and Treatment*, **2010**, 124, 419-24	4.4	20
1435	Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer. *Breast Cancer Research and Treatment*, **2010**, 124, 521-8	4.4	21

1434	Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation. *Breast Cancer Research and Treatment*, **2010**, 123, 901-5	4.4	9
1433	Mutation and association analysis of GEN1 in breast cancer susceptibility. *Breast Cancer Research and Treatment*, **2010**, 124, 283-8	4.4	7
1432	Combined UGT1A1 and UGT1A6 genotypes together with a stressful life event increase breast cancer risk. *Breast Cancer Research and Treatment*, **2010**, 124, 289-92	4.4	13
1431	Birth weight, breast cancer susceptibility loci, and breast cancer risk. **2010**, 21, 689-96		23
1430	Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women. **2010**, 21, 897-908		14
1429	The UK DNA banking network: a "fair access" biobank. **2010**, 11, 241-51		35
1428	Genome-wide association studies in economics and entrepreneurship research: promises and limitations. **2010**, 35, 1-18		34
1427	RASSF1A polymorphism in familial breast cancer. **2010**, 9, 263-5		15
1426	Breast cancer susceptibility variants alter risk in familial ovarian cancer. **2010**, 9, 503-6		4
1425	Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families. **2010**, 9, 537-40		12
1424	Identifying disease polymorphisms from case-control genetic association data. **2010**, 138, 1147-59		3
1423	Direct-to-Consumer Genetic and Genomic Testing: Preparing Nurse Practitioners for Genomic Healthcare. **2010**, 6, 585-594		5
1422	De-regulated FGF receptors as therapeutic targets in cancer. **2010**, 125, 105-17		140
1421	Genetic variation and risk of chronic lymphocytic leukaemia. **2010**, 20, 363-9		13
1420	Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. **2010**, 26, 132-41		121
1419	A method of predicting changes in human gene splicing induced by genetic variants in context of cis-acting elements. **2010**, 11, 22		15
1418	Inferring linkage disequilibrium from non-random samples. **2010**, 11, 328		6
1417	Association of DNMT1 gene polymorphisms in exons with sporadic infiltrating ductal breast carcinoma among Chinese Han women in the Heilongjiang Province. *Clinical Breast Cancer*, **2010**, 10, 373-7		22

1416	STAMP alters the growth of transformed and ovarian cancer cells. **2010**, 10, 128	6
1415	Characterization of the association between 8q24 and colon cancer: gene-environment exploration and meta-analysis. **2010**, 10, 670	50
1414	ERCC1 haplotypes modify bladder cancer risk: a case-control study. **2010**, 9, 191-200	26
1413	MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity?. **2010**, 1805, 72-86	35
1412	Cancer genetics and reproduction. **2010**, 24, 3-18	1
1411	rs2981582 is associated with FGFR2 expression in normal breast. **2010**, 197, 193-4	20
1410	Distribution of FGFR2, TNRC9, MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus elderly tumor-free women. **2010**, 199, 69-72	32
1409	Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families. **2010**, 49, 1082-94	6
1408	Bayesian mixture models for the incorporation of prior knowledge to inform genetic association studies. **2010**, 34, 418-26	14
1407	Evaluating the power to discriminate between highly correlated SNPs in genetic association studies. **2010**, 34, 463-8	43
1406	Identifying genetic interactions in genome-wide data using Bayesian networks. **2010**, 34, 575-81	48
1405	Pooled versus individual genotyping in a breast cancer genome-wide association study. **2010**, 34, 603-12	10
1404	Identifying candidate causal variants via trans-population fine-mapping. **2010**, 34, 653-64	27
1403	SNP selection in genome-wide and candidate gene studies via penalized logistic regression. **2010**, 34, 879-91	133
1402	Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients. **2010**, 126, 2858-62	22
1401	Genotyping and LOH Analysis on Archival Tissue using SNP Arrays. **2010**, 49-66	
1400	Genetic Mapping of Complex Traits. **2010**, 67-90	1
1399	Quantitative understanding of cell signaling: the importance of membrane organization. **2010**, 21, 677-82	27

1398	Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. **2010**, 76, S145-50	55
1397	A Markov blanket-based method for detecting causal SNPs in GWAS. **2010**, 11 Suppl 3, S5	42
1396	The impact of incomplete linkage disequilibrium and genetic model choice on the analysis and interpretation of genome-wide association studies. **2010**, 74, 375-9	6
1395	Bayesian methods for examining Hardy-Weinberg equilibrium. **2010**, 66, 257-65	24
1394	Genetic risk information for common diseases may indeed be already useful for prevention and early detection. **2010**, 40, 56-63	30
1393	Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. **2010**, 29, 2013-23	318
1392	Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. **2010**, 29, 6071-83	53
1391	Sporadic cases are the norm for complex disease. **2010**, 18, 1039-43	78
1390	Risk of breast and prostate cancer is not associated with increased homozygosity in outbred populations. **2010**, 18, 909-14	30
1389	Assessing sources of inconsistencies in genotypes and their effects on genome-wide association studies with HapMap samples. **2010**, 10, 364-74	18
1388	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. **2010**, 42, 132-6	196
1387	Variance component model to account for sample structure in genome-wide association studies. **2010**, 42, 348-54	1624
1386	Genome-wide association study identifies five new breast cancer susceptibility loci. **2010**, 42, 504-7	582
1385	Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. **2010**, 42, 570-5	498
1384	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. **2010**, 42, 885-92	276
1383	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. **2010**, 42, 978-84	408
1382	A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). **2010**, 42, 1126-1130	158
1381	Fibroblast growth factor signalling: from development to cancer. **2010**, 10, 116-29	1768

1380	Breast and prostate cancer: familial associations. **2010**, 10, 523	8
1379	Architecture of inherited susceptibility to common cancer. **2010**, 10, 353-61	161
1378	Kinase mutations in human disease: interpreting genotype-phenotype relationships. **2010**, 11, 60-74	250
1377	Methodological challenges of genome-wide association analysis in Africa. **2010**, 11, 149-60	143
1376	Testing for CHEK2 in the cancer genetics clinic: ready for prime time?. **2010**, 78, 1-7	45
1375	Clinical validity assessment of a breast cancer risk model combining genetic and clinical information. **2010**,	0
1374	Principles for the post-GWAS functional characterisation of risk loci. **2010**,	1
1373	Signaling from Fibroblast Growth Factor Receptors in Development and Disease. **2010**, 1939-1947	
1372	Inherited Susceptibility to Complex Disease. **2010**, 297-323	
1371	Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer. **2010**, 23, 1641-5	5
1370	Germline mutations and polymorphisms in the origins of cancers in women. **2010**, 2010, 297671	32
1369	Germline variation controls the architecture of somatic alterations in tumors. **2010**, 6, e1001136	31
1368	Multidimensional gene set analysis of genomic data. **2010**, 5, e10348	53
1367	Exploring the link between germline and somatic genetic alterations in breast carcinogenesis. **2010**, 5, e14078	31
1366	Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer. **2010**, 5, e15094	15
1365	BeadDatapackR: A Tool to Facilitate the Sharing of Raw Data from Illumina BeadArray Studies. **2010**, 9, 117693511000900	1
1364	Epidemiology of female breast cancer. 1-12	
1363	Estrogen receptor alpha polymorphisms: correlation with clinicopathological parameters in breast cancer. **2010**, 57, 306-15	15

1362	Phenotypic and Genotypic Variation. 155-156	
1361	Human Adaptation to High Altitude. 170-191	1
1360	Molecular and functional genetics of hepatocellular carcinoma. **2010**, 2, 117-34	17
1359	Search for cancer risk factors with microarray-based genome-wide association studies. **2010**, 9, 107-21	7
1358	Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. **2010**, 16, 5750-8	62
1357	A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. **2010**, 102, 846-58	58
1356	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. **2010**, 70, 9742-54	147
1355	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. **2010**, 19, 2886-97	56
1354	Predictive and prognostic molecular markers for cancer medicine. **2010**, 2, 125-48	138
1353	A genome-wide association study of prognosis in breast cancer. **2010**, 19, 1140-3	56
1352	[Search for new genes involved in breast tumorigenesis by "Omics" analysis]. **2010**, 97, 1365-80	
1351	Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. **2010**, 16, 4165-77	37
1350	Association mapping of quantitative disease resistance in a natural population of loblolly pine (Pinus taeda L.). **2010**, 186, 677-86	79
1349	Mammary gland growth factors: roles in normal development and in cancer. **2010**, 2, a003186	68
1348	Common genetic variants associated with breast cancer and mammographic density measures that predict disease. **2010**, 70, 1449-58	63
1347	Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. **2010**, 70, 4453-9	100
1346	No association between TERT-CLPTM1L single nucleotide polymorphism rs401681 and mean telomere length or cancer risk. **2010**, 19, 1862-5	40
1345	Risk of urinary bladder cancer is associated with 8q24 variant rs9642880[T] in multiple racial/ethnic groups: results from the Los Angeles-Shanghai case-control study. **2010**, 19, 3150-6	15

1344	Roles of fibroblast growth factor receptors in carcinogenesis. **2010**, 8, 1439-52		223
1343	Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. *Expert Review of Anticancer Therapy*, **2010**, 10, 1375-9	3.5	30
1342	Assessing women at high risk of breast cancer: a review of risk assessment models. **2010**, 102, 680-91		334
1341	Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. **2010**, 102, 972-81		73
1340	varLD: a program for quantifying variation in linkage disequilibrium patterns between populations. **2010**, 26, 1269-70		46
1339	Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. **2010**, 19, 3873-84		39
1338	DataSHIELD: resolving a conflict in contemporary bioscience--performing a pooled analysis of individual-level data without sharing the data. **2010**, 39, 1372-82		102
1337	GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. **2010**, 70, 7630-9		116
1336	The influence of common polymorphisms on breast cancer. **2010**, 155, 15-32		9
1335	Genetic variation of DKK3 may modify renal disease severity in ADPKD. **2010**, 21, 1510-20		49
1334	Genome-wide association studies in cancer--current and future directions. **2010**, 31, 111-20		82
1333	Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. **2010**, 304, 426-34		88
1332	Molecular diagnostics: between chips and customized medicine. **2010**, 48, 973-82		13
1331	Power to detect selective allelic amplification in genome-wide scans of tumor data. **2010**, 26, 518-28		7
1330	Long-range enhancers on 8q24 regulate c-Myc. **2010**, 107, 3001-5		182
1329	Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists. **2010**, 173, 214-24		27
1328	Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. **2010**, 19, 2143-51		31
1327	Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. **2010**, 16, 3769-78		52

1326	Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin. **2010**, 19, 1848-54	11
1325	Genetic counselling for hereditary predisposition to ovarian and breast cancer. **2010**, 21 Suppl 7, vii334-8	5
1324	FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. **2010**, 70, 2085-94	533
1323	Potential for targeting the fibroblast growth factor receptors in breast cancer. **2010**, 70, 5199-202	49
1322	Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. **2010**, 70, 4151-62	148
1321	MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein. **2010**, 285, 38818-31	18
1320	An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. **2010**, 20, 1191-7	162
1319	8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. **2010**, 107, 9742-6	295
1318	Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis. **2010**, 107, 17268-73	16
1317	Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. **2010**, 30, 1411-20	218
1316	Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". **2010**, 6, e1001016	42
1315	Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. **2010**, 6, e1001012	36
1314	Whole-genome linkage and association scan in primary, nonsyndromic vesicoureteric reflux. **2010**, 21, 113-23	51
1313	Quantification of population structure using correlated SNPs by shrinkage principal components. **2010**, 70, 9-22	40
1312	Identification of a functional genetic variant at 16q12.1 for breast cancer risk: results from the Asia Breast Cancer Consortium. **2010**, 6, e1001002	93
1311	Role of traditional and new biomarkers in breast carcinogenesis. **2009**, 3, 157	1
1310	Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. **2010**, 102, 650-62	45
1309	Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer. **2010**, 19, 74-9	18

1308	An interactive effect of batch size and composition contributes to discordant results in GWAS with the CHIAMO genotyping algorithm. **2010**, 10, 355-63		10
1307	Chromosome 8q24-Associated Cancers and MYC. **2010**, 1, 555-9		73
1306	Pathology of hereditary breast cancer. **2010**, 23 Suppl 2, S46-51		57
1305	MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility. **2010**, 8, 289-305		1
1304	New insights into susceptibility to glioma. **2010**, 67, 275-8		26
1303	Breast cancer as an infectious disease. **2010**, 6, 5-8		2
1302	Bioinformatics challenges for genome-wide association studies. **2010**, 26, 445-55		401
1301	Molecular Techniques for DNA Methylation Studies. **2010**, 199-228		1
1300	Genomewide association studies and assessment of the risk of disease. **2010**, 363, 166-76		1098
1299	Pharmacogenetics and Pharmacogenomics. **2010**, 325-345		
1298	Two-stage testing strategies for genome-wide association studies in family-based designs. *Methods in Molecular Biology*, **2010**, 620, 485-96	1.4	5
1297	Translational Genomics. **2010**, 163-174		
1296	The HapMap Project and Low-Penetrance Cancer Susceptibility Alleles. **2010**, 195-204		
1295	Genetic susceptibility to breast cancer. **2010**, 4, 174-91		236
1294	Role of Polymorphisms in Cancer Susceptibility. **2010**,		
1293	NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. **2010**, 9, 113		44
1292	A genome-wide association scan on estrogen receptor-negative breast cancer. *Breast Cancer Research*, **2010**, 12, R93	8.3	32
1291	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2010**, 12, R102	8.3	21

1290	Genetica. **2010**, 9, 155-159	
1289	Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. **2010**, 70, 2789-98	314
1288	Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. **2010**, 102, 1618-27	133
1287	A meta-analysis of four genome-wide association studies of survival to age 90 years or older: the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. **2010**, 65, 478-87	107
1286	Fine scale mapping of the breast cancer 16q12 locus. **2010**, 19, 2507-15	57
1285	Gender Differences in Hereditary Cancer Syndromes. **2010**, 481-494	
1284	Breast cancer susceptibility variants alter risks in familial disease. **2010**, 47, 126-31	34
1283	Evaluation of breast cancer susceptibility loci in Chinese women. **2010**, 19, 2357-65	87
1282	Polymorphisms in the TOX3/LOC643714 locus and risk of breast cancer in African-American women. **2010**, 19, 1320-7	44
1281	FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. **2010**, 31, 1417-23	100
1280	Human Evolution. **2010**, 529-555	
1279	Ensembl Genome Browser. **2010**, 923-939	3
1278	GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients. **2010**, 118, 7-12	27
1277	Unique features of breast cancer in Asian women--breast cancer in Taiwan as an example. **2010**, 118, 300-3	37
1276	[Endometriosis and genetics: what responsibility for the genes?]. **2010**, 39, 196-207	10
1275	Low-penetrance susceptibility to hematological malignancy. **2010**, 20, 245-50	7
1274	Common genetic variants and cancer risk in Mendelian cancer syndromes. **2010**, 20, 299-307	23
1273	Genome-wide association studies in common cancers--what have we learnt?. **2010**, 20, 201-9	86

1272	Genetic dissection of intermediate phenotypes as a way to discover novel cancer susceptibility alleles. **2010**, 20, 308-14		5
1271	Breast cancer risk, dietary intake, and methylenetetrahydrofolate reductase (MTHFR)single nucleotide polymorphisms. **2010**, 48, 1881-5		29
1270	[Cancer genetic predisposition: current events and perspectives in 2010]. **2010**, 58, 324-30		2
1269	The pursuit of genome-wide association studies: where are we now?. **2010**, 55, 195-206		172
1268	The molecular pathology of cancer. **2010**, 7, 251-65		182
1267	Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. **2010**, 375, 2143-51		97
1266	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. **2010**, 376, 235-44		1395
1265	Genome-wide association studies of cancer predisposition. **2010**, 24, 973-96		33
1264	Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. **2010**, 176, 2333-43		15
1263	Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer. **2010**, 177, 2860-9		8
1262	Multiple genetic variants in telomere pathway genes and breast cancer risk. **2010**, 19, 219-28		42
1261	Genome-wide association studies of cancer. **2010**, 28, 4255-67		127
1260	Molecular epidemiology and its current clinical use in cancer management. **2010**, 11, 383-90		30
1259	Narrowing the boundaries of the genetic architecture of schizophrenia. **2010**, 36, 14-23		86
1258	Development of a scoring system to screen for BRCA1/2 mutations. *Methods in Molecular Biology*, **2010**, 653, 237-47	1.4	6
1257	Statistical Methods in Molecular Biology. *Methods in Molecular Biology*, **2010**,	1.4	10
1256	Understanding the evolution of defense metabolites in Arabidopsis thaliana using genome-wide association mapping. **2010**, 185, 991-1007		142
1255	Performance of common genetic variants in breast-cancer risk models. **2010**, 362, 986-93		334

1254	Cancer Gene Profiling. *Methods in Molecular Biology*, **2010**,	1.4	1
1253	Receptor Tyrosine Kinases. 119-213		
1252	Breast Cancer Epidemiology. **2010**,		23
1251	Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer. *Breast Cancer Research*, **2010**, 12, R19	8.3	14
1250	Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. *Breast Cancer Research*, **2010**, 12, R10	8.3	27
1249	Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencing. **2010**, 11, R114		32
1248	Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?. **2010**, 2, 45		19
1247	Principles of Clinical Cancer Genetics. **2010**,		2
1246	Re: "underlying genetic models of inheritance in established type 2 diabetes associations". **2010**, 171, 1153-4; author reply 1154-5		4
1245	MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk. **2010**, 14, 335-42		14
1244	Human genetic variation recognizes functional elements in noncoding sequence. **2010**, 20, 311-9		46
1243	Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. **2011**, 20, 2222-31		27
1242	Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. **2011**, 103, 1252-63		134
1241	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. **2011**, 103, 250-63		513
1240	Fibroblast growth factors and their receptors in cancer. **2011**, 437, 199-213		404
1239	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. **2011**, 20, 3289-303		140
1238	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. **2011**, 43, 1210-4		253
1237	Common genetic variants associated with breast cancer in Korean women and differential susceptibility according to intrinsic subtype. **2011**, 20, 793-8		59

1236 Evaluation of nanofluidics technology for high-throughput SNP genotyping in a clinical setting. **2011**, 13, 305-12 22

1235 Genetic factors associated with age-related macular degeneration. **2011**, 226, 87-102 23

1234 An overview of the genetic susceptibility to alcoholism. **2011**, 51 Suppl 1, S2-6 22

1233 Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. **2011**, 5, 61-76 100

1232 Cancer evolution and individual susceptibility. **2011**, 3, 316-28 28

1231 Evaluation of functional genetic variants for breast cancer risk: results from the Shanghai breast cancer study. **2011**, 173, 1159-70 15

1230 Role of Bioinformatics in Genome-wide Association Studies. **2011**,

1229 Planning a genome-wide association study: points to consider. **2011**, 43, 451-60 14

1228 Genetic variants in the MRPS30 region and postmenopausal breast cancer risk. **2011**, 3, 42 13

1227 Cancer Systems Biology, Bioinformatics and Medicine. **2011**, 3

1226 Therapeutic approaches for women predisposed to breast cancer. **2011**, 62, 295-306 28

1225 Genome variation: a review of Web resources. *Methods in Molecular Biology*, **2011**, 713, 129-39 1.4 2

1224 Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. **2011**, 144, 703-18 214

1223 Disease-driven detection of differential inherited SNP modules from SNP network. **2011**, 489, 119-29 7

1222 Cytogenomic aberrations associated with prostate cancer. **2011**, 204, 57-67 5

1221 Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: a potential therapeutic target in colorectal cancer. **2011**, 309, 209-19 36

1220 What is a functional locus? Understanding the genetic basis of complex phenotypic traits. **2011**, 76, 638-42 7

1219 Targeting mutant fibroblast growth factor receptors in cancer. **2011**, 17, 283-92 96

1218	Heme oxygenase-1 promoter polymorphism is a predictor of disease relapse in pancreatic neuroendocrine tumors. **2011**, 166, e121-7		4
1217	The neuronal transporter gene SLC6A15 confers risk to major depression. **2011**, 70, 252-65		161
1216	Preventive therapy for breast cancer: a consensus statement. **2011**, 12, 496-503		177
1215	Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. **2011**, 12, 477-88		210
1214	Genome-wide association studies: results from the first few years and potential implications for clinical medicine. **2011**, 62, 11-24		73
1213	CYP2D6 gene variants and their association with breast cancer susceptibility. **2011**, 20, 1255-8		9
1212	Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. *Breast Cancer Research*, **2011**, 13, R6	8.3	65
1211	Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer development. *Breast Cancer Research*, **2011**, 13, R13	8.3	28
1210	Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. *Breast Cancer Research*, **2011**, 13, R20	8.3	85
1209	Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. *Breast Cancer Research*, **2011**, 13, R72	8.3	31
1208	The non-protein coding breast cancer susceptibility locus Mcs5a acts in a non-mammary cell-autonomous fashion through the immune system and modulates T-cell homeostasis and functions. *Breast Cancer Research*, **2011**, 13, R81	8.3	21
1207	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
1206	Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study. *Breast Cancer Research*, **2011**, 13, R114	8.3	30
1205	Genetic susceptibility to bladder cancer risk and outcome. **2011**, 8, 365-374		35
1204	AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011. **2011**, 6, 299-313		6
1203	Principles for the post-GWAS functional characterisation of risk loci. **2011**,		
1202	Bioinformatics Approaches. **2011**, 251-260		
1201	Biology of BRCA1 and BRCA2 genes and implications for cancer management. 57-74		

1200 Risk factors and control strategies for the rapidly rising rate of breast cancer in Korea. **2011**, 14, 79-87 24

1199 FGFR2 (fibroblast growth factor receptor 2). **2011**,

1198 Inherited and acquired alterations in development of breast cancer. **2011**, 4, 145-58 19

1197 The genetics of breast cancer: risk factors for disease. **2011**, 4, 11-9 21

1196 Genetics of childhood obesity. **2011**, 2011, 845148 38

1195 Replication of GWAS "Hits" by Race for Breast and Prostate Cancers in European Americans and African Americans. **2011**, 2, 37 13

1194 Most lung and colon cancer susceptibility genes are pair-wise linked in mice, humans and rats. **2011**, 6, e14727 14

1193 Data integration workflow for search of disease driving genes and genetic variants. **2011**, 6, e18636 3

1192 Multiple Wnt/β-catenin responsive enhancers align with the MYC promoter through long-range chromatin loops. **2011**, 6, e18966 41

1191 Common variants in a novel gene, FONG on chromosome 2q33.1 confer risk of osteoporosis in Japanese. **2011**, 6, e19641 27

1190 Therapy-related myeloid neoplasms. **2011**, 23, 672-80 37

1189 Development of genetic testing for breast, ovarian and colorectal cancer predisposition: a step closer to targeted cancer prevention. **2011**, 12, 1974-82 0

1188 Etiology and risk factors. **2011**, 6-15

1187 Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. **2011**, 108, 323-30 82

1186 Association of 8q24.21 loci with the risk of colorectal cancer: a systematic review and meta-analysis. **2011**, 26, 1475-84 23

1185 Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women. **2011**, 102, 2065-72 35

1184 Breast cancer: a neglected disease for the majority of affected women worldwide. **2011**, 17, 289-95 34

1183 Modeling interactions with known risk loci-a Bayesian model averaging approach. **2011**, 75, 1-9 16

1182	Correcting away the hidden heritability. **2011**, 75, 348-50		53
1181	Principles for the post-GWAS functional characterization of cancer risk loci. **2011**, 43, 513-8		326
1180	Genome-wide association of breast cancer: composite likelihood with imputed genotypes. **2011**, 19, 194-9		5
1179	Caution in generalizing known genetic risk markers for breast cancer across all ethnic/racial populations. **2011**, 19, 243-5		17
1178	Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders. **2011**, 19 Suppl 1, S6-44		60
1177	Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. **2011**, 104, 1478-81		62
1176	Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. **2011**, 104, 1656-63		127
1175	Variation in base excision repair capacity. **2011**, 711, 100-12		91
1174	Screening of women at high risk for breast cancer. **2011**, 53, 127-30		11
1173	A powerful hybrid approach to select top single-nucleotide polymorphisms for genome-wide association study. **2011**, 12, 3		2
1172	Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. **2011**, 61, 327-59		128
1171	Clinical trials in the era of personalized oncology. **2011**, 61, 365-81		43
1170	The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. **2011**, 19, 273-82		94
1169	New IBD genetics: common pathways with other diseases. **2011**, 60, 1739-53		418
1168	A candidate CpG SNP approach identifies a breast cancer associated ESR1-SNP. **2011**, 129, 1689-98		31
1167	Inherited mutations in breast cancer genes--risk and response. **2011**, 16, 3-15		52
1166	Mutations and polymorphic BRCA variants transmission in breast cancer familial members. *Breast Cancer Research and Treatment*, **2011**, 125, 651-7	4.4	18
1165	Association between polymorphisms of trinucleotide repeat containing 9 gene and breast cancer risk: evidence from 62,005 subjects. *Breast Cancer Research and Treatment*, **2011**, 126, 177-83	4.4	25

1164	Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects. *Breast Cancer Research and Treatment*, **2011**, 126, 663-70	4.4	16
1163	A combined analysis of genome-wide association studies in breast cancer. *Breast Cancer Research and Treatment*, **2011**, 126, 717-27	4.4	85
1162	LFA-1 gene polymorphisms are associated with the sporadic infiltrative duct breast carcinoma in Chinese Han women of Heilongjiang Province. *Breast Cancer Research and Treatment*, **2011**, 127, 265-71	4.4	5
1161	Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women. *Breast Cancer Research and Treatment*, **2011**, 127, 479-87	4.4	15
1160	Ability to predict breast cancer in Asian women using a polygenic susceptibility model. *Breast Cancer Research and Treatment*, **2011**, 127, 805-12	4.4	11
1159	Replication of genome-wide discovered breast cancer risk loci in the Cypriot population. *Breast Cancer Research and Treatment*, **2011**, 128, 267-72	4.4	7
1158	Risk of genome-wide association study newly identified genetic variants for breast cancer in Chinese women of Heilongjiang Province. *Breast Cancer Research and Treatment*, **2011**, 128, 251-7	4.4	26
1157	Image-guided sampling reveals increased stroma and lower glandular complexity in mammographically dense breast tissue. *Breast Cancer Research and Treatment*, **2011**, 128, 505-16	4.4	39
1156	A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients. *Breast Cancer Research and Treatment*, **2011**, 130, 425-36	4.4	17
1155	PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. *Breast Cancer Research and Treatment*, **2011**, 129, 195-201	4.4	59
1154	BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 853-9	4.4	87
1153	Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies. *Breast Cancer Research and Treatment*, **2011**, 127, 309-24	4.4	75
1152	Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-Hispanic white women living in the Southwestern United States. *Breast Cancer Research and Treatment*, **2011** , 129, 531-9	4.4	35
1151	Genetic variants of 6q25 and breast cancer susceptibility: a two-stage fine mapping study in a Chinese population. *Breast Cancer Research and Treatment*, **2011**, 129, 901-7	4.4	16
1150	Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families. *Breast Cancer Research and Treatment*, **2011**, 129, 255-63	4.4	10
1149	Evidence for a link between TNFRSF11A and risk of breast cancer. *Breast Cancer Research and Treatment*, **2011**, 129, 947-54	4.4	11
1148	Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome. *Breast Cancer Research and Treatment*, **2011**, 130, 905-16	4.4	24
1147	Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer. *Breast Cancer Research and Treatment*, **2011**, 130, 1021-8	4.4	22

1146	FAN1 variants identified in multiple-case early-onset breast cancer families via exome sequencing: no evidence for association with risk for breast cancer. *Breast Cancer Research and Treatment*, **2011**, 130, 1043-9	4.4	15
1145	Genomics of the NF-Β signaling pathway: hypothesized role in ovarian cancer. **2011**, 22, 785-801		22
1144	Association of a LSP1 gene rs3817198T>C polymorphism with breast cancer risk: evidence from 33,920 cases and 35,671 controls. **2011**, 38, 4687-95		15
1143	Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility. **2011**, 130, 529-37		39
1142	Current status of genome-wide association studies in cancer. **2011**, 130, 59-78		142
1141	Realizing the promise of population biobanks: a new model for translation. **2011**, 130, 333-45		25
1140	The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer. **2011**, 34, 281-8		7
1139	Mutual information and linkage disequilibrium based SNP association study by grouping case-control. **2011**, 33, 65-73		2
1138	Prediction of personalized drugs based on genetic variations provided by DNA sequencing technologies. **2011**, 33, 591-603		2
1137	ICOS gene polymorphisms are associated with sporadic breast cancer: a case-control study. **2011**, 11, 392		15
1136	Disease-specific prospective family study cohorts enriched for familial risk. **2011**, 8, 2		24
1135	DomainRBF: a Bayesian regression approach to the prioritization of candidate domains for complex diseases. **2011**, 5, 55		18
1134	FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype. **2011**, 4, 72		18
1133	MI-GWAS: a SAS platform for the analysis of inherited and maternal genetic effects in genome-wide association studies using log-linear models. **2011**, 12, 117		5
1132	Predicting functionally important SNP classes based on negative selection. **2011**, 12, 26		9
1131	Comparative analysis of methods for detecting interacting loci. **2011**, 12, 344		30
1130	Meta-analysis of genome-wide and replication association studies on prostate cancer. **2011**, 71, 209-24		45
1129	Estrogen receptor-positive breast cancer: a multidisciplinary challenge. **2011**, 3, 216-30		24

1128	Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling. **2011**, 35, 389-97	13
1127	Detecting genetic interactions for quantitative traits with U-statistics. **2011**, 35, 457-68	18
1126	Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. **2011**, 35, 506-514	63
1125	A transcriptional network signature characterizes lung cancer subtypes. **2011**, 117, 353-60	23
1124	A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence. **2011**, 128, 2335-43	16
1123	FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. **2011**, 129, 702-12	12
1122	Breast Cancer Risk - Genes, Environment and Clinics. **2011**, 71, 1056-1066	45
1121	Left-right asymmetry in embryonic development and breast cancer: common molecular determinants?. **2011**, 18, 5519-27	36
1120	Composite likelihood-based meta-analysis of breast cancer association studies. **2011**, 56, 377-82	5
1119	TOX3 is a neuronal survival factor that induces transcription depending on the presence of CITED1 or phosphorylated CREB in the transcriptionally active complex. **2011**, 124, 252-60	58
1118	Replication of breast cancer GWAS susceptibility loci in the Women's Health Initiative African American SHARe Study. **2011**, 20, 1950-9	48
1117	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. **2011**, 20, 3304-21	62
1116	A multistage association study identifies a breast cancer genetic locus at NCOA7. **2011**, 71, 3881-8	13
1115	Interest in genetic testing for modest changes in breast cancer risk: implications for SNP testing. **2011**, 14, 178-89	44
1114	Mcs5c: a mammary carcinoma susceptibility locus located in a gene desert that associates with tenascin C expression. **2011**, 4, 97-106	7
1113	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. **2011**, 20, 4693-706	66
1112	TGF-signaling pathway and breast cancer susceptibility. **2011**, 20, 1112-9	40
1111	Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. **2011**, 22 Suppl 1, i11-7	62

1110	Genes associated with adult cerebral venous thrombosis. **2011**, 42, 913-8	59
1109	Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective. **2011**, 17 Suppl 1, S12-21	6
1108	Relation of FGFR2 genetic polymorphisms to the association between oral contraceptive use and the risk of breast cancer in Chinese women. **2011**, 173, 923-31	13
1107	Common breast cancer susceptibility loci are associated with triple-negative breast cancer. **2011**, 71, 6240-9	100
1106	kConFab: a familial breast cancer consortium facilitating research and translational oncology. **2011**, 2011, 79-81	11
1105	Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. **2011**, 103, 425-35	201
1104	Genome-based prediction of breast cancer risk in the general population: a modeling study based on meta-analyses of genetic associations. **2011**, 20, 9-22	28
1103	Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of chinese, Japanese, and European ancestry. **2011**, 71, 1344-55	60
1102	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. **2011**, 103, 105-16	37
1101	Genome-wide association studies for detecting cancer susceptibility. **2011**, 97, 27-46	18
1100	Molecular biological aspects on canine and human mammary tumors. **2011**, 48, 132-46	69
1099	Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. **2011**, 20, 4491-503	58
1098	Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. **2011**, 20, 4991-9	79
1097	RAD51C is a susceptibility gene for ovarian cancer. **2011**, 20, 3278-88	111
1096	Multiple loci are associated with white blood cell phenotypes. **2011**, 7, e1002113	92
1095	A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. **2011**, 7, e1002165	125
1094	Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in men. **2011**, 7, e1002290	30
1093	Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study. **2011**, 32, 1862-6	4

1092	Genetic anticipation is associated with telomere shortening in hereditary breast cancer. **2011**, 7, e1002182	68
1091	Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. **2011**, 7, e1001387	98
1090	Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. **2011**, 7, e1002197	261
1089	Genome-wide association study identifies four loci associated with eruption of permanent teeth. **2011**, 7, e1002275	18
1088	Innovative technology for cancer risk analysis. **2011**, 22 Suppl 1, i37-43	1
1087	Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. **2011**, 7, e1002171	135
1086	Life stress, emotional health, and mean telomere length in the European Prospective Investigation into Cancer (EPIC)-Norfolk population study. **2011**, 66, 1152-62	91
1085	Associating GWAS Information with the Notch Signaling Pathway Using Transcription Profiling. **2011**, 10, 93-108	5
1084	Early detection of prostate cancer with emphasis on genetic markers. **2011**, 50 Suppl 1, 18-23	13
1083	An integrative genomics approach to biomarker discovery in breast cancer. **2011**, 10, 185-204	19
1082	Current concepts on primary open-angle glaucoma genetics: a contribution to disease pathophysiology and future treatment. **2012**, 26, 355-69	73
1081	Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. **2012**, 8, e1002532	118
1080	Dosimetric advantages of generalised equivalent uniform dose-based optimisation on dose-volume objectives in intensity-modulated radiotherapy planning for bilateral breast cancer. **2012**, 85, 1499-506	12
1079	A Collective Ranking Method for Genome-wide Association Studies. **2012**, 2012, 313-320	
1078	A systematic eQTL study of cis-trans epistasis in 210 HapMap individuals. **2012**, 20, 97-101	25
1077	An insulator loop resides between the synthetically interacting elements of the human/rat conserved breast cancer susceptibility locus MCS5A/Mcs5a. **2012**, 40, 132-47	17
1076	Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. **2012**, 21, 1156-66	92
1075	Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions. **2012**, 4, 122ra23	43

1074	FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. **2012**, 72, 2017-27	23
1073	Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. **2012**, 49, 601-8	49
1072	Integrating breast cancer genetics into clinical practice. **2012**, 8, 99-112	4
1071	Clinical and epidemiological issues in mammographic density. **2011**, 9, 33-40	89
1070	Evidence of association between methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a candidate-gene association study in a South-eastern European population. **2012**, 31, 193-8	22
1069	Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction. **2012**, 23, 1031-42	9
1068	Combined effect of low-penetrant SNPs on breast cancer risk. **2012**, 106, 389-96	32
1067	A two-stage association study identifies methyl-CpG-binding domain protein 2 gene polymorphisms as candidates for breast cancer susceptibility. **2012**, 20, 682-9	14
1066	FOXA1 and breast cancer risk. **2012**, 44, 1176-7	18
1065	A role for common genomic variants in the assessment of familial breast cancer. **2012**, 30, 4330-6	60
1064	Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages. **2012**, 16, 377-93	13
1063	Novel genetic markers of breast cancer survival identified by a genome-wide association study. **2012**, 72, 1182-9	56
1062	Genetic variation in peroxisome proliferator-activated receptor gamma, soy, and mammographic density in Singapore Chinese women. **2012**, 21, 635-44	14
1061	Admixture mapping identifies a locus on 6q25 associated with breast cancer risk in US Latinas. **2012**, 21, 1907-17	50
1060	Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer. **2012**, 2012, 574768	35
1059	Sj□gren□ Syndrome. **2012**,	7
1058	Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer. **2012**, 103, 129-45	27
1057	The role of genetic breast cancer susceptibility variants as prognostic factors. **2012**, 21, 3926-39	75

1056	Common polymorphisms in angiogenesis. **2012**, 2,	15
1055	A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24. **2012**, 21, 1565-73	9
1054	Estimating causal effects of genetic risk variants for breast cancer using marker data from bilateral and familial cases. **2012**, 21, 262-72	6
1053	Basal breast cancer: a complex and deadly molecular subtype. **2012**, 12, 96-110	139
1052	BRCA Unclassified Variants: How Can They be Classified?. **2012**, 8, 30-37	1
1051	Editorial from Guest Editor [Hot Topic: Familial and Hereditary Breast and Ovarian Tumors (Guest Editors: Antonio Russo and Massimo Federico)]. **2012**, 8, 2-3	
1050	Rat Mcs1b is concordant to the genome-wide association-identified breast cancer risk locus at human 5q11.2 and MIER3 is a candidate cancer susceptibility gene. **2012**, 72, 6002-12	18
1049	Progesterone receptor variants associated with the PROGINS haplotype exhibit functional properties similar to those of wild-type progesterone receptor. **2012**, 22, 629-41	7
1048	Polymorphisms in second intron of the FGFR2 gene are associated with the risk of early-onset breast cancer in Chinese Han women. **2012**, 226, 221-9	18
1047	FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma. **2012**, 119, 1029-31	22
1046	Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. **2012**, 44, 1182-4	84
1045	Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. **2012**, 18, 436-42	32
1044	Pooled sample-based GWAS: a cost-effective alternative for identifying colorectal and prostate cancer risk variants in the Polish population. **2012**, 7, e35307	29
1043	The complexity of prostate cancer: genomic alterations and heterogeneity. **2012**, 9, 652-64	138
1042	Genetic variants at 6p21.1 and 7p15.3 are associated with risk of multiple cancers in Han Chinese. **2012**, 91, 928-34	59
1041	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. **2012**, 44, 1326-9	151
1040	Genetics. Variable outcome of mutations. **2012**, 335, 44-5	3
1039	Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. **2012**, 13, 65-77	161

1038	Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women. *Breast Cancer Research*, **2012**, 14, R17	8.3	50
1037	Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. *Breast Cancer Research*, **2012**, 14, 208	8.3	31
1036	Reproductive aging-associated common genetic variants and the risk of breast cancer. *Breast Cancer Research*, **2012**, 14, R54	8.3	14
1035	A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study. *Breast Cancer Research*, **2012**, 14, R56	8.3	102
1034	Transcriptional enhancers in development and disease. **2012**, 13, 238		97
1033	Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians. *Breast Cancer Research and Treatment*, **2012**, 135, 715-24	4.4	69
1032	Association of common genetic variants with breast cancer risk and clinicopathological characteristics in a Chinese population. *Breast Cancer Research and Treatment*, **2012**, 136, 209-20	4.4	40
1031	Three novel functional polymorphisms in the promoter of FGFR2 gene and breast cancer risk: a HuGE review and meta-analysis. *Breast Cancer Research and Treatment*, **2012**, 136, 885-97	4.4	19
1030	The SLC4A7 variant rs4973768 is associated with breast cancer risk: evidence from a case-control study and a meta-analysis. *Breast Cancer Research and Treatment*, **2012**, 136, 847-57	4.4	34
1029	Personal genomic testing as part of the complete breast cancer risk assessment: a case report. **2012**, 21, 638-44		3
1028	Association of STXBP4/COX11 rs6504950 (G>A) polymorphism with breast cancer risk: evidence from 17,960 cases and 22,713 controls. **2012**, 43, 383-8		6
1027	Fuzzy-probabilistic multi agent system for breast cancer risk assessment and insurance premium assignment. **2012**, 45, 1021-34		20
1026	Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. **2012**, 187, 424-8		20
1025	The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy. **2012**, 13, 659-75		12
1024	Genome-wide copy number analysis in primary breast cancer. **2012**, 16 Suppl 1, S31-5		19
1023	Genome-wide association analysis identifies three new breast cancer susceptibility loci. **2012**, 44, 312-8		237
1022	Gene expression profiles in white blood cells of volunteers exposed to a 50 Hz electromagnetic field. **2012**, 178, 138-49		13
1021	Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. **2012**, 5, 943-51		79

1020	Race and the molecular origins of breast cancer in Chinese women: breast cancer in Chinese women. **2012**, 19, 4085-93	3
1019	Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. **2012**, 19, R115-29	35
1018	Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. **2012**, 11, 429-39	21
1017	1. Estrogen and Progestin Stimulation of Breast Proliferation. **2012**, 17-44	
1016	Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse. **2012**, 11, M111.014910	38
1015	9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. **2012**, 21, 1783-91	17
1014	The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-Β signaling. **2012**, 32, 4662-73	19
1013	Risk of breast cancer in families with cleft lip and palate. **2012**, 22, 37-42	28
1012	Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583. **2012**, 205, 25-33	20
1011	Polymorphisms of TREH, IL4R and CCDC26 genes associated with risk of glioma. **2012**, 36, 283-7	52
1010	The many roles of TOX in the immune system. **2012**, 24, 173-7	68
1009	. **2012**,	1
1008	High order interactions of xenobiotic metabolizing genes and P53 codon 72 polymorphisms in acute leukemia. **2012**, 53, 619-30	14
1007	The risk allele of SNP rs3803662 and the mRNA level of its closest genes TOX3 and LOC643714 predict adverse outcome for breast cancer patients. **2012**, 12, 621	23
1006	Interactive effect of genetic susceptibility with height, body mass index, and hormone replacement therapy on the risk of breast cancer. **2012**, 12, 17	7
1005	Genetic predisposition, parity, age at first childbirth and risk for breast cancer. **2012**, 5, 414	39
1004	Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. **2012**, 18, 1855-62	307
1003	Evidence-based psychiatric genetics, AKA the false dichotomy between common and rare variant hypotheses. **2012**, 17, 474-85	108

1002	Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations. **2012**, 33, 2409-16	49
1001	The general public's understanding and perception of direct-to-consumer genetic test results. **2012**, 15, 11-21	101
1000	SNP selection and classification of genome-wide SNP data using stratified sampling random forests. **2012**, 11, 216-27	41
999	Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. **2012**, 44, 1191-8	287
998	Correlation between tumor suppressor inhibitor of growth family member 4 expression and microvessel density in breast cancer. **2012**, 43, 1611-7	10
997	Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. **2012**, 43, 1559-66	68
996	Base excision repair and cancer. **2012**, 327, 73-89	185
995	Comprehensive genomic studies: emerging regulatory, strategic, and quality assurance challenges for biorepositories. **2012**, 138, 31-41	9
994	Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis. **2012**, 31, 306-16	19
993	Considerations on Dealing with Tissues and Cell Samples (Include Tissue Banking). **2012**, 21-31	
992	Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk. **2012**, 3, 258	8
991	Breast cancer genome-wide association studies: there is strength in numbers. **2012**, 31, 2121-8	89
990	Genetic Polymorphisms as Predictors of Breast Cancer Risk. **2012**, 4, 232-239	1
989	Breast Cancer Heterogeneity: Need to Review Current Treatment Strategies. **2012**, 4, 225-231	2
988	Genetic and environmental factors in human cleft lip and palate. **2012**, 16, 19-31	33
987	Low penetrance alleles as risk modifiers in familial and sporadic breast cancer. **2012**, 11, 629-36	11
986	Primary Liver Cancer. **2012**,	3
985	Gene Regulatory Sequences and Human Disease. **2012**,	4

984	iLOCi: a SNP interaction prioritization technique for detecting epistasis in genome-wide association studies. **2012**, 13 Suppl 7, S2	29
983	Identifying breast cancer risk loci by global differential allele-specific expression (DASE) analysis in mammary epithelial transcriptome. **2012**, 13, 570	16
982	Common genetic variants in miR-1206 (8q24.2) and miR-612 (11q13.3) affect biogenesis of mature miRNA forms. **2012**, 7, e47454	30
981	Polymorphisms on 8q24 are associated with lung cancer risk and survival in Han Chinese. **2012**, 7, e41930	20
980	Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. **2012**, 7, e35706	10
979	The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. **2012**, 7, e47325	35
978	Cohesin is required for activation of MYC by estradiol. **2012**, 7, e49160	21
977	Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. **2012**, 7, e49970	19
976	Using Clinical Proteomics to Discover Novel Anti-Cancer Targets for MAb Therapeutics. **2012**,	
975	Engineering Tissue Model for Anti-Breast Cancer Pharmacotherapy. **2012**, 1, 15-23	
974	The Investigation of Gene Regulation and Variation in Human Cancers and Other Diseases. **2012**,	
973	Alzheimer's disease. 371-381	1
972	The association between single-nucleotide polymorphisms of ORAI1 gene and breast cancer in a Taiwanese population. **2012**, 2012, 916587	6
971	Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson's disease. **2012**, 11, 469-81	13
970	Murine double minute clone 2,309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience. **2012**, 27, e105-10	8
969	Whole-genome sequencing in personalized therapeutics. **2012**, 91, 1001-9	33
968	Genetic architectures of psychiatric disorders: the emerging picture and its implications. **2012**, 13, 537-51	866
967	Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. **2012**, 33, 835-40	59

966	Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. **2012**, 105, 773-9		43
965	Stratification-score matching improves correction for confounding by population stratification in case-control association studies. **2012**, 36, 195-205		16
964	11q13 is a susceptibility locus for hormone receptor positive breast cancer. **2012**, 33, 1123-32		33
963	Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. **2012**, 33, 1665-75		42
962	Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. **2012**, 131, 930-7		59
961	Gene-gene interactions in breast cancer susceptibility. **2012**, 21, 958-62		33
960	Investigation of allelic heterogeneity of the CCK-A receptor gene in paranoid schizophrenia. **2012**, 159B, 741-7		9
959	Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience. **2012**, 118, 5060-8		19
958	Oncogenomics methods and resources. **2012**, 2012,		7
957	Identification of putative cancer genes through data integration and comparative genomics between plants and humans. **2012**, 69, 2041-55		6
956	Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. *Breast Cancer Research and Treatment*, **2012**, 132, 439-48	4.4	33
955	Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes. *Breast Cancer Research and Treatment*, **2012**, 133, 843-51	4.4	42
954	Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer. *Breast Cancer Research and Treatment*, **2012**, 133, 997-1008	4.4	19
953	A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. *Breast Cancer Research and Treatment*, **2012**, 132, 711-21	4.4	76
952	Genetic variants at chromosome 9p21, 10p15 and 10q22 and breast cancer susceptibility in a Chinese population. *Breast Cancer Research and Treatment*, **2012**, 132, 741-6	4.4	8
951	Association of CD27 and CD70 gene polymorphisms with risk of sporadic breast cancer in Chinese women in Heilongjiang Province. *Breast Cancer Research and Treatment*, **2012**, 133, 1105-13	4.4	11
950	Paternal age effect mutations and selfish spermatogonial selection: causes and consequences for human disease. **2012**, 90, 175-200		217
949	Genetic variation at the 8q24 locus confers risk to multiple myeloma. **2012**, 156, 133-6		4

948	Mechanisms of FGFR-mediated carcinogenesis. **2012**, 1823, 850-60		128
947	Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers. **2012**, 271, 331-43		42
946	Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). **2012**, 271, 366-78		39
945	Current knowledge and tomorrows challenges of breast, ovarian and prostate cancer genetics. **2012**, 271, 318-20		4
944	Prostate cancer genomics, biology, and risk assessment through genome-wide association studies. **2012**, 103, 607-13		26
943	Familial breast cancer. **2012**, 82, 105-14		122
942	No evidence for association of inherited variation in genes involved in mitosis and percent mammographic density. *Breast Cancer Research*, **2012**, 14, R7	8.3	2
941	Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. *Breast Cancer Research*, **2012**, 14, R25	8.3	93
940	Hereditary breast cancer: practical pursuit for clinical translation. **2012**, 19, 1723-31		23
939	Susceptibility loci affecting ERBB2/neu-induced mammary tumorigenesis in mice. **2012**, 51, 631-43		2
938	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. **2012**, 33, 690-702		31
937	Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy. **2012**, 130, 876-84		20
936	Genetic susceptibility to pancreatic cancer. **2012**, 51, 14-24		150
935	Family history of cleft lip and palate in subjects diagnosed with leukemia. **2012**, 158A, 678-9		16
934	Genome wide QTL mapping to identify candidate genes for carcass traits in Hanwoo (Korean Cattle). **2012**, 34, 43-49		13
933	Genetic variants of fibroblast growth factor receptor 2 (FGFR2) are associated with breast cancer risk in Chinese women of the Han nationality. **2012**, 64, 71-6		13
932	Single nucleotide polymorphism 6q25.1 rs2046210 and increased risk of breast cancer. **2013**, 34, 4073-9		3
931	Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group. **2013**, 74, 1130-3		26

930	Genetic Determinants of Osteoporosis. **2013**, 563-604		1
929	A conceptual and methodological framework for investigating etiologic heterogeneity. **2013**, 32, 5039-52		19
928	Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. **2013**, 13, 219		32
927	Beliefs and attitudes towards participating in genetic research - a population based cross-sectional study. **2013**, 13, 114		58
926	Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing. **2013**, 6, 21		19
925	Pleiotropic roles of AEG-1/MTDH/LYRIC in breast cancer. **2013**, 120, 113-34		25
924	Predicting the impact of deleterious mutations in the protein kinase domain of FGFR2 in the context of function, structure, and pathogenesis--a bioinformatics approach. **2013**, 170, 1853-70		8
923	Cancer of the Breast and Female Reproductive Tract. **2013**, 1-31		0
922	The complex genetic landscape of familial breast cancer. **2013**, 132, 845-63		94
921	Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. **2013**, 132, 523-36		24
920	Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model. *Breast Cancer Research and Treatment*, **2013**, 139, 887-96	4.4	25
919	Synthesis of Olaparib derivatives and their antitumor activities. **2013**, 29, 231-235		3
918	Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning?. **2013**, 183, 1038-1051		66
917	RAPPER: the radiogenomics of radiation toxicity. **2013**, 25, 431-4		23
916	Genetics of cleft lip and cleft palate. **2013**, 163C, 246-58		217
915	Associations between single-nucleotide polymorphisms and epidural ropivacaine consumption in patients undergoing breast cancer surgery. **2013**, 17, 489-93		4
914	FGFR signalling in women's cancers. **2013**, 45, 2832-42		51
913	Breast cancer in Arab populations: molecular characteristics and disease management implications. **2013**, 14, e417-24		97

912	Genetic ancestry modifies the association between genetic risk variants and breast cancer risk among Hispanic and non-Hispanic white women. **2013**, 34, 1787-93		22
911	Fibroblast growth factor receptors, developmental corruption and malignant disease. **2013**, 34, 2198-205		98
910	Male breast cancer: genetics, epigenetics, and ethical aspects. **2013**, 24 Suppl 8, viii75-viii82		66
909	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. **2013**, 93, 1046-60		80
908	Genetic susceptibility to triple-negative breast cancer. **2013**, 73, 2025-30		141
907	Hereditary breast cancer: ever more pieces to the polygenic puzzle. **2013**, 11, 12		38
906	Breast cancer prediction using genome wide single nucleotide polymorphism data. **2013**, 14 Suppl 13, S3		12
905	The associations between a polygenic score, reproductive and menstrual risk factors and breast cancer risk. *Breast Cancer Research and Treatment*, **2013**, 140, 427-34	4.4	15
904	Association of 8q24 rs13281615A > G polymorphism with breast cancer risk: evidence from 40,762 cases and 50,380 controls. **2013**, 40, 4065-73		4
903	Association between a novel polymorphism (rs2046210) of the 6q25.1 locus and breast cancer risk. *Breast Cancer Research and Treatment*, **2013**, 139, 267-75	4.4	13
902	Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. *Breast Cancer Research and Treatment*, **2013**, 138, 889-98	4.4	9
901	Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy. *Breast Cancer Research and Treatment*, **2013**, 138, 861-8	4.4	26
900	Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant. *Breast Cancer Research and Treatment*, **2013**, 138, 543-8	4.4	9
899	Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case-control study in Japanese women. **2013**, 13, 565		32
898	Adiposity, inflammation, genetic variants and risk of post-menopausal breast cancer findings from a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design approach. **2013**, 2, 638		3
897	Association of cellular and molecular responses in the rat mammary gland to 17β-estradiol with susceptibility to mammary cancer. **2013**, 13, 573		17
896	Risk of GWAS-identified genetic variants for breast cancer in a Chinese population: a multiple interaction analysis. *Breast Cancer Research and Treatment*, **2013**, 142, 637-44	4.4	17
895	Advances in Chronic Lymphocytic Leukemia. **2013**,		2

894	Estimation and partition of heritability in human populations using whole-genome analysis methods. **2013**, 47, 75-95		110
893	The FGF/FGFR axis as a therapeutic target in breast cancer. **2013**, 8, 391-402		34
892	Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status. **2013**, 52 Suppl 1, E52-9		10
891	Palifermin for the protection and regeneration of epithelial tissues following injury: new findings in basic research and pre-clinical models. **2013**, 17, 1065-87		33
890	Suggestive evidence for association between L-type voltage-gated calcium channel (CACNA1C) gene haplotypes and bipolar disorder in Latinos: a family-based association study. **2013**, 15, 206-14		18
889	The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta-analysis study. **2013**, 132, 2808-19		20
888	Common breast cancer risk variants in the post-COGS era: a comprehensive review. *Breast Cancer Research*, **2013**, 15, 212	8.3	41
887	Polymorphism of 8q24 rsl3281615 and breast cancer risk : a meta-analysis. **2013**, 34, 421-8		7
886	Epigenetics makes its mark on women-specific cancers--an opportunity to redefine oncological approaches?. **2013**, 128, 134-143		13
885	Deep whole-genome sequencing of 100 southeast Asian Malays. **2013**, 92, 52-66		122
884	Glycomics meets genomics, epigenomics and other high throughput omics for system biology studies. **2013**, 17, 34-40		45
883	Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation. **2013**, 12, 129-32		10
882	The SNPs in the human genetic blueprint era. **2013**, 30, 475-84		10
881	A genome-wide association study of breast cancer in women of African ancestry. **2013**, 132, 39-48		63
880	Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population. *Breast Cancer Research and Treatment*, **2013**, 137, 559-69	4.4	31
879	Germline mutations in FGF receptors and medulloblastomas. **2013**, 161A, 382-5		5
878	Long-range transcriptional regulation of breast cancer genes. **2013**, 52, 113-25		5
877	Exploring the genetic architecture of circulating 25-hydroxyvitamin D. **2013**, 37, 92-8		40

876	Single nucleotide polymorphism in genome-wide association of human population: A tool for broad spectrum service. **2013**, 14, 123-134	42
875	The T393C polymorphism of GNAS1 is a predictor for relapse and survival in resectable non-small cell lung cancer. **2013**, 79, 151-5	7
874	Tooth agenesis association with self-reported family history of cancer. **2013**, 92, 149-55	30
873	Racial/Ethnic Disparities in Breast Cancer Risk: Genomics Meets Metabolomics. **2013**, 24, 212-216	
872	Association between rs2981582 polymorphism in the FGFR2 gene and the risk of breast cancer in Mexican women. **2013**, 44, 459-66	19
871	Catechol-O-methyltransferase Val 108/158 Met polymorphism and breast cancer risk: a case control study in Syria. **2013**, 20, 62-6	9
870	Comparison of genetic variation of breast cancer susceptibility genes in Chinese and German populations. **2013**, 21, 1286-92	25
869	A common deletion in the APOBEC3 genes and breast cancer risk. **2013**, 105, 573-9	109
868	Emerging targeted agents in metastatic breast cancer. **2013**, 10, 191-210	138
867	Genetic predisposition syndromes and their management. **2013**, 93, 341-62	18
866	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. **2013**, 45, 353-61, 361e1-2	813
865	Etiology and Epidemiology of CLL. **2013**, 63-69	
864	Genetic polymorphism of the OPG gene associated with breast cancer. **2013**, 13, 40	18
863	The genetics of innate immunity sensors and human disease. **2013**, 32, 157-208	17
862	Haplotype analysis of eight genes of the monoubiquitinated FANCD2-DNA damage-repair pathway in breast cancer patients. **2013**, 37, 311-7	9
861	Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. **2013**, 22, 2539-50	75
860	Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK. **2013**, 84, 37-42	11
859	Breast cancer risk prediction and mammography biopsy decisions: a model-based study. **2013**, 44, 15-22	12

858	Association analysis between breast cancer genetic variants and mammographic density in a large population-based study (Determinants of Density in Mammographies in Spain) identifies susceptibility loci in TOX3 gene. **2013**, 49, 474-81	18
857	Prostate cancer genomics by high-throughput technologies: genome-wide association study and sequencing analysis. **2013**, 20, R171-81	6
856	Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. **2013**, 19, 3693-702	236
855	Mapping of three genetic determinants of susceptibility to estrogen-induced mammary cancer within the Emca8 locus on rat chromosome 5. **2013**, 6, 59-69	15
854	Rare variant association testing under low-coverage sequencing. **2013**, 194, 769-79	10
853	Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. **2013**, 34, 1520-8	24
852	Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis. **2013**, 73, 1228-1235	31
851	Master regulators of FGFR2 signalling and breast cancer risk. **2013**, 4, 2464	128
850	Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers. **2013**, 22, 2269-76	12
849	Hereditary breast cancer: the era of new susceptibility genes. **2013**, 2013, 747318	172
848	The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferation. **2013**, 9, e1003549	17
847	Genetic Epidemiology of Breast Cancer. **2013**, 1113-1125	
846	Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?. **2013**, 14, 12346-66	22
845	Personalized medicine for metastatic breast cancer. **2013**, 25, 615-24	4
844	Parkinson's disease genes do not segregate with breast cancer genes' loci. **2013**, 22, 1464-72	3
843	Transcription factor and chromatin features predict genes associated with eQTLs. **2013**, 41, 1450-63	22
842	TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness. **2013**, 73, 2840-9	27
841	Cost-effectiveness of a genetic test for breast cancer risk. **2013**, 6, 1328-36	9

840	Meta-analysis identifies a MECOM gene as a novel predisposing factor of osteoporotic fracture. **2013**, 50, 212-9	24
839	A common variant at 8q24.21 is associated with renal cell cancer. **2013**, 4, 2776	48
838	Inherited susceptibility to CLL. **2013**, 792, 293-308	8
837	Breast Cancer Genomics: From Portraits to Landscapes. **2013**, 255-294	
836	Genetic susceptibility loci for subtypes of breast cancer in an African American population. **2013**, 22, 127-34	63
835	Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. **2013**, 19, 2460-72	61
834	Gene-environment interactions for breast cancer risk among Chinese women: a report from the Shanghai Breast Cancer Genetics Study. **2013**, 177, 161-70	20
833	An investigation of the effects of FGFR2 and B7-H4 polymorphisms in breast cancer. **2013**, 9, 370-5	8
832	CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer. **2013**, 2013, 562197	10
831	Breed-predispositions to cancer in pedigree dogs. **2013**, 2013, 941275	146
830	The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. **2013**, 18, 493-500	24
829	Causes and consequences of intra- and inter-host heterogeneity in defence against nematodes. **2013**, 35, 362-73	28
828	Osteoporosis Genes Identified by Genome-wide Association Studies. **2013**, 243-256	
827	The human disease network. **2013**, 1, 20-28	22
826	Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors. **2013**, 108, 2241-9	9
825	Suitable trial designs and cohorts for preventive breast cancer agents. **2013**, 10, 677-87	4
824	Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer. **2013**, 108, 2610-22	4
823	New breast cancer risk variant discovered at 10q25 in East Asian women. **2013**, 22, 1297-303	5

822	MicroRNAs in farm animals. **2013**, 7, 1567-75		24
821	Genome-wide association study identifies possible genetic risk factors for colorectal adenomas. **2013**, 22, 1219-26		11
820	Genetic variation in transforming growth factor beta 1 and mammographic density in Singapore Chinese women. **2013**, 73, 1876-82		10
819	Multi-resolution-test for consistent phenotype discrimination and biomarker discovery in translational bioinformatics. **2013**, 11, 1343010		4
818	Common low-penetrance risk variants associated with breast cancer in Polish women. **2013**, 13, 510		14
817	Genome wide analysis reveals single nucleotide polymorphisms associated with fatness and putative novel copy number variants in three pig breeds. **2013**, 14, 784		44
816	The genetic contribution to disease risk and variability in response to diet: where is the hidden heritability?. **2013**, 72, 40-7		15
815	MR perfusion imaging in oncology: applications outside the brain. 238-254		
814	Genome-wide association studies of cancer predisposition. 10-20		
813	AKT in stromal fibroblasts controls invasion of epithelial cells. *Oncotarget*, **2013**, 4, 1103-16	3.3	15
812	Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence. **2013**, 8, e53850		17
811	Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. **2013**, 8, e55681		77
810	Single nucleotide polymorphism 8q24 rs13281615 and risk of breast cancer: meta-analysis of more than 100,000 cases. **2013**, 8, e60108		12
809	Identification of a breast cancer susceptibility locus at 4q31.22 using a genome-wide association study paradigm. **2013**, 8, e62550		11
808	Genome-wide small RNA sequencing and gene expression analysis reveals a microRNA profile of cancer susceptibility in ATM-deficient human mammary epithelial cells. **2013**, 8, e64779		7
807	Assessing SNP-SNP interactions among DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility. **2014**, 8, e64896		42
806	Quantitative assessment of the association between rs2046210 at 6q25.1 and breast cancer risk. **2013**, 8, e65206		1
805	Genetic variants at 12p11 and 12q24 are associated with breast cancer risk in a Chinese population. **2013**, 8, e66519		5

804	A unified framework integrating parent-of-origin effects for association study. **2013**, 8, e72208		5
803	TOX3 mutations in breast cancer. **2013**, 8, e74102		19
802	Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing. **2013**, 8, e78839		10
801	A novel multiplex tetra-primer ARMS-PCR for the simultaneous genotyping of six single nucleotide polymorphisms associated with female cancers. **2013**, 8, e62126		18
800	Case-control study on the fibroblast growth factor receptor 2 gene polymorphisms associated with breast cancer in chinese han women. **2013**, 16, 366-71		15
799	CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. *Oncotarget*, **2013**, 4, 1748-62	3.3	148
798	The UGT1A6_19_GG genotype is a breast cancer risk factor. **2013**, 4, 104		7
797	Colorectal cancer susceptibility variants alter risk of breast cancer in a Chinese Han population. **2013**, 12, 6268-74		18
796	Family and genome-wide association studies of restless legs syndrome. 335-350		
795	The MYC oncogene family in human cancer. 313-318		
794	H19 Locus. **2013**, 378-381		
793	Mutation analysis of the ERCC4/FANCQ gene in hereditary breast cancer. **2014**, 9, e85334		8
792	Association of polymorphisms and haplotypes in the insulin-like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women. **2014**, 9, e84532		21
791	Functional polymorphisms in interleukin-23 receptor and susceptibility to esophageal squamous cell carcinoma in Chinese population. **2014**, 9, e89111		15
790	Pleiotropy of cancer susceptibility variants on the risk of non-Hodgkin lymphoma: the PAGE consortium. **2014**, 9, e89791		14
789	Association between mitogen-activated protein kinase kinase kinase 1 polymorphisms and breast cancer susceptibility: a meta-analysis of 20 case-control studies. **2014**, 9, e90771		10
788	RANK rs1805034 T>C polymorphism is associated with susceptibility of esophageal cancer in a Chinese population. **2014**, 9, e101705		11
787	SNP identification by transcriptome sequencing and candidate gene-based association analysis for heat tolerance in the bay scallop Argopecten irradians. **2014**, 9, e104960		16

786	MicroRNA related polymorphisms and breast cancer risk. **2014**, 9, e109973		37
785	A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North India. **2014**, 9, e110426		29
784	Associations of two common genetic variants with breast cancer risk in a chinese population: a stratified interaction analysis. **2014**, 9, e115707		10
783	Architecture of inherited susceptibility to colorectal cancer: a voyage of discovery. **2014**, 5, 270-84		11
782	Association analysis of colorectal cancer susceptibility variants with gastric cancer in a Chinese Han population. **2014**, 13, 3673-80		12
781	Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. *Oncotarget*, **2014**, 5, 2736-49	3.3	219
780	Nucleic Acid-Based Diagnostics in Gynecological Malignancies. **2014**, 155-184		
779	Radiogenomics: the search for genetic predictors of radiotherapy response. **2014**, 10, 2391-406		54
778	A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response. **2014**, 20, 2761-72		55
777	Polymorphisms in the DNA repair gene ERCC2/XPD and breast cancer risk: a HapMap-based case-control study among Han Women in a Chinese less-developed area. **2014**, 18, 703-10		8
776	Pleiotropic effects of genetic risk variants for other cancers on colorectal cancer risk: PAGE, GECCO and CCFR consortia. **2014**, 63, 800-7		27
775	Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?. **2014**, 14, 87		8
774	Candidate gene-environment interactions in breast cancer. **2014**, 12, 195		8
773	Genome-wide association studies and the clinic: a focus on breast cancer. **2014**, 8, 287-96		11
772	An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer. **2014**, 59, 661-6		3
771	Eurocan Platform meeting: European recommendations for biomarker-based chemoprevention trials. **2014**, 8, 488		
770	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. **2014**, 10, e1004285		38
769	Risk-association of five SNPs in TOX3/LOC643714 with breast cancer in southern China. **2014**, 15, 2130-41		22

768	A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population. **2014**, 2, 94-102	3
767	Pleiotropic associations of risk variants identified for other cancers with lung cancer risk: the PAGE and TRICL consortia. **2014**, 106, dju061	28
766	Association of cancer susceptibility variants with risk of multiple primary cancers: The population architecture using genomics and epidemiology study. **2014**, 23, 2568-78	21
765	The ins and outs of fibroblast growth factor receptor signalling. **2014**, 127, 217-31	36
764	CHRNA9 polymorphisms and smoking exposure synergize to increase the risk of breast cancer in Taiwan. **2014**, 35, 2520-5	8
763	. **2014**,	1
762	Therapeutic strategies to inhibit MYC. **2014**, 4,	143
761	Genetics of alcohol dependence: a review of clinical studies. **2014**, 70, 77-94	21
760	Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium. **2014**, 180, 1018-27	29
759	Risk assessment of multistate progression of breast tumor with state-dependent genetic and environmental covariates. **2014**, 34, 367-79	8
758	The genetics of breast cancer susceptibility Polymorphism and the prospect of their use in a clinical setting. **2014**, 16, 445-448	2
757	Comparing the efficacy of SNP filtering methods for identifying a single causal SNP in a known association region. **2014**, 78, 50-61	12
756	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. **2014**, 23, 6096-111	48
755	Post-GWAS gene-environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort Consortium and a meta-analysis on 79,000 women. **2014**, 23, 5260-70	30
754	Validation of six genetic determinants of susceptibility to estrogen-induced mammary cancer in the rat and assessment of their relevance to breast cancer risk in humans. **2014**, 4, 1385-94	11
753	Breast cancer susceptibility variants and mammographic density phenotypes in norwegian postmenopausal women. **2014**, 23, 1752-63	6
752	Germline DNA variations in breast cancer predisposition and prognosis: a systematic review of the literature. **2014**, 144, 77-91	27
751	A comprehensive examination of breast cancer risk loci in African American women. **2014**, 23, 5518-26	28

750	Breast Cancer. **2014**, 391-408		1
749	Omics Approaches in Breast Cancer. **2014**,		8
748	Breast Cancer Genomics. **2014**, 53-103		
747	SNP discovery in the transcriptome of white Pacific shrimp Litopenaeus vannamei by next generation sequencing. **2014**, 9, e87218		55
746	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. **2014**, 6, 47		48
745	Replication of breast cancer susceptibility loci in whites and African Americans using a Bayesian approach. **2014**, 179, 382-94		18
744	MYC association with cancer risk and a new model of MYC-mediated repression. **2014**, 4, a014316		22
743	Breast cancer risk assessment using genetic variants and risk factors in a Singapore Chinese population. *Breast Cancer Research*, **2014**, 16, R64	8.3	22
742	Genetics of cleft lip and/or cleft palate: association with other common anomalies. **2014**, 57, 381-93		91
741	Reproductive windows, genetic loci, and breast cancer risk. **2014**, 24, 376-82		7
740	Genome-wide association study for radiographic vertebral fractures: A potential role for the 16q24 BMD locus. *Bone*, **2014**, 59, 20-27	4.7	29
739	CYP2B6*6 is associated with increased breast cancer risk. **2014**, 134, 426-30		20
738	Ept7 influences estrogen action in the pituitary gland and body weight of rats. **2014**, 25, 244-52		9
737	Association of genetic and non-genetic risk factors with the development of prostate cancer in Malaysian men. **2014**, 41, 2501-8		5
736	Association between polymorphisms within the susceptibility region 8q24 and breast cancer in a Chinese population. **2014**, 35, 2649-54		8
735	Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. *Breast Cancer Research and Treatment*, **2014**, 143, 181-7	4.4	15
734	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. **2014**, 23, 1934-46		28
733	Genome-wide association study identifies multiple loci associated with bladder cancer risk. **2014**, 23, 1387-98		101

732	Genetic variations of BRCA1 and BRCA2 genes in dogs with mammary tumours. **2014**, 38, 21-7		22
731	Does and should breast cancer genetic counselling include lifestyle advice?. **2014**, 13, 35-44		6
730	Association of genetic variants at TOX3, 2q35 and 8q24 with the risk of familial and early-onset breast cancer in a South-American population. **2014**, 41, 3715-22		28
729	Significant overlap between human genome-wide association-study nominated breast cancer risk alleles and rat mammary cancer susceptibility loci. *Breast Cancer Research*, **2014**, 16, R14	8.3	7
728	Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications. **2014**, 37, 1-8		12
727	A genome-wide association study of severe teenage acne in European Americans. **2014**, 133, 259-64		29
726	A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. **2014**, 23, 658-69		63
725	Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. **2014**, 135, 2352-61		24
724	Genetic variants and risk of cervical cancer: epidemiological evidence, meta-analysis and research review. **2014**, 121, 664-74		43
723	Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. **2014**, 35, 2068-73		17
722	BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. **2014**, 110, 535-45		167
721	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. **2014**, 35, 1012-9		121
720	Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe. **2014**, 13, 137-42		20
719	Integrated analysis of germline and somatic variants in ovarian cancer. **2014**, 5, 3156		199
718	Approaches in Integrative Bioinformatics. **2014**,		3
717	Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. **2014**, 5, 5260		89
716	Decade in review--genomics: a decade of discovery in cancer genomics. **2014**, 11, 632-4		12
715	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. **2014**, 5, 5303		84

714	Breast cancer subtypes and previously established genetic risk factors: a bayesian approach. **2014**, 23, 84-97		29
713	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. **2014**, 110, 1088-100		20
712	Genotyping single nucleotide polymorphisms in human genomic DNA with an automated and self-contained PCR cassette. **2014**, 16, 550-557		7
711	Modern approaches to cancer prevention: Universal or personal?. **2014**, 2, 93-96		
710	Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C. **2014**, 24, 1854-68		168
709	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. **2014**, 20, 1130-7		269
708	The Impact of GWAS Findings on Cancer Etiology and Prevention. **2014**, 1, 130-137		3
707	The distribution of insertionally polymorphic endogenous retroviruses in breast cancer patients and cancer-free controls. **2014**, 11, 62		26
706	Association study of susceptibility loci with specific breast cancer subtypes in Chinese women. *Breast Cancer Research and Treatment*, **2014**, 146, 503-14	4.4	19
705	Mammographic density-a review on the current understanding of its association with breast cancer. *Breast Cancer Research and Treatment*, **2014**, 144, 479-502	4.4	130
704	Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells. **2014**, 41, 19-24		9
703	The association between single-nucleotide polymorphisms of TRPM7 gene and breast cancer in Han Population of Northeast China. **2014**, 31, 51		10
702	Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy. **2014**, 12, 203-17		7
701	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. **2014**, 23, 6034-46		11
700	Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?. **2014**, 18, 665-78		8
699	Frequent mutation of rs13281615 and its association with PVT1 expression and cell proliferation in breast cancer. **2014**, 41, 187-95		25
698	Estimation du risque individuel de cancer du sein : intrt et limites des modles de calcul de risque. **2014**, 24, 97-104		1
697	FGF receptors: cancer biology and therapeutics. **2014**, 34, 280-300		332

696	Far beyond the usual biomarkers in breast cancer: a review. **2014**, 5, 559-71		39
695	Hereditary breast cancer: clinical, pathological and molecular characteristics. **2014**, 8, 145-55		50
694	A Single-Array-Based Method for Detecting Copy Number Variants Using Affymetrix High Density SNP Arrays and its Application to Breast Cancer. **2014**, 13, 95-103		
693	The emerging role of FGF receptor as a potential target in breast cancer. **2014**, 3, 215-218		
692	Association of three SNPs in TOX3 and breast cancer risk: Evidence from 97275 cases and 128686 controls. *Scientific Reports*, **2015**, 5, 12773	4.9	12
691	Functional annotation of HOT regions in the human genome: implications for human disease and cancer. *Scientific Reports*, **2015**, 5, 11633	4.9	20
690	The current progress and future prospects of personalized radiogenomic cancer study. **2015**, 5, 2		13
689	Hard Work Ahead: Fine Mapping and Functional Follow-up of Susceptibility Alleles in Cancer GWAS. **2015**, 2, 205-217		1
688	Characterization of familial breast cancer in Saudi Arabia. **2015**, 16 Suppl 1, S3		9
687	Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients. **2015**, 36, 1088-99		6
686	Identifying gene-gene interactions that are highly associated with Body Mass Index using Quantitative Multifactor Dimensionality Reduction (QMDR). **2015**, 8, 41		12
685	Hereditary Breast Cancer Syndromes: Molecular Pathogenesis and Diagnostics. **2015**, 1-16		1
684	CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. **2015**, 112, 622-8		13
683	Association of CYP450 single nucleotide polymorphisms with the efficacy of epidural ropivacaine during mastectomy. **2015**, 59, 640-7		2
682	Assessing the interactions between the associations of common genetic variants on 2q35 and 16q12 with breast cancer risk. **2015**, 62, 315-25		0
681	The Role of Constitutional Copy Number Variants in Breast Cancer. **2015**, 4, 407-23		5
680	Role of Fibroblast Growth Factor Receptor 2 in Pancreatic Cancer: Potential Target for New Therapeutic Approach?. **2015**, 05,		1
679	Ethical challenges and innovations in the dissemination of genomic data: the experience of the PERSPECTIVE project. **2015**, 283		1

678	Using parental phenotypes in case-parent studies. **2015**, 6, 221		1
677	An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. **2015**, 11, e1004350		21
676	Mammographic Breast Density and Common Genetic Variants in Breast Cancer Risk Prediction. **2015**, 10, e0136650		17
675	Heterogeneity of Breast Cancer Associations with Common Genetic Variants in FGFR2 according to the Intrinsic Subtypes in Southern Han Chinese Women. **2015**, 2015, 626948		13
674	A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1. **2015**, 22, 540-8		22
673	Prediction of breast cancer risk based on profiling with common genetic variants. **2015**, 107,		324
672	Association of common variants on chromosome 8q24 with gastric cancer in Venezuelan patients. **2015**, 566, 120-4		9
671	Gene analysis techniques and susceptibility gene discovery in´non-BRCA1/BRCA2 familial breast cancer. **2015**, 24, 100-9		19
670	Developing a clinical utility framework to evaluate prediction models in radiogenomics. **2015**, 9416,		3
669	Breast Cancer: Epidemiology and Etiology. **2015**, 72, 333-8		342
668	Identification and computational analysis of gene regulatory elements. **2015**, 2015, pdb.top083642		4
667	Runx3 at the interface of immunity, inflammation and cancer. **2015**, 1855, 131-43		40
666	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. **2015**, 90, E80-5		59
665	A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. *Breast Cancer Research and Treatment*, **2015**, 149, 517-23	4.4	19
664	Association of breast cancer risk loci with breast cancer survival. **2015**, 137, 2837-45		28
663	The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation. **2015**,		10
662	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. **2015**, 24, 2966-84		36
661	Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. *Breast Cancer Research and Treatment*, **2015**, 150, 1-8	4.4	90

660	Junk DNA and the long non-coding RNA twist in cancer genetics. **2015**, 34, 5003-11		231
659	MAPK genes interact with diet and lifestyle factors to alter risk of breast cancer: the Breast Cancer Health Disparities Study. **2015**, 67, 292-304		15
658	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. **2015**, 96, 5-20		59
657	Oxidatively induced DNA damage and its repair in cancer. **2015**, 763, 212-45		146
656	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. **2015**, 47, 373-80		406
655	Identification of differently expressed genes with specific SNP Loci for breast cancer by the integration of SNP and gene expression profiling analyses. **2015**, 21, 469-75		7
654	From candidate gene studies to GWAS and post-GWAS analyses in breast cancer. **2015**, 30, 32-41		65
653	The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer. **2015**, 403, 219-29		17
652	The contributions of breast density and common genetic variation to breast cancer risk. **2015**, 107,		128
651	Prostate cancer in East Asia: evolving trend over the last decade. **2015**, 17, 48-57		68
650	Genetic risk variants associated with in situ breast cancer. *Breast Cancer Research*, **2015**, 17, 82	8.3	20
649	DNA repair genes XRCC1 and ERCC1 polymorphisms and the risk of sporadic breast cancer in Han women in the Gansu Province of China. **2015**, 19, 387-93		8
648	Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. **2015**, 14, 531-8		34
647	Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy. **2015**, 51, 2289-95		20
646	Breast composition: Measurement and clinical use. **2015**, 21, 324-333		27
645	Association of genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 with the risk of endometrial carcinoma and clinicopathological parameters among Chinese Han women. **2015**, 184, 65-72		3
644	Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment. **2015**, 88, 20150172		30
643	DNA methylation as a promising landscape: A simple blood test for breast cancer prediction. **2015**, 36, 4905-12		27

642	Breast Cancer Risk Gene Discovery: Opportunities and Challenges. **2015**, 3, 82-91		
641	TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer. **2015**, 15, 22		24
640	Associations between breast density and a panel of single nucleotide polymorphisms linked to breast cancer risk: a cohort study with digital mammography. **2015**, 15, 143		12
639	The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms. *Breast Cancer Research*, **2015**, 17, 1	8.3	52
638	Role and therapeutic potential of G-protein coupled receptors in breast cancer progression and metastases. **2015**, 763, 178-83		22
637	Movement Disorder Genetics. **2015**,		
636	FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis. **2015**, 24, 3506-17		18
635	SNP-SNP interactions of immunity related genes involved in the CD28/B7 pathway with susceptibility to invasive ductal carcinoma of the breast. **2015**, 566, 217-22		10
634	Putative linkage signals identified for breast cancer in African American families. **2015**, 24, 442-7		2
633	FGFR as potential target in the treatment of squamous non small cell lung cancer. **2015**, 41, 527-39		46
632	Breast cancer prevention in the era of precision medicine. **2015**, 107,		6
631	The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men. **2015**, 24, 122-7		3
630	Genetic variant in 8q24 is associated with prognosis for gastric cancer in a Chinese population. **2015** , 30, 689-95		31
629	Two novel variants on 13q22.1 are associated with risk of esophageal squamous cell carcinoma. **2015**, 24, 1774-80		11
628	The association of copy number variation and percent mammographic density. **2015**, 8, 297		1
627	Hormone-related pathways and risk of breast cancer subtypes in African American women. *Breast Cancer Research and Treatment*, **2015**, 154, 145-54	4.4	26
626	Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. **2015**, 107,		47
625	Different patterns of allelic imbalance in sporadic tumors and tumors associated with long-term exposure to gamma-radiation. **2015**, 794, 8-16		

624	Personalized Screening for Breast Cancer: A Wolf in Sheep's Clothing?. **2015**, 205, 1365-71		10
623	Developing a utility decision framework to evaluate predictive models in breast cancer risk estimation. **2015**, 2, 041005		2
622	Interaction between common breast cancer susceptibility variants, genetic ancestry, and nongenetic risk factors in Hispanic women. **2015**, 24, 1731-8		12
621	Evaluation of the germline single nucleotide polymorphism rs583522 in the TNFAIP3 gene as a prognostic marker in esophageal cancer. **2015**, 208, 595-601		5
620	Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. **2015**, 25, 221-33		106
619	The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. **2015**, 13, 502-9		24
618	Clinical Phenotype and Genetics of Restless Legs Syndrome. **2015**, 1145-1162		
617	Personalized Medicine Through SNP Testing for Breast Cancer Risk: Clinical Implementation. **2015**, 24, 744-51		12
616	Marking Shifts in Human Research Ethics in the Development of Biobanking. **2015**, 8, 63-71		11
615	Prostate cancer risk locus at 8q24 as a regulatory hub by physical interactions with multiple genomic loci across the genome. **2015**, 24, 154-66		48
614	Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. **2015**, 88, 371-5		39
613	MiR-449a promotes breast cancer progression by targeting CRIP2. *Oncotarget*, **2016**, 7, 18906-18	3.3	42
612	Insulin-like Growth Factor 1 gene polymorphism and breast cancer risk. **2016**, 88, 2349-2356		5
611	Binding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity. *Oncotarget*, **2016**, 7, 68473-68488	3.3	4
610	DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA. *Oncotarget*, **2016**, 7, 64191-64202	3.3	23
609	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. *Oncotarget*, **2016**, 7, 80140-80163	3.3	21
608	Associations of Genetic Variants at Nongenic Susceptibility Loci with Breast Cancer Risk and Heterogeneity by Tumor Subtype in Southern Han Chinese Women. **2016**, 2016, 3065493		4
607	Genetic variants in FGFR2 and TNRC9 genes are associated with breast cancer risk in Pakistani women. **2016**, 14, 3443-51		10

606	Accounting for Population Structure in Gene-by-Environment Interactions in Genome-Wide Association Studies Using Mixed Models. **2016**, 12, e1005849		35
605	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. **2016**, 11, e0160316		11
604	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. **2016**, 139, 1303-1317		26
603	A Review of Whole-Exome Sequencing Efforts Toward Hereditary Breast Cancer Susceptibility Gene Discovery. **2016**, 37, 835-46		31
602	An efficient empirical Bayes method for genomewide association studies. **2016**, 133, 253-63		16
601	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
600	Pharmacogenetics and interstitial lung disease. **2016**, 22, 456-65		8
599	Next generation sequencing: implications in personalized medicine and pharmacogenomics. **2016**, 12, 1818-30		63
598	Handbook of HER2-Targeted Agents in Breast Cancer. **2016**,		
597	Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population. **2016**, 16, 165		16
596	TOX3 regulates neural progenitor identity. **2016**, 1859, 833-40		12
595	Genetic predisposition to ductal carcinoma in situ of the breast. *Breast Cancer Research*, **2016**, 18, 22	8.3	31
594	Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium. *Breast Cancer Research and Treatment*, **2016**, 155, 355-63	4.4	10
593	Association of the CCDC26 rs4295627 polymorphism with the risk of glioma: Evidence from 7,290 cases and 11,630 controls. **2016**, 4, 878-882		6
592	Five endometrial cancer risk loci identified through genome-wide association analysis. **2016**, 48, 667-674		56
591	Breath biomarkers in toxicology. **2016**, 90, 2669-2682		24
590	Identification of novel susceptibility markers for the risk of overall breast cancer as well as subtypes defined by hormone receptor status in the Chinese population. **2016**, 61, 1027-1034		6
589	Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. **2016**, 25, 4835-4846		34

588	Nonsyndromic cleft lip with or without cleft palate and cancer: Evaluation of a possible common genetic background through the analysis of GWAS data. **2016**, 10, 22-9		13
587	Extraordinary Cancer Epigenomics: Thinking Outside the Classical Coding and Promoter Box. **2016**, 2, 572-584		16
586	The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance. *Breast Cancer Research*, **2016**, 18, 99	8.3	50
585	Genetic predisposition of six well-defined polymorphisms in HMGB1/RAGE pathway to breast cancer in a large Han Chinese population. **2016**, 20, 1966-73		22
584	Increasing Generality and Power of Rare-Variant Tests by Utilizing Extended Pedigrees. **2016**, 99, 846-859		13
583	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. **2016**, 99, 903-911		43
582	TOX3 protein expression is correlated with pathological characteristics in breast cancer. **2016**, 11, 1762-1768		9
581	Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. **2016**, 17 Suppl 7, 525		97
580	Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. **2016**, 23, T69-84		46
579	Saving the spandrels? Adaptive genomic variation in conservation and fisheries management. **2016**, 89, 2697-2716		37
578	Association of single nucleotide polymorphism rs3803662 with the risk of breast cancer. *Scientific Reports*, **2016**, 6, 29008	4.9	9
577	FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness. **2016**, 37, 741-750		28
576	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. **2016**, 7, 11375		64
575	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. **2016**, 7, 12675		53
574	Association of polymorphisms in intron 2 of FGFR2 and breast cancer risk in Chinese women. *Cytology and Genetics*, **2016**, 50, 312-317	0.7	2
573	4C-seq revealed long-range interactions of a functional enhancer at the 8q24 prostate cancer risk locus. *Scientific Reports*, **2016**, 6, 22462	4.9	25
572	Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer. **2016**, 7, 13183		51
571	Deep targeted sequencing of 12 breast cancer susceptibility regions in 4611 women across four different ethnicities. *Breast Cancer Research*, **2016**, 18, 109	8.3	4

570	Non-coding single nucleotide variants affecting estrogen receptor binding and activity. **2016**, 8, 128		4
569	11 Genetics of Nonsyndromic Orofacial Clefting. **2016**,		
568	Glaucoma Genetics: Recent Advances and Future Directions. **2016**, 5, 256-9		17
567	Genomic Disparities in Breast Cancer Among Latinas. **2016**, 23, 359-372		32
566	TNRC9 rs12443621 and FGFR2 rs2981582 polymorphisms and breast cancer risk. **2016**, 14, 50		15
565	Discriminatory power of common genetic variants in personalized breast cancer diagnosis. **2016**, 9787,		2
564	Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. *Breast Cancer Research and Treatment*, **2016**, 155, 531-40	4.4	2
563	Genetic analysis of intestinal polyp development in Collaborative Cross mice carrying the Apc (Min/+) mutation. **2016**, 17, 46		13
562	GENESIS: a French national resource to study the missing heritability of breast cancer. **2016**, 16, 13		9
561	Genome-wide association study in East Asians identifies two novel breast cancer susceptibility loci. **2016**, 25, 3361-3371		22
560	PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women: A Hospital-Based Observational Study. **2016**, 95, e3760		31
559	Association analysis of ERCC5 gene polymorphisms with risk of breast cancer in Han women of northwest China. **2016**, 23, 479-85		15
558	Relationship between five GWAS-identified single nucleotide polymorphisms and female breast cancer in the Chinese Han population. **2016**, 37, 9739-44		10
557	FGFR Signaling as a Target for Lung Cancer Therapy. **2016**, 11, 9-20		63
556	Comparing Mammography Abnormality Features to Genetic Variants in the Prediction of Breast Cancer in Women Recommended for Breast Biopsy. **2016**, 23, 62-9		7
555	Male breast cancer is not congruent with the female disease. **2016**, 101, 119-24		38
554	A family-based, genome-wide association study of young-onset breast cancer: inherited variants and maternally mediated effects. **2016**, 24, 1316-23		10
553	Origins of Bladder Cancer. **2016**, 11, 149-74		101

552	Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status. **2016**, 37, 10209-18		3
551	Association of polymorphisms with a family history of cancer and the presence of germline mutations in the BRCA1/BRCA2 genes. **2016**, 14, 2		0
550	Resistance to Targeted Therapies in Breast Cancer. *Methods in Molecular Biology*, **2016**, 1395, 105-36	1.4	14
549	Variants of FGFR2 and their associations with breast cancer risk: a HUGE systematic review and meta-analysis. *Breast Cancer Research and Treatment*, **2016**, 155, 313-35	4.4	20
548	Review: High-performance computing to detect epistasis in genome scale data sets. **2016**, 17, 368-79		29
547	Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. **2016**, 17, 672-7		5
546	Assessment of Tumor Angiogenesis: Dynamic Contrast-enhanced MR Imaging and Beyond. **2016**, 24, 45-56		9
545	An Updated and Comprehensive Meta-Analysis of Association Between Seven Hot Loci Polymorphisms from Eight GWAS and Glioma Risk. **2016**, 53, 4397-405		5
544	Therapeutic uses of FGFs. **2016**, 53, 144-54		23
543	Molecular epidemiology, and possible real-world applications in breast cancer. **2016**, 23, 33-38		19
542	Association of Genome-Wide Association Study (GWAS) Identified SNPs and Risk of Breast Cancer in an Indian Population. *Scientific Reports*, **2017**, 7, 40963	4.9	11
541	A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. **2017**, 49, 341-348		54
540	Hydrogen donors and acceptors and basic amino acids jointly contribute to carcinogenesis. **2017**, 98, 42-44		33
539	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. **2017**, 35, 743-750		51
538	Investigation of G-quadruplex formation in the FGFR2 promoter region and its transcriptional regulation by liensinine. **2017**, 1861, 884-891		8
537	FGFR-targeted therapeutics for the treatment of breast cancer. **2017**, 26, 303-311		21
536	A polygenic risk score for breast cancer risk in a Taiwanese population. *Breast Cancer Research and Treatment*, **2017**, 163, 131-138	4.4	23
535	Sequence robust association test for familial data. **2017**, 73, 876-884		1

534	Candidate Gene Analysis of Breast Cancer in the Jordanian Population of Arab Descent: A Case-Control Study. **2017**, 35, 256-270		15
533	Male Breast Cancer. **2017**,		1
532	The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. **2017**, 54, 111-113		42
531	Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy. *Breast Cancer Research*, **2017**, 19, 18	8.3	67
530	Computational Analysis of Breast Cancer GWAS Loci Identifies the Putative Deleterious Effect of STXBP4 and ZNF404 Gene Variants. **2017**, 118, 4296-4307		6
529	Association Study Confirmed Three Breast Cancer-Specific Molecular Subtype-Associated Susceptibility Loci in Chinese Han Women. **2017**, 22, 890-894		11
528	An alternative model for (breast) cancer predisposition. **2017**, 3, 13		3
527	Association of TOX3 polymorphisms with breast cancer: A meta-analysis. **2017**, 13, 70-77		1
526	Fibroblast growth factor receptors in breast cancer. **2017**, 39, 1010428317698370		17
525	Structural variants caused by insertions are associated with risks for many human diseases. **2017**, 114, E3984-E3992		68
524	Managing hereditary breast cancer risk in women with and without ovarian cancer. **2017**, 146, 205-214		11
523	Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231. **2017**, 34, 45-52		23
522	Cohort Profile: The Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA). **2017**, 46, 1740-1741g		62
521	Mutational Signatures in Breast Cancer: The Problem at the DNA Level. **2017**, 23, 2617-2629		73
520	Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. **2017**, 26, 1016-1026		12
519	Runx3 in Immunity, Inflammation and Cancer. **2017**, 962, 369-393		21
518	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. **2017**, 24, 375-397		37
517	Association of combinations of polymorphisms in fibroblast growth factor receptor 2 gene with breast cancer among various ethnic groups. **2017**, 53, 1042-1047		

516	Genome-wide association studies of cancer: current insights and future perspectives. **2017**, 17, 692-704		173
515	miR-449a: a potential therapeutic agent for cancer. **2017**, 28, 1067-1078		27
514	Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations. **2017**, 50, 35		20
513	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. **2017**, 49, 1767-1778		186
512	Niche harmony search algorithm for detecting complex disease associated high-order SNP combinations. *Scientific Reports*, **2017**, 7, 11529	4.9	22
511	The receptor protein tyrosine phosphatase PTPRB negatively regulates FGF2-dependent branching morphogenesis. **2017**, 144, 3777-3788		14
510	Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort. **2017**, 3, 4		2
509	Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. **2017**, 77, 651-659		12
508	Cohort Profile: The Melbourne Collaborative Cohort Study (Health 2020). **2017**, 46, 1757-1757i		83
507	Novel applications of next-generation sequencing in breast cancer research. **2017**, 4, 149-153		4
506	Speed and accuracy improvement of higher-order epistasis detection on CUDA-enabled GPUs. **2017** , 20, 1899-1908		7
505	[Entitlement to prophylactic treatment in cases of genetic predisposition for breast cancer : Interdisciplinary perspectives]. **2017**, 60, 1102-1108		3
504	Counseling and Testing for Inherited Predisposition to Cancer. **2017**, 45-57		
503	Germline copy number variations are associated with breast cancer risk and prognosis. *Scientific Reports*, **2017**, 7, 14621	4.9	31
502	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. **2017**, 77, 667-678		11
501	Pubertal development in girls by breast cancer family history: the LEGACY girls cohort. *Breast Cancer Research*, **2017**, 19, 69	8.3	13
500	Previous GWAS hits in relation to young-onset breast cancer. *Breast Cancer Research and Treatment*, **2017**, 161, 333-344	4.4	9
499	Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast. **2017**, 140, 825-832		9

498	The impact of the Biomolecular Era on breast cancer surgery. **2017**, 15, 169-181	5
497	Epidemiology of Breast Cancer. **2017**, 151-172	
496	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. **2017**, 19, 599-603	51
495	Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients. **2017**, 14, 4384-4390	2
494	Biomarker Studies in Early Detection and Prognosis of Breast Cancer. **2017**, 1026, 27-39	31
493	Downregulation of Caspase 8 in a group of Iranian breast cancer patients - A pilot study. **2017**, 29, 191-195	12
492	Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK. **2017**, 7, e017675	12
491	Curcumin: Towards molecularly targeted chemoprevention of cancer. **2017**, 2, 20	1
490	GWAS in Breast Cancer. **2017**,	1
489	3. Pharmakogenetik In Der Praxis. **2017**, 218-440	
488	Pharmacogenomics in Clinical Care and Drug Discovery. **2017**, 281-303	
487	Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/Exons 2-8) in Normal and Cancerous Breast and Prostate Cells. **2016**, 18,	5
486	Exome Sequencing in a Family with Luminal-Type Breast Cancer Underpinned by Variation in the Methylation Pathway. **2017**, 18,	7
485	Genetic variants in long noncoding RNA contribute to the risk of breast cancer in a southeast China Han population. **2017**, 10, 4369-4378	24
484	Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. **2017**, 13, 1163-1171	27
483	Modeling Cancer Using CRISPR-Cas9 Technology. **2017**, 905-924	
482	Association of single nucleotide polymorphisms in FGF-RAS/MAP signalling cascade with breast cancer susceptibility. **2017**, 36, 565-572	3
481	Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. **2017**, 13, e1006727	6

480	Physical Confirmation and Comparative Genomics of the Rat Quantitative Trait Locus. **2017**, 7, 1767-1773		2
479	Allogeneic Hematopoietic Stem Cell Transplantation In Therapy-Related Myeloid Neoplasms (t-MN) of the Adult: Monocentric Observational Study and Review of the Literature. **2018**, 10, e2018005		7
478	Precision Molecular Pathology of Prostate Cancer. **2018**,		1
477	Prostate Cancer Risk: Single Nucleotide Polymorphisms (SNPs). **2018**, 117-128		
476	Polymorphisms in the TOX3/LOC643714 and risk of breast cancer in south China. **2018**, 1724600818755633		6
475	Prognostic implications of fibroblast growth factor receptor 4 polymorphisms in primary breast cancer. **2018**, 57, 988-996		9
474	Psychological Features of Breast Cancer in Mexican Women I: Personality Traits and Stress Symptoms. **2018**, 7, 3-15		1
473	Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future. **2018**, 27, 380-394		65
472	Role of micro-RNAs in breast cancer surgery. **2018**, 105, e19-e30		6
471	Genome-Wide Association Studies in Glioma. **2018**, 27, 418-428		21
470	Assessment of a FBXW8 frameshift mutation, c.1312_1313delGT, in breast cancer patients and controls from Central Europe. **2018**, 220, 38-43		1
469	The´molecular biology of prostate cancer: current understanding and clinical implications. **2018**, 21, 22-36		40
468	Profile of common prostate cancer risk variants in an unscreened Romanian population. **2018**, 22, 1574-1582		4
467	The biology of male breast cancer. **2018**, 38, 132-135		12
466	A network approach to exploring the functional basis of gene-gene epistatic interactions in disease susceptibility. **2018**, 34, 1741-1749		10
465	Genetic determinants of sporadic breast cancer in Sri Lankan women. **2018**, 18, 180		6
464	The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. **2018**, 18, 454		10
463	Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs. *Breast Cancer Research*, **2018**, 20, 3	8.3	11

462	A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. **2018**, 102, 890-903	42
461	MicroRNA-449a functions as a tumor suppressor in pancreatic cancer by the epigenetic regulation of ATDC expression. **2018**, 103, 782-789	18
460	Personalized prevention in high risk individuals: Managing hormones and beyond. **2018**, 39, 139-147	15
459	Capture Hi-C identifies putative target genes at 33 breast cancer risk loci. **2018**, 9, 1028	58
458	Making Sense of SNPs: Women's Understanding and Experiences of Receiving a Personalized Profile of Their Breast Cancer Risks. **2018**, 27, 702-708	18
457	Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. **2018**, 8, 354-369	40
456	A comprehensive analysis of polymorphic variants in steroid hormone and insulin-like growth factor-1 metabolism and risk of in situ breast cancer: Results from the Breast and Prostate Cancer Cohort Consortium. **2018**, 142, 1182-1188	
455	Identification of Pleiotropic Cancer Susceptibility Variants from Genome-Wide Association Studies Reveals Functional Characteristics. **2018**, 27, 75-85	16
454	Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. **2018**, 36, 1513-1520	29
453	Nutrient Sensing, Signaling and Ageing: The Role of IGF-1 and mTOR in Ageing and Age-Related Disease. **2018**, 90, 49-97	21
452	When pitch adds to volume: coregulation of transcript diversity predicts gene function. **2018**, 19, 926	
451	CLDN10 single nucleotide polymorphism rs1325774 alters the risk of breast cancer in south chinese women. **2018**, 97, e13187	3
450	Recursive Feature Elimination by Sensitivity Testing. **2018**, 2018, 40-47	7
449	Single Nucleotide Polymorphisms: Identification and Association with Breast Cancer Using Biocomputing Approach. **2018**,	
448	SIPA1 Gene Polymorphisms and the Risk of Breast Carcinoma among the Egyptian Females: A Pilot Study. **2018**, 07,	
447	Genetics of Exfoliation Syndrome. **2018**, 27 Suppl 1, S12-S14	14
446	A CRISPR-Cas9-triggered strand displacement amplification method for ultrasensitive DNA detection. **2018**, 9, 5012	148
445	[Next generation biobanking: the challenge of data]. **2018**, 34, 849-851	0

444	Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models. **2018**, 18, 1233		4
443	A genome wide SNP genotyping study in the Tunisian population: specific reporting on a subset of common breast cancer risk loci. **2018**, 18, 1295		11
442	Hereditary breast cancer; Genetic penetrance and current status with BRCA. **2019**, 234, 5741-5750		35
441	Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. **2018**, 78, 1110-1118		5
440	Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis. **2018**, 10, 5869-5880		6
439	Validation of a genetic risk score for Arkansas women of color. **2018**, 13, e0204834		7
438	Epidemiology of Moderate Alcohol Consumption and Breast Cancer: Association or Causation?. *Cancers*, **2018**, 10,	6.6	12
437	Therapy-related myeloid neoplasms: clinical perspectives. **2018**, 11, 5909-5915		9
436	Women's preferences, willingness-to-pay, and predicted uptake for single-nucleotide polymorphism gene testing to guide personalized breast cancer screening strategies: a discrete choice experiment. **2018**, 12, 1837-1852		6
435	The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer. **2018**, 4, 810-822		49
434	Personalised medicine and population health: breast and ovarian cancer. **2018**, 137, 769-778		25
433	Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3. *Scientific Reports*, **2018**, 8, 13551	4.9	68
432	gene polymorphism rs2981582 is associated with non-functioning pituitary adenomas in Chinese Han population: a case-control study. **2018**, 38,		3
431	Elucidating the Underlying Functional Mechanisms of Breast Cancer Susceptibility Through Post-GWAS Analyses. **2018**, 9, 280		7
430	Cancer genetics, precision prevention and a call to action. **2018**, 50, 1212-1218		57
429	Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. **2018**, 13, e0196245		2
428	Genetic Testing, Genetic Variation, and Genetic Susceptibility. **2018**, 629-649		
427	The personal and clinical utility of polygenic risk scores. **2018**, 19, 581-590		582

426	Current Development in Genome Wide Association Studies of Glaucoma. **2018**, 6, 79-85		
425	Breast cancer associated germline structural variants harboring small noncoding RNAs impact post-transcriptional gene regulation. *Scientific Reports*, **2018**, 8, 7529	4.9	9
424	miRNA 196a2(rs11614913)´&´146a(rs2910164) polymorphisms & breast cancer risk for women in an Iranian population. **2018**, 15, 279-289		13
423	Osteoporosis Genes Identified by Genome-Wide Association Studies. **2018**, 377-395		
422	Mutational Analysis of Oncogenic AKT1 Gene Associated with Breast Cancer Risk in the High Altitude Ecuadorian Mestizo Population. **2018**, 2018, 7463832		22
421	Genome-wide mapping of quantitative trait loci in admixed populations using mixed linear model and Bayesian multiple regression analysis. **2018**, 50, 32		15
420	Alteration of Epigenetic Regulation by Long Noncoding RNAs in Cancer. **2018**, 19,		97
419	Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. **2018**, 7,		32
418	Effects of FGFR1 Gene Polymorphisms on the Risk of Breast Cancer and FGFR1 Protein Expression. **2018**, 47, 2569-2578		8
417	The proliferation of colorectal cancer cells is suppressed by silencing of EIF3H. **2018**, 82, 1694-1701		5
416	Applications of RNA Indexes for Precision Oncology in Breast Cancer. **2018**, 16, 108-119		11
415	Genetic Modifiers of the Breast Tumor Microenvironment. **2018**, 4, 429-444		17
414	Genetic Variants in pre-miR-146a, pre-miR-499, pre-miR-125a, pre-miR-605, and pri-miR-182 Are Associated with Breast Cancer Susceptibility in a South American Population. **2018**, 9,		20
413	Rat models of 17β-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention. **2018**, 50, 215-234		19
412	Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. **2018**, 78, 481-492		27
411	Transmission of breast cancer polygenic risk based on single nucleotide polymorphisms. **2018**, 41, 14-18		3
410	Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. **2019**, 14, e0219566		11
409	GWAS of Behavioral Traits. **2019**, 42, 1-34		

408	Polygenic Risk Scores in Breast Cancer. **2019**, 11, 117-122		
407	Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention. **2019**, 38, e100852		32
406	Genetic Variation Underpinning ADHD Risk in a Caribbean Community. **2019**, 8,		11
405	Divergent lncRNA MYMLR regulates MYC by eliciting DNA looping and promoter-enhancer interaction. **2019**, 38, e98441		16
404	DNA damage and hormone-related cancer: a repair pathway view. **2019**, 28, R180-R186		2
403	A Review of the Hereditary Component of Triple Negative Breast Cancer: High- and Moderate-Penetrance Breast Cancer Genes, Low-Penetrance Loci, and the Role of Nontraditional Genetic Elements. **2019**, 2019, 4382606		22
402	Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis. **2019**, 76, 4275-4289		64
401	RAPPER - A Success Story for Collaborative Translational Radiotherapy Research. **2019**, 31, 416-419		7
400	Oncogenic effects of germline variants in lysosomal storage disease genes. **2019**, 21, 2695-2705		3
399	AA genotype of cyclin D1 G870A polymorphism increases breast cancer risk: Findings of a case-control study and meta-analysis. **2019**, 120, 16452-16466		2
398	Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma. **2019**, 58, 1715-1725		2
397	Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies. *Cancers*, **2019**, 11,	6.6	11
396	Integrated Transcriptome and Pathway Analyses Revealed Multiple Activated Pathways in Breast Cancer. *Frontiers in Oncology*, **2019**, 9, 910	5.3	24
395	Nuclear action of FGF members in endocrine-related tissues and cancer: Interplay with steroid receptor pathways. **2019**, 152, 108492		4
394	Genetic association of gene polymorphisms with breast cancer among Jordanian women. **2019**, 12, 7923-7928		4
393	The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights. **2019**, 20,		145
392	An in silico approach to characterize nonsynonymous SNPs and regulatory SNPs in human TOX3 gene. *Journal of Genetics*, **2019**, 98, 1	1.2	0
391	Single Nucleotide Polymorphisms Influence Histological Type and Grade of Canine Malignant Mammary Tumours. **2019**, 172, 72-79		3

390	Correlation of FGFR2 rs2981582 polymorphisms with susceptibility to breast cancer: a case-control study in a Chinese population. **2019**, 47, 4753-4763	2
389	Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors. **2019**, 28, 903-916	4
388	Association between mitochondrial genetic variation and breast cancer risk: The Multiethnic Cohort. **2019**, 14, e0222284	1
387	FAM84B promotes prostate tumorigenesis through a network alteration. **2019**, 11, 1758835919846372	8
386	Evaluation of significant genome-wide association studies risk - SNPs in young breast cancer patients. **2019**, 14, e0216997	1
385	Update Mammakarzinom 2018 (Teil 3) Genomforschung, individualisierte Medizin und Immuntherapien mitten in einer neuen Ära: Prävention und Therapie des frühen Mammakarzinoms. **2019**, 16, 23-32	
384	Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. **2019**, 10, 245	75
383	Breast Cancer Risk Assessment and Genetic Testing. **2019**, 367-382	
382	Predictive accuracy of the breast cancer genetic risk model based on eight common genetic variants: The BACkSIDE study. **2019**, 299, 1-7	2
381	An Integrated Approach to Plant Biology via Multi-Analogous Methods. **2019**, 57-126	
380	Systematic evaluation of cancer-specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts. **2019**, 8, 3196-3205	12
379	Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. **2019**, 12, 38	38
378	Robust Reference Powered Association Test of Genome-Wide Association Studies. **2019**, 10, 319	1
377	Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. **2019**, 19, 313	20
376	Clinical use of current polygenic risk scores may exacerbate health disparities. **2019**, 51, 584-591	711
375	Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation. **2019**, 8, e1593801	9
374	Association between rs2188380 and the risk of breast cancer in southwest Chinese population. **2019**, 33, e22889	1
373	Breast cancer genetic susceptibility: With focus in Saudi Arabia. **2019**, 5, 6-12	5

372	Genetic Epidemiology of Breast Cancer in Latin America. **2019**, 10,		18
371	Integrative Modeling and Novel Technologies in Human Genomics. **2019**, 155-189		
370	Adventures in the environment and genes. **2019**, 34, 1111-1117		2
369	Breast Cancer in African Populations. **2019**, 199-216		
368	Identification of two novel breast cancer loci through large-scale genome-wide association study in the Japanese population. *Scientific Reports*, **2019**, 9, 17332	4.9	5
367	Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer. **2019**, 58, 135-146		35
366	Identification of novel common breast cancer risk variants at the 6q25 locus´among Latinas. *Breast Cancer Research*, **2019**, 21, 3	8.3	23
365	Methylation pattern and mutational status of BRCA1 in canine mammary tumors in a Brazilian population. **2019**, 28, 63-67		1
364	PCAT-1: A pivotal oncogenic long non-coding RNA in human cancers. **2019**, 110, 493-499		12
363	Interaction between genetic ancestry and common breast cancer susceptibility variants in Colombian women. **2019**, 144, 2181-2191		5
362	Significant association of TOX3/LOC643714 locus-rs3803662 and breast cancer risk in a cohort of Iranian population. **2019**, 46, 805-811		5
361	Statistical Association Mapping of Population-Structured Genetic Data. **2019**, 16, 638-649		1
360	ErbB4 3'-UTR Variant (c.*3622A>G) is Associated with ER/PR Negativity and Advanced Breast Cancer. **2020**, 35, 115-120		8
359	Association of the functional genetic variants of TOX3 gene with breast cancer in Iran: A case-control study. **2020**, 18, 100511		1
358	Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium. **2020**, 49, 216-232		13
357	Genetic Factors: Hereditary Cancer Predisposition Syndromes. **2020**, 180-208.e11		2
356	Statistical genomics in rare cancer. **2020**, 61, 1-10		6
355	Individual and joint performance of DNA methylation profiles, genetic risk score and environmental risk scores for predicting breast cancer risk. **2020**, 14, 42-53		7

354	Association of polymorphisms in LOC105377871 and CASC16 with breast cancer in the northwest Chinese Han population. **2020**, 22, e3131		2
353	Statistical genetic concepts in psychiatric genomics. **2020**, 103-116		
352	Discovery of rare coding variants in OGDHL and BRCA2 in relation to breast cancer risk in Chinese women. **2020**, 146, 2175-2181		5
351	Regulation of tumor growth by leukocyte-specific protein 1 in T cells. **2020**, 8,		1
350	Maternal Liver Metabolic Response to Chronic Vitamin D Deficiency Is Determined by Mouse Strain Genetic Background. **2020**, 4, nzaa106		0
349	Cancer PRSweb: An Online Repository with Polygenic Risk Scores for Major Cancer Traits and Their Evaluation in Two Independent Biobanks. **2020**, 107, 815-836		20
348	Association of HOTAIR (rs920778 and rs1899663) and NME1 (rs16949649 and rs2302254) gene polymorphisms with breast cancer risk in India. **2020**, 762, 145033		3
347	Effect of functional variant rs11466313 on breast cancer susceptibility and TGFB1 promoter activity. *Breast Cancer Research and Treatment*, **2020**, 184, 237-248	4.4	1
346	Correlation between P53 Arg72Pro and MDM4 gene rs4245739 polymorphisms in breast cancer. **2020**, 20, 100785		
345	Transcriptional regulation of MYC through G-quadruplex structures. **2020**, 54, 361-407		1
344	ESR1 gene variants, haplotypes and diplotypes may influence the risk of breast cancer and mammographic density. **2020**, 47, 8367-8375		3
343	Critical Analysis of Genome-Wide Association Studies: Triple Negative Breast Cancer. **2020**, 21,		1
342	Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. *Breast Cancer Research and Treatment*, **2020**, 184, 311-324	4.4	6
341	Polymorphism of lncRNAs in breast cancer: Meta-analysis shows no association with susceptibility. **2020**, 22, e3271		4
340	Genetic architecture of complex traits and disease risk predictors. *Scientific Reports*, **2020**, 10, 12055	4.9	6
339	A cryptic tubulin-binding domain links MEKK1 to curved tubulin protomers. **2020**, 117, 21308-21318		5
338	Supervariants identification for breast cancer. **2020**, 44, 934-947		2
337	Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987-2020). *Cancers*, **2020**, 12,	6.6	2

336	Integrative genomic analysis implicates ERCC6 and its interaction with ERCC8 in susceptibility to breast cancer. *Scientific Reports*, **2020**, 10, 21276	4.9	3
335	Genomic Diversity in Sporadic Breast Cancer in a Latin American Population. **2020**, 11,		1
334	Single nucleotide polymorphisms in microRNAs action as biomarkers for breast cancer. **2020**, 44, 284-294		0
333	Genome-wide association studies for the number of teats and teat asymmetry patterns in Large White pigs. **2020**, 51, 595-600		5
332	Predictive role of single nucleotide polymorphism (rs11614913) in the development of breast cancer in Pakistani population. **2020**, 17, 213-227		5
331	Ancestry-specific predisposing germline variants in cancer. **2020**, 12, 51		12
330	Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer. *Frontiers in Oncology*, **2020**, 10, 617	5.3	23
329	The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments. **2020**, 21,		25
328	GenEpi: gene-based epistasis discovery using machine learning. **2020**, 21, 68		10
327	The Oncogenic Potential of the Centromeric Border Protein FAM84B of the 8q24.21 Gene Desert. **2020**, 11,		5
326	Prediction of blood test values under different lifestyle scenarios using time-series electronic health record. **2020**, 15, e0230172		3
325	A sequential methodology for the rapid identification and characterization of breast cancer-associated functional SNPs. **2020**, 11, 3340		8
324	The emerging field of polygenic risk scores and perspective for use in clinical care. **2020**, 29, R165-R176		16
323	Predicting breast cancer risk using interacting genetic and demographic factors and machine learning. *Scientific Reports*, **2020**, 10, 11044	4.9	12
322	Variants in the 8q24 region associated with risk of breast cancer: Systematic research synopsis and meta-analysis. **2020**, 99, e19217		1
321	Low-penetrance susceptibility variants and postmenopausal oestrogen receptor positive breast cancer. *Journal of Genetics*, **2020**, 99, 1	1.2	2
320	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. **2020**, 44, 442-468		9
319	Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer. **2020**, 9,		8

318	Evidence for penetrance in patients without a family history of disease: a systematic review. **2020**, 28, 539-550		8
317	PCOS-GWAS Susceptibility Variants in , and Are Associated With Metabolic Syndrome or Insulin Resistance in Women With PCOS. **2020**, 11, 274		10
316	Sure independence screening in the presence of missing data. **2021**, 62, 817-845		0
315	Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets. **2021**, 220, 107722		3
314	Common Susceptibility Loci for Male Breast Cancer. **2021**, 113, 453-461		4
313	Vineyard environments influence Malbec grapevine phenotypic traits and DNA methylation patterns in a clone-dependent way. **2021**, 40, 111-125		7
312	Relationships of physical and breast cancer phenotypes with three single-nucleotide polymorphisms (rs2046210, rs3757318, and rs3803662) associated with breast cancer risk in Japanese women. **2021**, 28, 478-487		0
311	Potpourri: An Epistasis Test Prioritization Algorithm via Diverse SNP Selection. **2021**, 28, 365-377		0
310	The Capacity of Associated Subsequence Retrieval. **2021**, 67, 790-804		
309	Cancer health disparities in racial/ethnic minorities in the United States. **2021**, 124, 315-332		110
308	Breast Cancer-Related Low Penetrance Genes. **2021**, 1187, 419-434		1
307	Genetics of osteoporosis. **2021**, 405-451		1
306	Protein co-expression networks identified from HOT lesions of ER+HER2-Ki-67high luminal breast carcinomas. *Scientific Reports*, **2021**, 11, 1705	4.9	0
305	Insights into the Links between MYC and 3D Chromatin Structure and Epigenetics Regulation: Implications for Cancer Therapy. **2021**, 81, 1925-1936		1
304	Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility. **2021**, 148, 1895-1909		2
303	Rare Coding Variants Associated with Breast Cancer. **2021**, 1187, 435-453		
302	Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors. **2021**, 30, 342-360		3
301	Biomarkers. **2021**,		0

300	Personalized Screening for Breast Cancer: Rationale, Present Practices, and Future Directions. **2021**, 28, 4306-4317		9
299	Pten regulates collagen fibrillogenesis by fibroblasts through SPARC. **2021**, 16, e0245653		2
298	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. **2021**, 12, 1078		4
297	Promotes Ovarian Estrogen Synthesis: An RNA-Sequencing and Network Study. **2020**, 11, 615846		2
296	Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer. **2021**, 10,		9
295	Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients. *Oncotarget*, **2021**, 12, 686-697	3.3	1
294	The potential of long noncoding RNAs for precision medicine in human cancer. **2021**, 501, 12-19		10
293	First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion. **2021**, 4, 176-179		0
292	Does Subtelomeric Position of COMMD5 Influence Cancer Progression?. *Frontiers in Oncology*, **2021**, 11, 642130	5.3	1
291	Evaluating the Association between Polymorphism (rs333) and the Risk of Breast Cancer in a Cohort of Iranian Population. **2021**, 50, 583-591		1
290	A unified framework for cross-population trait prediction by leveraging the genetic correlation of polygenic traits. **2021**, 108, 632-655		11
289	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with -mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. **2021**, 106, 2986-2989		1
288	Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing. **2021**, 516, 55-63		0
287	Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling. **2021**, 10,		9
286	Navigating Multi-scale Cancer Systems Biology towards Model-driven Personalized Therapeutics.		1
285	Genetic variations in 3'UTRs of SMUG1 and NEIL2 genes modulate breast cancer risk, survival and therapy response. **2021**, 36, 269-279		0
284	Multidisciplinary Tinnitus Research: Challenges and Future Directions From the Perspective of Early Stage Researchers. **2021**, 13, 647285		2
283	Sequencing for germline mutations in Swedish breast cancer families reveals novel breast cancer risk genes. *Scientific Reports*, **2021**, 11, 14737	4.9	

282	A Personal Breast Cancer Risk Stratification Model Using Common Variants and Environmental Risk Factors in Japanese Females. *Cancers*, **2021**, 13,	6.6	1
281	Technological readiness and implementation of genomic-driven precision medicine for complex diseases. **2021**, 290, 602-620		6
280	Fibroblast growth factor receptor 2 gene () rs2981582T/C polymorphism and susceptibility to breast cancer in Saudi women. **2021**, 28, 6112-6115		
279	Risks and Function of Breast Cancer Susceptibility Alleles. *Cancers*, **2021**, 13,	6.6	1
278	Translating polygenic risk scores for clinical use by estimating the confidence bounds of risk prediction. **2021**, 12, 5276		0
277	BRCA1/2 normal meme kanserli kad□nlarda genotip-fenotip ili□kisinin arat□r□lmas□: Türkiye'den tek merkez deneyimi.		
276	The prevalence of ataxia telangiectasia mutated (ATM) variants in patients with breast cancer patients: a systematic review and meta-analysis. **2021**, 21, 474		1
275	The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?. **2022**, 150, 73-79		1
274	The potential roles of genetic factors in predicting ageing-related cognitive change and Alzheimer's disease. **2021**, 70, 101402		3
273	Combination of a 15-SNP Polygenic Risk Score and Classical Risk Factors for the Prediction of Breast Cancer Risk in Cypriot Women. *Cancers*, **2021**, 13,	6.6	0
272	Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy. **2021**, 8, e2100974		3
271	Improving Pain and Outcomes in the Perioperative Setting. **2022**, 607-612		
270	From to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes. **2021**, 16, 202-213		1
269	Risk-Adjusted Prevention. Perspectives on the Governance of Entitlements to Benefits in the Case of Genetic (Breast Cancer) Risks. **2021**, 218, 47-66		0
268	Precise diagnosis of three top cancers using dbGaP data. *Scientific Reports*, **2021**, 11, 823	4.9	0
267	Coffee Intake Interacted with the rs1944420, rs7236090, and rs2849382 Haplotype to Influence Breast Cancer Risk in Middle-Aged Women. **2021**, 1-10		1
266	An Overview of Genes Associated with Hereditary Breast and Ovarian Cancer in India. **2021**, 19, 1		
265	as New Hotspot Mutation for Breast Cancer in Indian Population and Has a Role in DNA Damage and Repair in Mammalian Cells. **2020**, 11, 609758		2

264	Replication and Meta-analysis of Genome-Wide Association Studies. **2019**, 631-650		1
263	Understanding the Pathogenesis of Endometriosis: Gene Mapping Studies. 54-64		2
262	Genetic Susceptibility and High Risk Groups for Pancreatic Cancer. **2010**, 565-600		1
261	Pharmacogenomics of endocrine therapy in breast cancer. **2008**, 630, 220-31		14
260	Identification of Genetic Risk Factors for Prostate Cancer: Analytic Approaches Using Hereditary Prostate Cancer Families. **2010**, 203-228		5
259	The Identification of Rare and Common Variants Which Predispose to Prostate Cancer. **2010**, 229-248		3
258	Bioinformatics challenges in genome-wide association studies (GWAS). *Methods in Molecular Biology*, **2014**, 1168, 63-81	1.4	31
257	Familial Breast Cancer and Genetic Predisposition in Breast Cancer. **2015**, 15-37		2
256	Application of SNP genotype arrays to determine somatic changes in cancer. *Methods in Molecular Biology*, **2009**, 538, 179-206	1.4	5
255	Introduction to omics. *Methods in Molecular Biology*, **2010**, 593, 1-23	1.4	2
254	Short tandem repeats and genetic variation. *Methods in Molecular Biology*, **2010**, 628, 297-306	1.4	6
253	Cancer genome analysis informatics. *Methods in Molecular Biology*, **2010**, 628, 75-102	1.4	7
252	Fine-scale structure of the genome and markers used in association mapping. *Methods in Molecular Biology*, **2011**, 713, 71-88	1.4	1
251	Genome-wide association studies. *Methods in Molecular Biology*, **2011**, 713, 89-103	1.4	3
250	Molecular epidemiology of DNA repair genes in bladder cancer. *Methods in Molecular Biology*, **2009**, 472, 281-306	1.4	8
249	Breast Cancer. **2020**, 417-438		3
248	Breast Cancer Epidemiology. **2016**, 125-137		4
247	Ultra-Fast Detection of Higher-Order Epistatic Interactions on GPUs. **2017**, 421-432		1

246	Rat Genome Mapping and Genomics. **2012**, 217-256	4
245	The "delayed infection" (aka "hygiene") hypothesis for childhood leukaemia. **2009**, 239-255	6
244	Cancer Screening, Risk Stratification and the Ethics of Apt Categorisation: A Case Study. **2013**, 141-152	2
243	Genetic Factors: Hereditary Cancer Predisposition Syndromes. **2008**, 171-191	1
242	Neoplasia. **2010**, 259-330	25
241	Fibroblast growth factor signalling: from development to cancer.	1
240	Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers. **2021**, 113, 893-899	4
239	Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study. **2013**, 20, 354-8	12
238	Cancer PRSweb: An Online Repository with Polygenic Risk Scores (PRS) for Major Cancer Traits and Their Phenome-wide Exploration in Two Independent Biobanks.	1
237	Genetic Architecture of Complex Traits and Disease Risk Predictors.	3
236	Identification of Novel Common Breast Cancer Risk Variants in Latinas at the 6q25 Locus.	1
235	GenEpi: Gene-based Epistasis Discovery Using Machine Learning.	2
234	Current clinical use of polygenic scores will risk exacerbating health disparities.	15
233	Genetic variants of miRNA sequences and non-small cell lung cancer survival. **2008**, 118, 2600-8	420
232	On quality control measures in genome-wide association studies: a test to assess the genotyping quality of individual probands in family-based association studies and an application to the HapMap data. **2009**, 5, e1000572	6
231	The 'common disease-common variant' hypothesis and familial risks. **2008**, 3, e2504	42
230	Silencing of keratinocyte growth factor receptor restores 5-fluorouracil and tamoxifen efficacy on responsive cancer cells. **2008**, 3, e2528	26
229	Identification of PLCL1 gene for hip bone size variation in females in a genome-wide association study. **2008**, 3, e3160	51

228	Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. **2009**, 4, e5983	33
227	Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. **2010**, 5, e10858	24
226	A bayesian method for evaluating and discovering disease loci associations. **2011**, 6, e22075	25
225	Nucleotide discrimination with DNA immobilized in the MspA nanopore. **2011**, 6, e25723	118
224	The association between ATM IVS 22-77 T>C and cancer risk: a meta-analysis. **2012**, 7, e29479	9
223	FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells. **2013**, 8, e51671	39
222	Evaluating genome-wide association study-identified breast cancer risk variants in African-American women. **2013**, 8, e58350	58
221	Association of single nucleotide polymorphisms in Wnt signaling pathway genes with breast cancer in Saudi patients. **2013**, 8, e59555	41
220	Activating somatic FGFR2 mutations in breast cancer. **2013**, 8, e60264	24
219	Comprehensive functional annotation of seventy-one breast cancer risk Loci. **2013**, 8, e63925	38
218	Quantitative assessment of 2q35-rs13387042 polymorphism and hormone receptor status with breast cancer risk. **2013**, 8, e66979	5
217	Assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies. **2013**, 8, e69056	4
216	Quantitative assessment of common genetic variants on chromosome 5p12 and hormone receptor status with breast cancer risk. **2013**, 8, e72154	4
215	Assessing interactions between the association of common genetic variant at 1p11 (rs11249433) and hormone receptor status with breast cancer risk. **2013**, 8, e72487	3
214	Genome-wide association study of breast cancer in the Japanese population. **2013**, 8, e76463	30
213	A functional variant rs1820453 in YAP1 and breast cancer risk in Chinese population. **2013**, 8, e79056	9
212	A common variant in the SIAH2 locus is associated with estrogen receptor-positive breast cancer in the Chinese Han population. **2013**, 8, e79365	11
211	Association study of germline variants in CCNB1 and CDK1 with breast cancer susceptibility, progression, and survival among Chinese Han women. **2013**, 8, e84489	23

210	A MAP3k1 SNP predicts survival of gastric cancer in a Chinese population. **2014**, 9, e96083		6
209	Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes. **2015**, 10, e0134463		14
208	Identifying Triple-Negative Breast Cancer Using Background Parenchymal Enhancement Heterogeneity on Dynamic Contrast-Enhanced MRI: A Pilot Radiomics Study. **2015**, 10, e0143308		91
207	Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer. **2016**, 11, e0165559		19
206	Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. **2017**, 12, e0168601		14
205	Expression Quantitative Trait loci (QTL) in tumor adjacent normal breast tissue and breast tumor tissue. **2017**, 12, e0170181		9
204	BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. **2017**, 4,		68
203	Association of and polymorphisms and their association with breast cancer risk among Iranian population. **2019**, 18, 429-438		4
202	Genetic polymorphisms (rs10636 and rs28366003) in metallothionein 2A increase breast cancer risk in Chinese Han population. **2017**, 9, 547-555		22
201	Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in -mutated -negative metastatic or advanced breast cancer: a network meta-analysis. **2020**, 13, 450-459		6
200	The breast cancer susceptibility-related polymorphisms at the TOX3/LOC643714 locus associated with lung cancer risk in a Han Chinese population. *Oncotarget*, **2016**, 7, 59742-59753	3.3	7
199	The LSP1 rs3817198 T > C polymorphism contributes to increased breast cancer risk: a meta-analysis of twelve studies. *Oncotarget*, **2016**, 7, 63960-63967	3.3	5
198	Association between 8q24 (rs13281615 and rs6983267) polymorphism and breast cancer susceptibility: a meta-analysis involving 117,355 subjects. *Oncotarget*, **2016**, 7, 68002-68011	3.3	4
197	The precision relationships between eight GWAS-identified genetic variants and breast cancer in a Chinese population. *Oncotarget*, **2016**, 7, 75457-75467	3.3	10
196	Quantitative assessment of polymorphisms in H19 lncRNA and cancer risk: a meta-analysis of 13,392 cases and 18,893 controls. *Oncotarget*, **2016**, 7, 78631-78639	3.3	24
195	GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients. *Oncotarget*, **2016**, 7, 77358-77364	3.3	9
194	Trans-ethnic follow-up of breast cancer GWAS hits using the preferential linkage disequilibrium approach. *Oncotarget*, **2016**, 7, 83160-83176	3.3	8
193	Increased breast cancer risk with HABP1/p32/gC1qR genetic polymorphism rs2285747 and its upregulation in northern Chinese women. *Oncotarget*, **2017**, 8, 13932-13941	3.3	7

192	Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. *Oncotarget*, **2017**, 8, 20925-20938	3.3	26
191	Upregulation of FAM84B during prostate cancer progression. *Oncotarget*, **2017**, 8, 19218-19235	3.3	20
190	Genetic variants within the cancer susceptibility region 8q24 and ovarian cancer risk in Han Chinese women. *Oncotarget*, **2017**, 8, 36462-36468	3.3	8
189	What are genome-wide association studies telling us about B-cell tumor development?. *Oncotarget*, **2010**, 1, 367-372	3.3	8
188	Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women. *Oncotarget*, **2017**, 8, 65759-65769	3.3	8
187	Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese. *Oncotarget*, **2018**, 9, 12796-12804	3.3	13
186	A recessive variant of XRCC4 predisposes to non- BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. *Oncotarget*, **2014**, 5, 12218-32	3.3	4
185	A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients. *Oncotarget*, **2016**, 7, 5042-52	3.3	7
184	Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province. *Oncotarget*, **2015**, 6, 34023-9	3.3	18
183	Klotho is a novel marker and cell survival factor in a subset of triple negative breast cancers. *Oncotarget*, **2016**, 7, 2611-28	3.3	8
182	gene associated polymorphisms and Wilms tumor risk in Chinese children: a four-center case-control study. **2019**, 7, 475		6
181	Molecular genetics of breast and ovarian cancer: recent advances and clinical implications. **2012**, 15, 75-80		1
180	Bridging the Data Gap in Breast Cancer Risk Assessment to Enable Widespread Clinical Implementation across the Multiethnic Landscape of the US. **2018**, 2, 1-6		4
179	Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. **2016**, 4, 1-210		48
178	Genome-wide association studies--a summary for the clinical gastroenterologist. **2009**, 15, 5377-96		12
177	Association between polymorphism rs6983267 and gastric cancer risk in Chinese population. **2011**, 17, 1759-65		18
176	Exome sequencing in a breast cancer family without BRCA mutation. **2015**, 33, 149-54		14
175	PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells. **2014**, 26, 142-7		7

174	Association of CYP1A1 M2 (A2455G) Polymorphism with Susceptibility to Breast Cancer in Mazandaran Province, Northern Iran: A Case-control Study. **2019**, 10, 92		5
173	Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer. **2015**, 6, 290-300		82
172	ER and PR Positive, or Her2 Negative Tumor of rs2363956 and rs3803662 GWAS in Breast Cancer. **2017**, 4,		2
171	HER4 rs1595065 3'UTR Variant is a Possible Risk Factor for HER2 Positivity Among Breast Cancer Patients. **2016**, 5,		12
170	Breast cancer association studies in a Han Chinese population using 10 European-ancestry-associated breast cancer susceptibility SNPs. *Asian Pacific Journal of Cancer Prevention*, **2014**, 15, 85-91	1.7	7
169	Current evidence on the association between rs3757318 of C6orf97 and breast cancer risk: a meta-analysis. *Asian Pacific Journal of Cancer Prevention*, **2014**, 15, 8051-5	1.7	2
168	CCDC26 gene polymorphism and glioblastoma risk in the Han Chinese population. *Asian Pacific Journal of Cancer Prevention*, **2014**, 15, 3629-33	1.7	8
167	Targeted Resequencing of 30 Genes Improves the Detection of Deleterious Mutations in South Indian Women with Breast and/or Ovarian Cancers. *Asian Pacific Journal of Cancer Prevention*, **2015**, 16, 5211-7	1.7	17
166	A pilot genome-wide association study of breast cancer susceptibility loci in Indonesia. *Asian Pacific Journal of Cancer Prevention*, **2015**, 16, 2231-5	1.7	10
165	Statistical analysis for genome-wide association study. *Journal of Biomedical Research*, **2015**, 29, 285-97	1.5	40
164	Hereditary Cancers and Genetics. **2021**, 65-98		
163	Geneticists identify four new breast-cancer genes. *Nature*,	50.4	
162	The Genetic Epidemiology of Hereditary Breast Cancer. **2007**, 1-17		
161	Risk Prediction in Breast Cancer. **2007**, 19-33		
160	An Evolutionary Framework for Common Disease.		
159	Human Genome Project: Importance in Clinical Genetics.		
158	Models of Absolute Risk. **2008**, 259-274		
157	Design Considerations in Molecular Epidemiology. **2008**, 1-18		

156 Reporting and Interpreting Results. **2008**, 275-292

155 Principles of High-Quality Genotyping. **2008**, 63-79

154 Haplotype Association Analysis. **2008**, 205-224

153 Management of BRCA Mutation-Negative Patients. **2008**, 107-115

152 Multivariate Nonparametric Regression. **2009**, 1-24

151 On the Role and Potential of High-Dimensional Biologic Data in Cancer Research. **2009**, 1-11

150 Risk assessment and management. **2009**, 327-337

149 Study designs in genetic epidemiology. *Methods in Molecular Biology*, **2009**, 520, 247-57 1.4 1

148 High-Frequency Low-Penetrance Alleles. **2009**, 249-262

147 Tumorigenesis. **2009**, 1-17

146 Genetic Modifiers of Risk of BRCA1- and BRCA2-Related Breast and Ovarian Cancers. **2009**, 107-129

145 Common Genetic Susceptibility Loci. **2010**, 301-320

144 Complex Multifactorial Genetic Diseases.

143 Susceptibility Alleles for Testicular Germ Cell Tumor. **2010**, 317-335

142 Recent Advances in Cancer Genomics and Cancer-Associated Genes Discovery. **2010**, 11-29

141 Genetics of Hereditary Breast Cancer. **2010**, 41-51

140 Functional Genomics and Proteomics in Allergy Research. **2010**, 1-18

139 Analysis of Inherited and Acquired Genetic Variation. **2010**, 13-31

138 A Systematic Review and Analysis of Reporting Quality of Studies of Germline Genetic Variants Influencing Susceptibility to Nonmedullary Thyroid Cancer. **2010**, 2, 119-126

137 Hereditary Factors and Pre-invasive Disease. **2011**, 31-40

136 Gene Discovery by MMTV Mediated Insertional Mutagenesis. **2011**, 39-75

135 Genome-wide Association Studies of Cancers.

134 Genomics and Viruses in Sjögren's Syndrome. **2011**, 93-110

133 Expression and Genetic Variation Databases for Cancer Research. **2011**, 153-164

132 Molecular genetics of atherosclerosis and acute coronary syndromes. **2011**, 35-43

131 Unraveling the Role of GPER in Breast Cancer. **2012**, 115-127

130 Inherited Diseases. **2012**, 1239-1292

129 Genomics of Hepatocellular Carcinoma. **2012**, 45-78

128 Hereditary Prostate Cancer and Genetic Risk. **2012**, 79-101

127 Implication of the Strand-Specific Imprinting and Segregation Model: Integrating Hormone Exposure, Stem Cell and Lateral Asymmetry Hypotheses in Breast Cancer Aetiology. **2013**, 2013, 0

126 Cis-Regulatory Variation and Cancer. **2012**, 195-216

125 HER2-Positive Metastatic Breast Cancer: Second-Line Treatment. **2013**, 61-74

124 Genome-Wide Association Studies in Colorectal Cancer. **2013**, 289-302

123 Reproductive System. **2014**, 89-136

122 Breast Cancer Prevention. **2014**, 445-489

121 Genetic Factors in Breast Cancer. 35-57

120 Molecular Diagnosis of Cancer. **2014**, 249-346 1

119 Computational Biomarker Discovery. **2014**, 355-386 0

118 Genetics of Childhood Obesity. **2013**, 1-21

117 Encyclopedia of Cancer. **2014**, 1-7

116 Encyclopedia of Machine Learning and Data Mining. **2014**, 1-24

115 Genetic Factors. **2014**, 169-187.e7 1

114 The genetics of breast cancer, risk-reducing surgery and prevention. **2014**, 127-145

113 Omics of Hereditary Breast Cancer. **2014**, 17-40

112 Genetics of Restless Legs Syndrome (RLS). **2015**, 331-351

111 Association Studies to Map Genes for Disease-Related Traits in Humans. **2015**, 53-66

110 HER2-positive metastatic breast cancer: second-line treatment. **2016**, 71-86

109 DcR3 gene polymorphisms are associated with sporadic breast infiltrating ductal carcinoma in Northeast Chinese women. *Oncotarget*, **2016**, 7, 57970-57977 3.3 4

108 Statistical Association Mapping of Population-Structured Genetic Data.

107 Familial heterogeneity in breast cancer predisposition: a study of 22 Utah families.

106 Encyclopedia of Machine Learning and Data Mining. **2017**, 143-163

105 Genetics. **2017**, 51-62

104 The H19 Locus ?. **2017**,

103 Encyclopedia of Cancer. **2017**, 635-640

102	Association of genetic polymorphism with the mutation status of the BRCA1/2 genes in spontanous breast cancer. **2017**, 33, 393-400		1
101	Breast cancer susceptibility: an integrative analysis of genomic data.		1
100	Robust Reference Powered Association Test of genome-wide association studies.		
99	The Association of Single Nucleotide Polymorphisms with Cancer Risk. **2019**, 87-144		
98	Gene-level heritability analysis explains the polygenic architecture of cancer.		
97	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.		1
96	Potpourri: An Epistasis Test Prioritization Algorithm via Diverse SNP Selection.		
95	P21 Ser31Arg and FGFR2 rs2981582 Polymorphisms as Risk Factors for Early Onset of Breast Cancer in Yogyakarta, Indonesia. *Asian Pacific Journal of Cancer Prevention*, **2019**, 20, 3305-3309	1.7	1
94	A cryptic tubulin-binding domain links MEKK1 to microtubule remodelling.		
93	Ancestry-Specific Predisposing Germline Variants in Cancer.		
92	Functional annotation of breast cancer risk loci: current progress and future directions. **2021**,		1
91	Pathway-Affecting Single Nucleotide Polymorphisms (SNPs) in RPS6KA1 and MBIP Genes are Associated with Breast Cancer Risk. *Asian Pacific Journal of Cancer Prevention*, **2020**, 21, 2163-2168	1.7	1
90	Transcriptome and interactome analyses identify theTP53interacting geneRCCD1as a candidate susceptibility gene at the 15p26.1 breast and ovarian cancer risk locus.		
89	A Systematic Review of Risk Factors and Risk Assessment Models for Breast Cancer. **2021**, 509-519		1
88	Correlation between and Polymorphisms and the Susceptibility to Breast Cancer. **2020**, 9, 291-296		1
87	Genome-wide association studies: progress in identifying genetic biomarkers in common, complex diseases. **2007**, 2, 283-92		12
86	BeadDataPackR: A Tool to Facilitate the Sharing of Raw Data from Illumina BeadArray Studies. **2010**, 9, 217-27		1
85	Pattern discovery in breast cancer specific protein interaction network. **2009**, 2009, 1-5		2

84	In search of breast cancer culprits: suspecting the suspected and the unsuspected. **2008**, 1, 1-5		
83	Effect of genome-wide simultaneous hypotheses tests on the discovery rate. *International Journal of Molecular Epidemiology and Genetics*, **2011**, 2, 163-77	0.9	
82	What are genome-wide association studies telling us about B-cell tumor development?. *Oncotarget*, **2010**, 1, 367-72	3.3	5
81	Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario. *Canadian Family Physician*, **2012**, 58, e258-66	0.9	6
80	Regulators of gene expression as biomarkers for prostate cancer. *American Journal of Cancer Research*, **2012**, 2, 620-57	4.4	14
79	MetaSeq: privacy preserving meta-analysis of sequencing-based association studies. *Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing*, **2013**, 356-67	1.3	3
78	Genetic variation and its role in malignancy. *International Journal of Biomedical Science*, **2011**, 7, 158-71		10
77	Genetic variants improve breast cancer risk prediction on mammograms. **2013**, 2013, 876-85	0.7	10
76	Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus. *Bone*, **2014**, 59, 20-7	4.7	16
75	G protein signaling modulator-3: a leukocyte regulator of inflammation in health and disease. *American Journal of Clinical and Experimental Immunology*, **2014**, 3, 97-106	1.2	12
74	Unique SNP in CD44 intron 1 and its role in breast cancer development. *Anticancer Research*, **2010**, 30, 1263-72	2.3	19
73	Graphical-model Based Multiple Testing under Dependence, with Applications to Genome-wide Association Studies. **2012**, 2012, 511-522	0.8	8
72	BRCA1 Gene Mutations in Breast Cancer Patients from Kerman Province, Iran. *Iranian Journal of Cancer Prevention*, **2012**, 5, 210-5		5
71	New genetic variants improve personalized breast cancer diagnosis. *AMIA Summits on Translational Science Proceedings*, **2014**, 2014, 83-9	1.1	13
70	Melanoma: Molecular Pathogenesis and Therapeutic Management. *Molecular and Cellular Pharmacology*, **2014**, 6, 228		54
69	CCDC26 rs4295627 polymorphism and glioma risk: a meta-analysis. *International Journal of Clinical and Experimental Medicine*, **2015**, 8, 3862-8		3
68	FGFR2 gene polymorphisms are associated with breast cancer risk in the Han Chinese population. *American Journal of Cancer Research*, **2015**, 5, 1854-61	4.4	22
67	Correlation between LSP1 polymorphisms and the susceptibility to breast cancer. *International Journal of Clinical and Experimental Pathology*, **2015**, 8, 5798-802	1.4	12

66	Associations of immunity-related single nucleotide polymorphisms with overall survival among prostate cancer patients. *International Journal of Clinical and Experimental Medicine*, **2015**, 8, 11470-6		5
65	TGF-β1-509C/T polymorphism and the risk of ESCC in a Chinese Han population. *International Journal of Clinical and Experimental Medicine*, **2015**, 8, 11524-8		
64	Predictive and prognostic molecular markers for cholangiocarcinoma in Han Chinese population. *International Journal of Clinical and Experimental Medicine*, **2015**, 8, 13680-9		1
63	TOX gene: a novel target for human cancer gene therapy. *American Journal of Cancer Research*, **2015**, 5, 3516-24	4.4	16
62	[Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer]. *Chinese Journal of Lung Cancer*, **2018**, 21, 116-120	0.6	2
61	Improving breast cancer risk prediction by using demographic risk factors, abnormality features on mammograms and genetic variants. **2018**, 2018, 1253-1262	0.7	
60	delGA (rs67491583) variant and colorectal cancer risk in an indigenous African population. *African Journal of Medicine and Medical Sciences*, **2012**, 41, 271-5		
59	The Associations of Common Genetic Susceptibility Variants with Breast Cancer in Jordanian Arabs: A Case-Control Study. *Asian Pacific Journal of Cancer Prevention*, **2020**, 21, 3045-3054	1.7	1
58	Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. *Journal of Neuro-Oncology*, **2021**, 1	4.8	0
57	The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection. *Mass Spectrometry Reviews*, **2021**, e21748	11	2
56	Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics.. *Frontiers in Oncology*, **2021**, 11, 712505	5.3	0
55	Biological Significance and Targeting of the FGFR Axis in Cancer. *Cancers*, **2021**, 13,	6.6	6
54	Genetic variant CHST9 Rs1436904 in breast cancer prognosis. *AIP Conference Proceedings*, **2021**,	0	
53	Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic.. *Breast Cancer Research and Treatment*, **2022**, 192, 375	4.4	0
52	Associations of genetic susceptibility to 16 cancers with risk of breast cancer overall and by intrinsic subtypes.. *Human Genetics and Genomics Advances*, **2022**, 3, 100077	0.8	1
51	SNP rs2240688 in gene on susceptibility and clinicopathological features of hepatocellular carcinoma.. *Translational Cancer Research*, **2020**, 9, 5940-5948	0.3	1
50	The Associations of Common Genetic Susceptibility Variants with Breast Cancer in Jordanian Arabs: A Case-Control Study. *Asian Pacific Journal of Cancer Prevention*, **2020**, 21, 3045-3054	1.7	2
49	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. *Breast Cancer Research*, **2022**, 24, 2	8.3	3

48	Risk Association of and Gene Polymorphisms with Sporadic Breast Cancer in Mexican Women.. *Current Oncology*, **2022**, 29, 1008-1017	2.8	0
47	An approach to characterize nonsynonymous SNPs and regulatory SNPs in human gene. *Journal of Genetics*, **2019**, 98,	1.2	
46	Melanoma therapeutics: a literature review.. *Journal of Biomedical Research*, **2022**, 1-21	1.5	1
45	Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer.. *Open Biology*, **2022**, 12, 210373	7	0
44	The Interaction of NTN4 and miR-17-92 Polymorphisms on Breast Cancer Susceptibility in a Chinese Population.. *Clinical Breast Cancer*, **2021**,	3	0
43	MAP3K1 SNP rs889312 potential risk and MAP3K9 SNP rs11628333 menopause dependent association for breast cancer. *Biyokimya Dergisi*, **2021**,	0.7	
42	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women.. *Scientific Reports*, **2022**, 12, 6199	4.9	
41	Systems biology of cancer progression. 1-6		
40	Lessons from cancer genome sequencing. 7-19		
39	Image_1.TIFF. **2019**,		
38	Image_2.TIFF. **2019**,		
37	Image_3.TIFF. **2019**,		
36	Image_4.TIFF. **2019**,		
35	Table_1.XLS. **2019**,		
34	Table_2.XLS. **2019**,		
33	Table_3.XLS. **2019**,		
32	Table_4.xls. **2019**,		
31	Table_5.xls. **2019**,		

30	Table_6.xls. **2019**,		
29	Data_Sheet_1.docx. **2020**,		
28	Table_1.XLSX. **2019**,		
27	Table_2.DOCX. **2019**,		
26	Table_3.XLS. **2019**,		
25	From Genotype to Phenotype: Polygenic Prediction of Complex Human Traits.. *Methods in Molecular Biology*, **2022**, 2467, 421-446	1.4	
24	The TOX Subfamily: All-round Players in the Immune System.. *Clinical and Experimental Immunology*, **2022**,	6.2	0
23	Inhibition of Fibroblast Growth Factor Receptor Attenuates Ultraviolet B-Induced Skin Carcinogenesis.. *Journal of Investigative Dermatology*, **2022**,	4.3	0
22	Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations. *Expert Review of Anticancer Therapy*, 1-7	3.5	
21	Exome sequencing identifies novel susceptibility genes and defines the contribution of coding variants to breast cancer risk.		0
20	Seven-Single Nucleotide Polymorphism Polygenic Risk Score for Breast Cancer Risk Prediction in a Vietnamese Population. *Cytology and Genetics*, **2022**, 56, 379-390	0.7	
19	Dynamic metabolome profiling uncovers potential TOR signaling genes.		
18	MTHSA-DHEI: multitasking harmony search algorithm for detecting high-order SNP epistatic interactions. *Complex & Intelligent Systems*,	7.1	0
17	Association between the rs4784227-CASC16 polymorphism and the risk of breast cancer: A meta-analysis. **2022**, 101, e30218		0
16	Resequencing of sweetpotato germplasm resources reveals key loci associated with multiple agronomic traits.		0
15	Recent Advances on Penalized Regression Models for Biological Data. **2022**, 10, 3695		0
14	The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis. **2022**, 101, e31548		0
13	Role of DEK in carcinogenesis, diagnosis, prognosis, and therapeutic outcome of breast cancer: An evidence-based clinical review. **2023**, 181, 103897		0

12	The Revelation of Continuously Organized, Co-Overexpressed Protein-Coding Genes with Roles in Cellular Communications in Breast Cancer. **2022**, 11, 3806	1
11	Hereditary breast cancer: syndromes, tumour pathology and molecular testing. **2023**, 82, 70-82	4
10	MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta-analysis.	0
9	Machine Learning Reveals Genetic Modifiers of the Immune Microenvironment of Cancer.	0
8	Dynamic metabolome profiling uncovers potential TOR signaling genes. 12,	0
7	The Influence of Omics in Shaping Precision Medicine. 50-55	0
6	Synthesis of Biocompatible Nanoporous ZIF-8-Gum Arabic as a New Carrier for the Targeted Delivery of Curcumin.	0
5	SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. **2022**, 24,	0
4	MYC oncogenes as potential anticancer targets. **2023**, 191-219	0
3	Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. **2023**, 15,	0
2	Evaluation of the Association between FGFR2 Gene Polymorphisms and Breast Cancer Risk in the Bangladeshi Population. **2023**, 14, 819	0
1	The prognostic value and biological functions of HFM1 in breast cancer.	0